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Summary 
Assigning the cellular target(s) of bioactive small molecules, whether the 
compounds are discovered by cell-based phenotypic or target-based screens of 
chemical libraries, remains an ongoing challenge. The ability of accurately and 
thoroughly determining of SMtarget interaction profiles as well as mapping of 
metabolic and signaling pathways on the proteomic scale would therefore be more 
illuminating, as it could provide invaluable biological insights for a drug candidate by 
both understanding the primary mechanism-of-action, and at the same time, side 
effects due to unexpected “off-target” interactions at a very early stage of drug 
development, which should help to reduce the attrition rate in development. In many 
cases such a capability could find new potential therapeutic value for an established 
drug as well as it could also offer strong clues for compound optimization in order to 
maximize the therapeutic potential and minimize potential cellular toxicity of a drug. 
The data may also serve to define previously unknown protein functions, based on the 
phenotypes induced by compounds. Recent advances in chemical proteomics (or 
activity-based proteomics), a multidisciplinary research area integrating biochemistry 
and cell biology with organic synthesis and mass spectrometry, have enabled a more 
direct and unbiased analysis of a drug’s mechanism of action in the context of the 
proteomes as expressed in the target cell or the tissue of interest.  
In this thesis, I describe the design and synthesis of Orlistat
TM
-like natural 
product-based probes (Chapter 2, 3 & 4), K11777-like drug candidate-based probes 
(Chapter 5) and azanitrile-containing  small molecules (Chapter 6), determination of 
 xi 
structure-activity relationships of these compounds, cellular target identification, 
validation and cellular localization in subsequent molecular biology and cell 
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1.1 Drug Target Identification – An Overview 
Assigning the cellular target(s) of bioactive small molecules (SMs), whether 
the compounds are discovered by cell-based phenotypic or target-based screens of 
chemical libraries, remains an ongoing challenge, as testified to by the fact that the 
primary targets of various clinically approved drugs remain unknown. The ability of 
accurately and thoroughly determining of SMtarget interaction profiles as well as 
mapping of metabolic and signaling pathways on the proteomic scale would therefore 
be more illuminating, as it could provide invaluable biological insights for a drug 
candidate both by understanding the primary mechanism-of-action, and at the same 
time, side effects due to unexpected “off-target” interactions at a very early stage of 
drug development, which should help to reduce the attrition rate in development. In 
many cases such a capability could find new potential therapeutic value for an 
established drug as well as it could also offer strong clues for compound optimization 
in order to maximize the therapeutic potential and minimize potential cellular toxicity 
of a drug. “Target ID” has been approached using a variety of genetic, computational 
ands biochemical methods, such as genome-wide genetic assays, expression profiling, 
bioinformatics and affinity chromatography.
[1]
 While all of these methods can provide 
valuable information on the mode of action of drug candidates, each method has 
distinct advantages and disadvantages, for example, genome-wide suppression screens 
have not yet been performed in mammalian cells because analogous genome-wide 
heterozygous cell line collections do not exist; the same is true for various 
modifications of the yeast two-hybrid method.
  
 3 
To date, affinity chromatography combined with identification by mass 
spectrometry remains the most popular and straightforward method used to isolate the 
protein target(s).
[2]
 Examples (Figure 1.1) include several key molecular targets, such 
as trapoxin (known as K-trap Affinity Matrix), FK-506, (R)-roscovitine 
((S)-roscovitine used as negative control), withaferin A, (-)-diazonamide A 
(seco-analog used as negative control), stauprimide, QS11, thalidomide, pateamine A, 
ICG-001 and so on.
[3]
 In this method, a chemical derivative of the bioactive small 
molecule is covalently immobilized on a solid matrix support (e.g., agarose, sepharose 
or magnetic beads). Then, the SMlinked beads are incubated with protein extracts, 
followed by extensive washing to remove nonspecifically bound proteins. Finally, the 
binding proteins are eluted with excess free drug or under denaturing conditions. 
Small molecule-immobilized chromatography is certainly a very useful tool to unravel 
unknown protein targets of natural products. However, this method typically involves 
a solid support that can only capture potential protein target(s) in vitro but not in 
living system, especially given the fact that certain SMprotein interactions may 
require conditions in the living systems (i.e., native cellular environments) that are not 
preserved in protein extracts.
[4]
 Moreover, it is often challenging to prepare SM 
affinity reagents that retain the desired biological activity. To address these issues, a 
new chemical proteomics strategy, called activity-based protein profiling (ABPP), 
which makes use of small molecules that can covalently attach to catalytic residues in 
an enzyme active site, has recently been successfully applied to the elucidation of the 




 have been published recently in the field of ABPP describing the variety of 
probes and breadth of applications of this technology. Because this field is covered in 
detail elsewhere, only the basic concepts and advances in ABPP with a particular 
















Figure 1.1 Representative structures of molecules whose target proteins (in brackets) 
were identified using affinity chromatography. The compounds of interest are 
modified and immobilized onto either a solid support or a biotin moiety (indicated by 





1.2 Activity-Based Protein Profiling (ABPP) 
1.2.1 Introduction  
The completion of the human genome sequencing project
[6] 
has provided a 
wealth of new information that have shifted the focus of new biotechnologies from 
those that facilitate the characterization of single genes or proteins to methods that 
enable the rapid monitoring of all possible transcripts (so called genomics) or proteins 
(so called proteomics) contained in a living organism. Proteomics is the study of the 
proteome (defined as the entire complement of proteins expressed by a cell, tissue, or 
organism) and involves the technology used to identify and characterize the 
expression pattern and function of protein on a global scale.
[7]
 In human, such 
information is crucial in order to design better diagnostic and therapeutic strategies.  
Conventional proteomics approaches that heavily rely on two-dimensional 
gel electrophoresis (2DE) encounter difficulty detecting important fractions of the 
proteome, including membrane-associated and low-abundance proteins.
[8]
 Therefore, 
over the years, several gel-free proteomics techniques have been developed to the use 
of isotopic tagging of proteins (ICAT) or peptides (iTRAQ) or metabolic 
incorporation of isotopically tagged amino acids (SILAC),
[9]
 which enables the 
comparative analysis of protein expression levels by liquid chromatograph-tandem 
MS (LC-MS/MS). LC-based strategies have overcome some of the resolution 
problems of 2DE, providing improved access to proteins of low-abundance; however, 
these techniques, like 2DE, are restricted to detecting changes in protein abundance 
(part A of Figure 1.2). However, the abundance of a protein is not necessarily directly 
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coupled to its activity. Moreover, numerous posttranslational forms of protein 
regulation, including those governed by protein–protein interactions, remain 
undetected.
[10]
 To address these limitations, a chemical proteomics strategy referred to 
as activity-based protein profiling (ABPP) has been introduced that makes use of 
synthetic small molecules that can be used to covalently modify a set of related 
enzymes in an activity dependent manner and subsequently allow their purification 
and/or identification. Therefore, such an approach could potentially distinguish active 














Figure 1.2 (A) Comparison of conventional proteomic approaches and ABPP. (B) 
Experimental workflow in a classical ABPP. 
Protomics
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1.2.2 Activity-Based Probe Design 
The small molecules used in ABPP, termed activity-based probes (ABPs),
[5]
 
generally consist of three basic elements: 1) a warhead (or an electrophilic trap) that 
can covalently attach to the active site of an enzyme, 2) a flexible linker that connects 
with 3) a tag that can be use for visualization (e.g. fluorophore, isotope), isolation and 
identification (e.g., biotin). In a typical ABPP proteomic experiment (part B of Figure 
1.2), a proteome is labeled by ABP and probe-labeled proteins detected by either 
in-gel fluorescence scanning (for fluorophore-conjugated probes) or avidin 
enrichment, trypsin digestion and liquid chromatograpy–mass spectrometry (LC–MS) 
analysis (for biotinylated probes).  
ABPs can be classified as either mechanism-based or affinity-based, 
depending on the mode by which the covalent linkage with the enzyme is established. 
Mechanism-based ABPs (also known as a directed approach), which are mainly based 
on irreversible enzyme inhibitors (or suicide inhibitors), use electrophilic warheads 
that specifically react with catalytic residues in the enzyme’s active site.[11] 
Examples
[12]
 include fluorophosphonate (FP) which reacts highly specifically with the 
enzymes of the serine hydrolase family, epoxide, diazomethyl ketone, acyloxymethyl 
ketone (AOMK), and -haloketones showing a clear preference for cysteine proteases 
(Figure 1.3). Such an ABP could provide a fundamental understanding of the related 
enzyme’s catalytic mechanism, substrate and/or inhibitor preference as well as 
functional roles. As noted, mechanism-based ABP is only applicable to targets that 
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possess a nucleophilic active site residue (mainly Ser, Cys or Lys) susceptible to 
covalent labeling by an electrophile. When this is lacking, three strategies have been 
developed for the design of affinity-based ABPs: (i) a photoreactive cross-linker (e.g., 
benzophenone, diazirine, aryl azide), which is conjugated to the probe that tightly 
binds within an active site, results in modification of potentially non-catalytic residues 
upon irradiation with UV light, (ii) a masked electrophile (also refered as to a latent 
electrophilic probe) that becomes activated upon cleavage by the enzyme, which 
means these reagents serve as bona fide enzyme substrates and only become into 
reactive probes after turnover. Examples include tyrosine phosphatase, glycosidase, 
and protease quinone methide probes,
 [13]
 and (iii) a novel ligand-directed tosyl (LDT) 
chemistry that can site-specifically introduce synthetic probes to the surface of 



































Figure 1.3 Structures of probes based on reactive groups (colored in red), 




1.2.3 Bioorthogonal Chemistry in ABPP 
A drawback encountered in classic ABPP, however, is the finding that the 
presence of the reporter entity generally diminishes or even precludes cellular uptake 
and distribution of probes, necessitating cell lysis prior to the labeling experiment. As 
mentioned before, certain SMprotein interactions may require conditions in the 
living systems that are not preserved in cell lysates. To overcome this shortcoming, 
several small latent ligation groups (mainly an alkyne or azide group) for a reporter 
tag have been introduced, with the idea that such constructs would likely to be 
cell-permeable. After labeling in living cells, attachment of the reporter tag may then 
be performed ex vivo through highly specific bioorthogonal ligation chemistry that 
show low reactivity towards other biomolecules, and can be easily conducted in 
aqueous media, such as the Staudinger ligation
[15]
(Figure 1.4), and the copper 
catalyzed or strain-promoted azide alkyne cycloadditions (often referred to as “click” 
chemistry)
[16]
. However, the Staudinger ligation, initially developed to probe protein 
glycosylation events on cell surfaces, suffers from slow reaction kinetics and 
background phosphine oxidiation. CuAAC is a rapid reaction, but the Cu(I) catalyst is 
toxic to live cells, limiting its applications. The strain-promoted cycloaddition with 
fluorinated cyclooctyne reagents is currently the optimal bioorthogonal reaction for 
the azide, but the cyclooctynes are difficult to synthesize and still exhibit reactivity 
only one order of magnitude faster than the Staudinger ligation. These limitations 
have therefore promoted the recent expansion of the arsenal of other bioorthogonal 
chemical reactions used to label proteins in living systems, such as inverse-electron 
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demand Diels-Alder reactions between 1,2,4,5-tetrazines and strained dienophiles 
such as norbornene, cyclooctyne, and trans-cyclooctene.
[17]
 The main advantages of 
this reaction are the following: there is no requirement of a catalyst; the bimolecular 






) with appropriate choice of 
tetrazine and strained dienophile. To date, the main limitation to the reaction 
compared to conventional azide/alkyne or Staudinger ligations is that the strained 
alkenes are rather large, perhaps preventing their metabolic incorporation. It should be 
noted that although alkenes are naturally found in lipids, fatty acids, cofactors and 
other natural products, most of other new bioorthogonal reactions employ activated 
alkenes that could be able to react selectively in the presence of endogenous olefins.  
With these successful strategies, “tag-free” probes carrying small surrogate 
tags have been developed for various classes of enzymes with enhanced selectivity 
and improved pharmacological properties for selective labeling of protein targets in 
living cells (Figure 1.5). Recent examples include serine phospholipases, protein 
phosphatase methylesterase-1 (e.g., aza--lactams), transglutaminase-2 (e.g., 
3-bromo-4,5-dihydroisoxazoles), α-haloacetamidines for dimethylarginine 
dimethylaminohydrolase (DDAH) or protein arginine deiminase (PAD), cytochrome 
P450s (i.e., aryl alkynes are oxidized to reactive ketene intermediates that inactivate 
P450s by covalent adduction to the protein), 14-3-3  (e.g., isothiocyanate as an 
affinity bait), RSK kinase (e.g., fmk-pa, fluoromethyl ketone-propargylamine), and 
Abelson (Abl) tyrosine kinase (e.g., a derivative of Imatinib) as well as histone 
deacetylases (HDACs), and methionine aminopeptidase.
[18]
 Of note, the decoupling of 
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detection tags from chemical probes alters and often improves the specificity of 
protein labeling compared to directly modified chemical probes, which is readily 























Figure 1.4 Two-step ABPP labeling assisted by the bioorthogonal reactions, such as 


































Figure 1.5 “Tag-free” probes for two-step ABPP labeling ordered by enzyme or 




Although the aforementioned directed-ABPs derived from known inhibitors 
are widely employed for targeting various classes of enzymes, non-directed ABPs are 
particularly useful for enzyme classes that do not have well-defined cognate affinity 
labels. A combinatorial or non-directed approach usually employs libraries of probes 
to identify “specific” protein-labeling events. Examples include sulfonate esters,[19] 
and α-chloroacetamides.[20] In addition to well-defined electrophiles (e.g. sulfonate 
ester, or α-chloroacetamide) serving as the warhead in non-directed approaches, 
reactive groups akin to those present in bioactive natural products like fumagillin, 
luminacin D and FR901464 have also been used to profile proteomes (Figure 1.6). 
Evans et al. used a 50-member natural product inspired spiroepoxide library for in situ 
profiling of mechanistic different enzyme classes and identified a compound,
[4]
 MJE3 
that inhibits breast cancer cell proliferation. Further analysis identified brain-type 
phosphoglycerate mutase-1 (PGAM-1), a key enzyme in glycolysis that converts 
3-phosphoglycerate to 2-phosphoglycerate as cellular target for MJE3 and 
interestingly enough, PGAM-1 inhibition was observed only in intact cells, thereby 
implying PGAM1 as a regulator of cancer cell viability. These findings are of 
pharmacological significance since it provides straightforward ways to couple cellular 
phenotype with underlying biochemical mechanisms and further expands the utility of 
non-directed probes as invaluable tools to probe cellular functions in forward 
chemical genetic screens.  
Similar approach was also applied to study the Hepatitis C Virus (HCV) 
replication by Pezacki and coworkers.
[21]
 In this study, non-directed phenyl sulfonate 
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ester probe library with alkyne handle was used to selectively target a broad range of 
enzyme families that show differential activity during HCV replication. Most recently, 
Sieber group employing an ABP library of trans--lactones to different bacterial 
proteomes resulted in identification of over twenty enzymes with either a nucleophilic 
cysteine or serine residue in their active sites.
[22]
 Among the identified enzymes, a key 
virulence regulator ClpP in S. aureus is of particular interest, as it is essential for the 










Figure 1.6 “Tag-free” non-directed ABPs inspired by natural products containing 
well-defined reactive groups. 
 
Another major application of bioorthogonal chemistry in ABPP is linker 
systems that allow mild cleavage under conditions ideally orthogonal to 
functionalities present in the biological system. Biotinylated ABPs are often used for 
enrichment of captured enzymes, for instance, by pull-down with avidin-coated beads. 
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The main disadvantage of this approach, however, is the harsh denaturing conditions 
required to disrupt the biotin-avidin interation, as thus both endogenously biotinylated 
proteins and (denatured) avidin can contaminate the target proteins. To address this 
issue, several groups have developed linker systems that can be incorporated in a 
given ABP, or alternatively in a bioorthogonal reagent for two-step ABPP labeling, 
and that can be cleaved in a chemo-selective manner after affinity pull-down. 
Examples (Figure 1.7) include the disulfide, diazobenzene, bisaryl hydrazone, and the 
enzyme (e.g., TEV) cleavable or the photocleavable linker.
[23]
 Clearly, synthetic 
chemistry has played a major role by providing additional orthogonal functional 
group and new cleavable linkers and improving the kinetics and selectivities of the 












Figure 1.7 Cleavable linkers (colored in red) in ABPP that can be cleaved in a 
selective manner (colored in blue) after affinity pull-down. 
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1.2.4 Application of ABPP for Target ID of Natural Products 
Natural products, and their derivatives and mimics, have rendered an 
enormous contribution to the treatment of diseases such as infentions and cancers over 
the past decades. Notable examples include antibiotics -lactam penicillin G, the 
tetracyclines (e.g., tetracycline, chlortetracycline), the glycopeptides vancomycin, and 
the lipopetide daptomycin; Taxol (Paclitaxel), vinca alkaloids, and etoposide are 
plant-derived chemotherapeutic anti-cancer agents.
[24]
 Natural products are 
biosynthesized or modified by proteins, and as such natural product have to bind them. 
However, the interaction of many bioactive natural products with their target proteins 
is often unknown. Recent advances in proteomics (e.g., chemical proteomics, 
expression proteomics), yeast three hybrid (Y3H) system, phage and mRNA display 
technologies have greatly accelerated target identification.
[1b]
 In this section I 
overview the recent application of ABPP to elucidate the potential target(s) of a given 
natural product (Figure 1.8).  
Wortmannin is a metabolite natural product produced by the fungus 
Penicillium wortmannii and has long been recognized as a highly specific inhibitor of 
phosphoinositide-3 kinase (PI-3K) enzyme superfamily. Wortmannin reacts in an 
irreversible manner with a critical lysine residue in the kinase domain of the PI- 3 
kinases, and this lysine is conserved in the different PI-3 kinase and PIKK family 
members. Attachment of tags (e.g., BODIPY, rhodamine, or biotin) to the wortmannin 
scaffold has enabled both visualization and purification of target proteins in lysates 
and in living cells. Other than previously reported target PI-3 kinase and its related 
 18 
kinases, Liu et al. identified Polo-like kinase 1 (PLK1) and Polo-like kinase 3 (PLK3), 
which were further confirmed by in vitro kinase assay with wortmannin.
[25]
 
Additionally, BODIPY-wortmannin, a cell permeable probe may provide a potentially 
tool for studying the biological activity of target kinases within living cells. Using 
similar approach appending a reporter group to natural product structure, many more 
ABPsbased on natural products have been developed and their target proteins have 
been identified. Examples include microcycins targeting serine/threonine protein 
phospharases in Jurkat cell lysates, cyclostreptin (-)-FR182877 targeting 
carboxylesterase-1 in the proteome derived from a variety of mouse tissues.
[26a]
 
Recently, Buey et al. found that cyclostreptin binds covalently to -tubulin in cellular 
microtubules either with Thr220 (at the outer surface of a pore in the microtubule wall) 
or Asn228 (at the luminal paclitaxel site), but only Thr220 is modified when 
cyclostreptin interacts with unpolymerized tubulin.
[26b]
 One further example is the 
showdomycin probe that can be used to identify the molecular targets in living 
Gram-positive and Gram-negative pathogenic bacteria, thereby explaining the 
antibacterial effects of showdomycin.
[27]
  
Since HUN-7293 interacts reversibly with its targets, a photoreactive group 
(e.g., diazirine) has been incorporated into the HUN-7293 scaffold resulting in 
identification of the target protein, Sec61,in endoplasmic reticulum (ER) microsome 
fraction.
[28]
 Example of this type of affinity-based photo-cross-linking probe includes 
the vancomycin-based probe that revealed the specific labeling of two previously 
unknown targets, the bifunctional antolysin (ATL) in methicillin-resistant S. aureus 
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(MRSA) and a peptide ABC transporter (pABC) in vancomycin susceptible E. 
faecalis (VSE).
[29]
 Staub et al. using probes derived from the naturally occurring 
antibiotics ampicillin, cephalosporin and aztreonam as well as some synthetic 
-lactams to reveal a variety of penicillin binding proteins (PBPs) and additional 
enzymes, including a resistance-associated -lactamase via tunning the core 
 -lactam ring.[30] Moreover, probes were also used to profile target 















Figure 1.8 Examples of natural products with either a reactive group (arrow) or 
photoreactive group used as ABPs to identify their target proteins. 
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1.2.5 Application of ABPP for Imaging of Protein Activities 
ABPs have also been adapted for demanding application such as monitoring 
of protein activity and revealing their spatial localization in real time in living systems. 
Several cell-permeable mechanism-based probes such as DCG-04, MGP140 and 
GB111 have been generated for visualization of cathepsin cysteine proteases in live 
cells and in vivo
[31]
 (Figure 1.9). These probes contain either an epoxide (e.g., 
DCG-04, MGP140), or an acyloxymethylketone (AOMK) reactive electrophile (e.g., 
GB111) that covalently reacts with active site cysteine residue. Likewise, MV151 has 
been reported to label numerous active subunits of the proteasome and 
immunoproteasome in living cells. Additionally, administration of MV151 to mice 
allowed for in vivo labeling of proteasomes, which correlated with inhibition of 
proteasomal degradation in the affected tissues.
[32] 
While the aforementioned cell- 
permeable probes have enabled the visualization of enzyme activity in live systems, 
these have limitations due to large fluorophore groups with their potential ability to 
alter the specificity of protein labeling or passive diffusion into cells with background 
fluorescence. To address this issue, the bioorthogonal reactions have been applied to 
facilitate imaging of protein activity. For instance, Hang et al. reported “tag-free” 
mechanism-based probe azido-E64 equipped with a small azide handle that can be 
conjugated with phosphine-biotin (p-biotin) via the Staudinger ligation, enabling the 
visualization active cathepsin B in S. typhimurium-infected primary macrophage and 
also allowing affinity enrichment of labeled proteins for MS-base proteomic 
analysis.
[33]
 In addition to using bioorthogonal labeling reactions for visualizing 
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enzyme activities, Edgington et al. reported the AOMK-based caspase probe, 
tAB50-Cy5a containing a Tat peptide that makes use of multiple positively charged 
amino acids to carry attached cargo across membranes and has previously been used 
to increase cellular uptake.
[34]
 The author used this probe to monitor the kinetics of 
apoptosis in multiple mouse models. 
Recently, the development of quenched activity-based probes (qABPs) 
provides another alterative solution for reducing background fluorescence, whilst 
enabling live cell imaging of enzyme activity. Blum et al. reported cell-permeable 
AOMK-based probes that are modified with a fluorophore (e.g., BODIPY) and 
quencher (e.g., QSY7) such that covalent modification of an active cathepsin cysteine 
protease would result in a loss of the quenching group with the simultaneous recovery 
of the fluorescence (“turn-on”).[35a] Furthermore, using quenched near-infra red ABPs 
(qNIRF-ABP) the authors were able to extend their approach to the in vivo 
non-invasive, whole-body imaging in mice bearing grafted tumours.
[35b]
 Importantly 
the stable nature of the probes was useful for ex vivo biochemical identification of 
specific proteases as well as in monitoring small molecule inhibition of protease 




















Figure 1.9 Examples of ABPs derive from suicide inhibitor motifs (see dashed boxes) 
that have been use to visualize their active target proteins in living systems. 
 
While these qABPs have provided good sensitivity for detecting endogenous 
cysteine protease activity, one of the major limitations of the AOMK-based qABPs 
lies in that its target protein is deactivated upon labeling by qABP due to its suicide 
inhibitor nature. Thus, there is no signal amplification of the target enzymes, thereby 
limiting its sensitivity when screening low-abundance targets. Most recently, Hu et al. 
reported a new class of qABPs which are based on quinine methide chemistry for 
imaging of enzyme activity in live cells (Figure 1.10). Importantly, these qABPs 
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allow amplification of the target signal in situ, as they do not inactivate the enzyme 
target. Additionally, the authors also have also incorporated two-photon dyes into 
modular probe design, enabling firstly activity-based, fluorogenic two-photon 















Figure 1.10 Structures of qABPs based on quinine methide chemistry that consist of 
the motifs recognized by active enzymes (see dashed boxes). 
 
Collectively, all these examples bode well for the future, in which creative 
thinking from an organic chemistry background will continue to provide new tools 
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, or tetrahydrolipstatin (THL), is an FDA-approved antiobesity 
drug with potential antitumor activities. Cellular off-targets and potential side effects 
of Orlistat in cancer therapies, however, have not been extensively explored thus far. 
In this study, we report the total of synthesis of THL-like protein-reactive probes, in 
which extremely conservative modifications (i.e., an alkyne handle) were introduced 
in the parental THL structure to maintain the native biological properties of Orlistat, 
while providing the necessary functionality for target identification via the 
bio-orthogonal click chemistry. With these natural product-like, cell-permeable probes, 
we were able to demonstrate, for the first time, this chemical proteomic approach is 
suitable for the identification of previously unknown cellular targets of Orlistat. In 
addition to the expected fatty acid synthase (FAS), we identified a total of eight new 
targets, some of which were further validated by experiments including Western 
blotting, recombinant protein expression, and site-directed mutagenesis. Our findings 
have important implications in the consideration of Orlistat as a potential anticancer 
drug at its early stages of development for cancer therapy. Our strategy should be 
broadly useful for off-target identification against quite a number of existing drugs 







Drug discovery is a long and costly process, yet most drugs have side effects, 
ranging from simple nuisances to life-threatening complications.
[37]
 Unanticipated 
effects of a drug, often revealed either during clinical trials or sometimes after the drug 
enters the market, could lead to termination of a drug development program/recall of 
the drug, or, in some rare cases where the effects are beneficial, new drug 
applications.
[37b-c]
 Therefore one of the most critical steps in the drug discovery process 
is the effective identification of the so-called off-targets and anticipation of their 
potential side effects a priori. 
Orlistat
TM
, a saturated derivative of naturally occuring lipstatin, which was 
isolated from the bacterium Streptomyces toxytricini, is administered orally as an 
anti-obesity drug. It works primarily on pancreatic and gastric lipases within the 
gastrointestinal (GI) tract.
[38]
 Pancreatic lipase is the key enzyme of dietary 
triglyceride absorption by hydrolyzing triglycerides into diglycerides and 
subsequently into monoglycerides and free fatty acids. Orlistat forms a covalent bond 
with the active site serine residue of pancreatic lipase, thereby blocking the hydrolysis 
of triglycerides from nutrition into free fatty acids (Figure 2.1). Recently, Orlistat was 
found to inhibit the thioesterase domain of fatty acid synthase (FAS), an enzyme 
essential for the growth of cancer cells, but not normal cells.
[39,40]
 By effectively 
blocking the cellular FAS activity, Orlistat induces endoplasmic reticulum stress in 
tumor cells, inhibits endothelial cell proliferation and angiogenesis, and consequently 
delays tumor progression on a variety cancer cells, including prostate, breast, ovary, 
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and melanoma cancer cells.
[39] 
As a result, this compound (as well as other orlistat-like 
analogs with improved potency and bioavailability
[41]
) is being pursued as a promising 
anti-cancer drug. Cellular off-targets and potential side effects of orlistat in cancer 
therapies, however, have not been extensively explored thus far.
[42]
 Our long-term 
research goals focus on developing novel chemical proteomic strategies that enable 
large-scale studies of therapeutically relevant enzymes, as well as small molecules (i.e. 
potential drug candidates) that can modulate these enzymes’ cellular activities.[43] In the 
current study, we set out to look for new cellular targets, including off-targets, of orlistat 
at its early stages of development for cancer therapy. Herein, we report, for the first 
time, by using a novel chemical proteomic approach, the identification and putative 



































Figure 2.2. Surface representation of the complex (the thioesterase domain of FAS 
inhibited by Orlistat) highlighting the different binding channels and pockets (PDB 
entry 2PX6, image generated with PyMOL).  
 
 
2.2 Results and Discussion 




Our strategy is based on the well-established activity-based protein profiling 
(ABPP) approach,
[5]
 by making use of THL-like protein-reactive probes 2-1, 2-2 and 
2-3 (i.e. THL-R, THL-L and THL-T, respectively, in Figure 2.3). We took advantage of 
several key properties known to THL in the design of our probes: (1) THL (being 
derived from a natural product) is cell-permeable, making our probes applicable for 
direct in situ cell-based screening; (2) THL reacts with its known cellular targets via a 





 in pancreatic lipase and FAS
[39b]
, respectively) of the 
target protein, resulting in the formation of an isolatable protein/THL complex; (3) 
previous minor structural modifications at either the 16-carbon or 6-carbon aliphatic 
chains of THL did not significantly alter its native biological activities.
[41b]
  
Accordingly, probes 2-1, and 2-2, in which a terminal C-C triple bond was introduced 
into THL to replace the terminal C-C single bond of the aliphatic chains, were 
synthesized. We also synthesized probe 2-3 by substituting the CHO group in the 
N-formyl-L-leucine moiety of THL with a propiolic acyl group (Figure 2.3; shaded in 
pink). These extremely conservative modifications of introducing an alkyne handle in 
the parental THL structure were aimed at maintaining the native biological properties 
of Orlistat, whilst providing the necessary functionality for identification and 
characterization (i.e. imaging) of previously unknown cellular targets by downstream 




























Figure 2.3. Overall strategy for cell-based proteome profiling of potential Orlistat targets using alkyne-containing, cell-permeable THL 
analogues, 2-1, 2-2 & 2-3. The alkyne handles in the probes are shaded (pink circle). 
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2.2.2 Retrosynthetic Analysis 
Numerous strategies for the total synthesis of THL have been reported.
[41] 
Our retrosynthetic analysis is outlined in Scheme 2.1. THL-R can be readily derived 
from β-lactone intermediate via simple silyl deprotection and Mitsunobu esterification. 
Trans-β-lactone in turn could be obtained using a tandem Mukaiyama 
aldol-lactonization (TMAL) reaction of optically active TBS-protected -hydroxy 
aldehyde and thiopyridyl ketene acetal as the key step. The TBS-protected -hydroxy 
aldehyde can be produced from homoallylic alcohol in a straightforward 2-step 
sequence of TBS-protection and ozonolysis/oxidation. Chiral homoallylic alcohol 
would be prepared from asymmetric allylation of aldehyde or resolution of racemic 











Scheme 2.1. Retrosynthetic analysis of THL-R (2-1). 
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2.2.3 Synthesi of Orlistat-like Probes 
Synthesis of optically pure aldehyde 2-8a relied on the asymmetric resolution 
of racemic allylic alcohols (Scheme 2.2). Briefly, lauraldehyde 2-4, which was 
prepared from dodecan-1-ol by PCC oxidation and treated with allylmagnesium 
bromide followed by esterification with O-acetyl-D-mandelic acid gave the 
diastereomeric esters 2-5a and 2-5b which could be easily separated by 
chromatography. Deacylation of 2-5a led to the optically pure homoallylic alcohol 
2-6a. The diastereomeric 2-5b could be converted to the desired 2-6a by 
desterification and inversion of configuration via a modified Mitsunobu reaction. The 
alcohol 2-6a was then TBS-protected and the olefin oxidatively cleaved with 
ozonolysis to afford 2-8a. The key ZnCl2-mediated, tandem Mukaiyama 
aldol-lactonization (TMAL) between the -hydroxy aldehyde 2-8a and the thiopyridyl 
ketene acetal 2-11 (prepared in three steps involving alkylation of 6-bromohexanoic 
acid with ethynyltrimethylsilane, generation of thiopyridyl ester 2-10 and an 
enolization/silylation) giving the desired -lactone as a mixture of diastereomers 
(~9:1 anti/syn) with complete selectivity for the trans--lactone. Following 
O-desilylation and silica gel separation, the enantiomerically pure -hydroxy 
-lactone 2-12 was isolated. The trans configuration of the -lactone core was 
unambiguously confirmed by coupling constant analysis (JH2, H3 ~ 4.4 Hz).
[41a]
 
Subsequent C-desilylation with AgNO3/2,6-lutidine gave terminal acetylene 2-13, 
which was subjected to Mitsunobu conditions with N-formyl-L-leucine (2-14) to give 







































Scheme 2.3. Synthesis of THL-R (2-1). 
 
For the synthesis of 2-2 (THL-L), an alternative route to obtain the optically 
active aldehyde 2-21 was explored (Scheme 2.4). Starting from 10-bromo-1-decanol, 
TBS-protection, alkylation of lithium acetylene, TBS-deprotection, PCC oxidation, 
and asymmetric allylation with allyltributyl stannane in the presence of chiral 
(S)-BINOL-InCl3 complex
[44]
 to afford the chiral homoallylic alcohol 2-19. The 
enantiomeric excess was determined to be 62.4% by 
1
H NMR (500 MHz) analysis of 
its S-Mosher derivative at δ 5.63, and the absolute configuration of 2-19 was 
unequivocally determined as to be R using Mosher ester analysis
[45]




Subsequently, two steps sequence of TBS-protection and oxidative cleavage gave 
2-21 which reacted with 2-23 under TMAL conditions to give 2-24 (~11:1 anti/syn) 
and eventually 2-2. For the synthesis of 2-3 (THL-T), the known hydroxyl--lactone 
2-27
 
(~8:1 anti/syn) was first prepared based on published procedures,
[5a]
 then reacted 
with 2-30 (obtained in four steps from Fmoc-Leu-OH involving O-protection, Fmoc 
deprotection, DCC coupling, and O-deprotection) under Mitsunobu conditions, giving 



























Scheme 2.5. Determination of absolute configuration of 2-19. (A) Synthesis of (S)- 
and (R)-Mosher esters 2-25 & 2-26. (B) shows the ΔδSR values from the 1H NMR 
spectra of the (S)- and (R)-MTPA esters of homoallylic alcohol 2-19. Based on model 









Scheme 2.6. Synthesis of THL-T (2-3). 
 
 
2.2.4 Effects on Cell Proliferation, Phosphorylation of eIf2and Activation of 
Caspase-8
With three probes in hand, we next evaluated their biological activities 




on previously established orlistat biology were used.
[39a, 39c-e]
 First, the 
anti-proliferation activity of the four compounds (THL-R, THL-L, THL-T & Orlistat) 
against HepG2 cells (a human hepatocellular liver carcinoma cell line) were evaluated 
using the XTT assay (part A of Figure 2.4);
[39a]
 all four compounds showed a 
dose-dependent inhibition of tumor cell proliferation over a 72 h time period with 
comparable potency. Second, we carried out comparative analysis of the compounds 
in their ability to induce phosphorylation of eIf2 in the prostate cancer PC-3 cells.[39c] 
Previous studies had shown that inhibition of FAS by Orlistat induces endoplasmic 
reticulum (ER) stress and results in the phosphorylation of the translation initiation 
factor eIF2. As shown in part B of Figure 2.4, PC-3 cells treated with different 
amounts of each compound showed similarly elevated eIF2 phosphorylation. 
Because the phosphorylation of eIF2leads to the inhibition of protein synthesis, we 
did metabolic labeling (illustrated in Figure 2.5) with azidohomoalanine (AHA, 




to measure the levels of newly synthesized proteins in 
cells treated with orlistat, THL-R or cycloheximide (a well-known protein synthesis 
inhibitor). As shown in part C of Figure 2.4, greatly reduced levels of protein 
synthesis were observed in cells treated each of the three compounds. The inhibition 
of protein synthesis was dose-dependant, which is consistent with previous findings 




. Lastly, inhibition of FAS by Orlistat 
was previously shown to induce tumor cell apoptosis by activating caspase-8.
[39e]
 We 
therefore tested the compounds against the invasive human breast cancer MCF-7 cells 
(part D of Figure 2.4); similar degrees of caspase-8 activation (as evidenced by the 
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appearance of the p41/43 bands corresponding to cleaved caspase-8) were observed 
against all four compounds (at either 5 or 25 M). Collectively, these data show the 
introduction of a terminal alkyne handle at various designated locations in Orlistat 
scaffold did not noticeably affect its biological activities, thus 2-1, 2-2 and 2-3 were 
indeed suitable chemical probes for cell-based proteome profiling and identification 











Figure 2.4. Biological evaluation of three Orlistat analogues. (A) Dose–dependent 
inhibition of HepG2 cell proliferation by Orlistat and three analogs (THL-R, THL-L 
and THL-T) using XTT assay. Data represent the average standard deviation for two 
trials. (B) Western blot analysis of eIF2 phosphorylation in PC-3 cells upon 
treatment with the four compounds. GAPDH was used as a loading control. (C) 
Inhibition of protein synthesis in HepG2 cells treated with the indicated 
concentrations of Orlistat, THL-R or CHX (cycloheximide, an inhibitor of protein 
biosynthesis) for 12 h and then pulsed with AHA (L-Azidohomoalanine) for 4 h. Cell 
lysates were prepared and subjected to click chemistry with a rhodamine-alkyne tag, 
SDS-PAGE analysis, and in-gel fluorescence scanning (fluorescent gel shown in 
grayscale). (D) Activation of caspase-8 in MCF-7 cells treated with the indicated 
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Figure 2.5. (A) Metabolic labeling with AHA and sequential click chemistry reactions 
with rho-alk allowing simultaneous visualization of the protein synthesis. (B) 
Structures of AHA, rho-alk and CHX used in this study.  
 
 
2.2.5 In situ and in vitro Proteome Profiling 
We next compared the in situ proteome reactivity profiles of the three probes 
to identify proteins that were covalently labeled by the probes in live HepG2 cells.
[4]
 
Probes (1-20 M) were directly added to the cell culture medium, either alone or in 
the presence of 100 M competing Orlistat. After 2 h, the cells were washed (to 
remove excessive probes), homogenized, incubated with rhodamine-azide (2-33) 
under click-chemistry conditions, separated by SDS/PAGE gel, and analyzed by 
in-gel fluorescence scanning (Figure 2.6). In addition to the expected FAS band, 
confirmed by treatment with an anti-FAS antibody (265 kDa, marked with red arrow 
in part C of Figure 2.7), we also observed a number of Orlistat-sensitive targets, that 
is, those labeled bands that were competed away by treatments with excessive Orlistat 
(marked with blue arrows and asterisks in parts A and B of Figure 2.6). Most of these 
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labeled bands were clearly visible even at a low probe concentration (e.g., 1 μM of 
THL-R; lane 1 in part A of Figure 2.6). Both THL-R and THL-L gave similar 
proteome labeling profiles, whereas THL-T consistently produced weaker labeled 
bands (possibly caused by inefficient click-chemistry conjugation due to 
inaccessibility of the alkyne handle located at the N-formyl-L-leucine end, which, 




To assess which nucleophilic residue of the labeled proteins might have been 
covalently modified by our probes, SDS-PAGE gels from the in situ labeling were 
subjected to in-gel treatment with hydroxylamine (NH2OH), which preferentially 
cleaves thioesters, and esters to a lesser extent, under neutral pH conditions.
[47]
 As 
shown in part C of Figure 2.6, the labeled FAS and most other Orlistat-sensitive bands 
showed a much reduced fluorescence signal upon treatment with NH2OH, suggesting 
likely involvement of a cysteine/serine residue in the labeling between these proteins 
and THL (vide infra). It is interesting to note that the labeled FAS band was to some 
degree resistant to NH2OH treatment, clearly indicating the formation of a more 




 and THL-R. In a related 
experiment, we also performed competitive ABPP with cerulenin, a known FAS 
inhibitor which irreversibly inactivates the -ketoacyl-ACP synthase domain but not 
the thioesterase domain of FAS;
[48] 
as expected (part D of Figure 2.6), Cerulenin did 
not abolish the labeling of the THL probes toward FAS as well as most other 
Orlistat-sensitive proteins. This indicates that the labeling of our probes is both target- 
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and domain-specific, and they may in the future be used to distinguish different 
domains of FAS. As shown in part E of Figure 2.6, when compared to in situ (live cell) 
labeling, similar proteome labeling profiles, albeit with significantly higher 
background labeling, were obtained when whole-cell lysates were used instead. This 
shows the importance of the in situ labeling (made possible by the cell-permeable 

































Figure 2.6. Comparison of in situ versus in vitro labeling profiles by THL analogs 
(THL-R, THL-L & THL-T) over a concentration range of 1-20 M. (A) In situ 
proteome labeling of HepG2 cells, followed by click chemistry with a 
rhodamine-azide reporter tag (2-33), SDS/PAGE analysis, and in-gel fluorescence 
scanning (fluorescent gel shown in grayscale). Multiple THL-R-sensitive targets 
(marked with blue arrows) were isolated and identified in separate reactions using 
biotin-azide tag (2-34), followed by pull-down/MS procedure, and summarized in 
Table 2.1. (B) Specifically labeled targets of THL-R were defined as proteins whose 
labeling was completed by excess Orlistat (marked with asterisks). (C) 
Hydroxylamine sensitivity of proteins (with decreased fluorescence) in live HepG2 
cells labeled with THL analogs (THL-R, THL-L & THL-T). (D) in situ competition 
experiment with Cerulenin. (E) in vitro labeling of HepG2 whole cell proteome. (F) in 
situ competition experiment with Orlistat. 
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2.2.6 Target Identification and Validation 
Subsequently, the labeled protein extract was enriched (following 
click-chemistry conjugation with biotin-azide 2-34) by avidin-agarose beads, 
separated by SDS-PAGE gel, confirmed by strepavidin blotting, subjected to in-gel 
trypsin digestion, and identified by MS/MS analysis. In addition to FAS, eight new 
proteins were identified (numbered 2 to 9, in part A of Figure 2.7 & Table 2.1), of 
which one is an unnamed protein. Two of the proteins, GAPDH and -tubulin, are 
house-keeping genes constitutively expressed in most cell lines but are known to be 
expressed more highly in cancer cells.
[49]
 Both GAPDH (a dehydrogenase) and 
-tubulin (a hydrolase) possess nucleophilic active-site cysteine residues. It is 
therefore not surprising they were targets of Orlistat and their labeling was reversed 
by NH2OH treatment. It should be noted that tubulins are well-known targets of 
anticancer drugs (e.g., taxol
[50]
). Three other proteins identified, RPL7a, RPL14, and 
RPS9, are ribosomal proteins. They are known to be implicated in protein synthesis, 
control of cellular transformation, tumor growth, aggressiveness and metastasis. 
Overexpression of these proteins had previously been reported in colon, brain liver, 
breast and prostate carcinoma.
[51a-d]
 In retrospect, our earlier findings that protein 
synthesis was greatly inhibited in HepG2 cells treated with Orlistat, as shown in part 
C of Figure 2.4, may also imply that these ribosomal proteins are probable cellular 
targets of the drug. The remaining two proteins, Annexin A2 and Hsp90AB1, are 
















E value ion score localization protein funtion 
2 Hsp90AB1 Gi39644662 75 088/72 18 136 2e-007 43 
cytoplasm, 
nucleus 
molecule chaperone with 
ATPase acitivity; stress 
response 





4 -tubulin Gi29788785 49 671/52 17 536 3.2e-049 116 nucleus 
GTPase acitivity and cell 
division cell division 
5 Annexin A2 Gi4757756 38 808/39 16 185 2.5e-012 38 
cytoplasm, 
nucleus 
calcium binding; cell division 
6 GAPDH Gi7669492 36 201/36 17 296 2e-023 62 
cytoplasm, 
nucleus 
glycolysis; energy production 
7 RPL7a Gi4506661 30 148/30 11 202 4.9e-014 72 
cytoplasm, 
ribosome 
biogenesis; protein synthesis 
8 RPL14 Gi7513316 23 902/23 9 149 9.8e-009 65 
cytoplasm, 
ribosome 
biogenesis; protein synthesis 
9 RPS9 Gi14141193 22 635/22 16 213 3.9e-015 47 
cytoplasm, 
ribosome 
biogenesis; protein synthesis 




In an effort to further validate the MS results, we carried out pull-down and 
Western blotting experiments with the respective antibodies (part C of Figure 2.7);
[52]
 
results confirmed all proteins tested (including FAS) were indeed positively labeled 
by THL-R, and thus likely are true cellular targets of orlistat. Four of the proteins 
(-tubulin, GAPDH, RPL7a, & RPL14) were taken for additional validation 
experiments. First, the c-Myc fusions of these proteins were transiently expressed in 
HEK-293T cells (part B of Figure 2.7), labeled (by THL-R in situ), immune-purified 
(with c-Myc agarose beads), subjected to click chemistry (with rhodamine-azide 2-33), 
and analyzed by SDS-PAGE (part D of Figure 2.7); results unambiguously confirmed 
that all four proteins were fluorescently labeled by the probe.  
To confirm whether labeling of the probe is active site-directed, GAPDH, 
whose active site residue Cys
151
 had previously been characterized,
[16b]
 was taken as 
an example for further site-directed mutagenesis experiments. GAPDH is a 
multifunction protein and well known for its primary role as a glycolytic enzyme. 
Recently, increasing evidence has suggested that this enzyme is also involved in a 
variety of activities which are unrelated to energy production, including membrane 
fusion, microtubule bundling, DNA repair, and apoptosis.
[49b]
 An active site (Cys
151
 to 
Ala) mutant of GAPDH was therefore generated, transiently expressed and purified 
from HEK-293T cells, labeled with THL-R, reacted with rhodamine-azide 2-33, then 
finally analyzed by SDS-PAGE followed by in-gel fluorescence scanning (part E of 
Figure 2.7); as expected, probe THL-R only labeled the wild-type GAPDH and not 
the Cys151Ala mutant, thus confirming Cys
151
 as the residue in GAPDH being 
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covalently labeled by THL-R. This also confirms the active site-directed nature of the 
probe.  
It should be noted that, in a series of recent reports as described in Chapter 
1,
[22]
 Sieber et al. had developed activity-based probes based on small molecule 
libraries containing a reactive -lactone moiety. The authors concluded that -lactones 
are promising privileged structures and could be used to identify a variety of 
mechanistically distinct enzymes. Our Orlistat-based probes, though structurally much 
more complex, appear to behave similarly and are capable of targeting a number of 
other cellular proteins in addition to FAS. Even though the exact physiological roles 
of these proteins in connection with Orlistat and its pharmacological effects have not 
been established from this study, we believe these putative cellular targets of Orlistat 




























Figure 2.7. Affinity pull-down and target validation of the identified “hits”. (A) Silver 
staining of gels of pulled-down fractions from THL-R-labeled or DMSO-treated 
HepG2 live cell lysates. (B) Western blotting of recombinantly expressed proteins 
with anti-c-Myc. (C) Western blot analysis of pulled-down fractions of HepG2 live 
cells treated with THL-R (or DMSO as negative controls; right lanes) with their 
respective antibodies. Biotin-azide 2-34 was used in the click chemistry with 
avidin-agarose beads for pull-down experiments. (D) In situ labeling of recombinantly 
expressed -tubulin, GAPDH, RPL7a & RPL14 by THL-R (fluorescent gel shown in 
grayscale). (E) Comparative analysis of labeling of wild-type GAPDH and Cys
151 
Ala 
mutant (upper panel; fluorescent gel shown in grayscale); (lower panel, silver-stained 






















































dA                               B













































































2.2.7 Cellular Imaging 
To demonstrate the utility of our cell-permeable probes for cellular imaging 
of Orlistat targets, we performed fluorescence microscopy to visualize probe-treated 
cells (Figure 2.8). Live HepG2 cells were first treated with THL-R (2-1), fixed with 
PFA, permeabilized with Triton X-100, conjugated to rhodamine-azide (2-33) by click 
chemistry and imaged (colored in Red). Immunofluorescence was also carried out on 
the same cells to visualize the localization of endogenous FAS (colored in Green in 
top panels). Minimal fluorescence was observed in samples treated with only DMSO, 
whereas in THL-R treated cells, fluorescence was mostly distributed in endoplasmic 
reticulum (ER). Note that endogenous FAS was mostly cytosolic (which includes ER). 
Thus our imaging results are consistent with previous findings that inhibition of FAS 
with Orlistat induces ER stress specifically in tumor cells.
[3c]
 We take note, however, 
that, at its current state, THL-R might not be the most suitable chemical probe for 
bioimaging of FAS, as it also labels a number of other cellular proteins (as evidenced 


























Figure 2.8. Cellular imaging of HepG2 cells treated with probes. (A) 
Immunofluorescence analysis of FAS in HepG2 cells not labeled in the absence or 
labeled in the presence of THL-R (20 M). (B) Fluorescence microsocopy of HepG2 
cells labeled with 20 M probes (i.e., THL-R, THL-L, and THL-T) or DMSO. Live 
cells were treated with probe for 2 h, fixed, permeabilized, reacted with 
rhodamine-azide (10 M; colored in red), incubated with anti-FAS primary antibodies, 





 FL), and followed by Hoechst (blue) stain. Images were 
acquired by an Olympus IX71 inverted microscope, equipped with a 60X oil objective 
(NA 1.4, WD 0.13 mm) and CoolSNAP HQ CCD camera (Roper Scientific, Tucson, 
AZ, USA). Scale Bar = 8 m. All images were acquired similarly. 
A
B
ER                              THL-R                      Hoechst                   Overlay
ER                              THL-L                       Hoechst                  Overlay
ER                              THL-T                       Hoechst                  Overlay
ER                              DMSO                      Hoechst                   Overlay
Anti-FAS                   THL-R                       Hoechst                   Overlay




We have developed a novel chemical proteomic approach that enabled, for 
the first time, identification and putative validation of several previously unknown 
cellular targets of Orlistat. The potential of these cell-permeable probes to be used as 
future imaging probes has also been explored. Whereas further studies are needed to 
better understand the exact relevance of Orlistat and its pharmacological effects in 
relation to these newly identified cellular targets, our findings point to a likely 
scenario that these proteins might be potential off-targets of Orlistat. It is also possible 
that the antitumor activities of Orlistat might have originated from the drug’s ability to 
inhibit both FAS (as previously reported
[39]
) and some of these newly identified 
targets. In either case, our findings have important implications in consideration of 
Orlistat as a potential anticancer drug. Finally, our strategy should be broadly useful 
for off-target identification against quite a number of existing drugs and/or drug 
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, also known as tetrahydrolipstatin (THL), is an FDA-approved 
anti-obesity drug with potential anti-cancer activity. In Chapter 2, we developed a 
chemical proteomic approach, based on the Orlistat-like probe (THL-R) for 
large-scale identification of unknown cellular targets of Orlistat in human hepatocytes. 
In this chapter, we report the chemical synthesis and biological evaluation of an 
expanded set of Orlistat-like compounds, with the intention to further dissect and 
manipulate potential cellular targets of Orlistat. In doing so, we carried out 
proteome-wide activity-based profiling and large-scale pull-down/LCMS analysis of 
these compounds in live HepG2 cells, and successfully identified many putative 
cellular targets for Orlistat and its structural analogues. By qualitatively assessing the 
spectra counts of potential protein hits against each of the seventeen Orlistat 
analogues, we obtained both common and unique targets of these probes. Our results 
revealed that subtle structural modifications of Orlistat led to noticeable changes in 
both the cellular potency and target profiles of the drug. In order to further improve 
the cellular activity of Orlistat, we successfully applied the well-established 
AGT/SNAP-tag technology to our cell-permeable, benzylguanine (BG)-containing 
Orlistat variant (3-4). We showed that the drug could be delivered and effectively 
retained in different sub-cellular organelles of living cells. This strategy may provide 
a general and highly effective chemical tool for the potential sub-cellular targeting of 




Accurate and thorough determination of drugtarget interaction is of great 
importance in drug discovery. It offers invaluable biological insights for a drug 
candidate, such as its mode of action both in vitro and in vivo. It also provides clues for 
compound optimization in order to maximize the therapeutic potential and minimize 
potential cellular toxicity of a drug.
[1,54]
 Recent advances in chemical proteomics, a 
multidisciplinary research area integrating biochemistry and cell biology with organic 
synthesis and mass spectrometry, have enabled a more direct and unbiased analysis of a 
drug’s mechanism of action in the context of the proteomes as expressed in the target 
cell or the tissue of interest.
[1c,55] 
However, at present, few methods are available for 
large-scale profiling of drug-protein interaction in an in vivo setting.
[56]
 We described 
(in Chapter 2) a chemical proteomic method that makes use of natural-productlike 
small-molecule probes for proteome-wide profiling of putative drug targets in living 
cells.
[57] 
That strategy is based on the concept of activity-based protein profiling 
(ABPP), originally coined by Cravatt group and further developed by other groups.
[5]
  
In our studies, terminal-alkynecontaining probes based on OrlistatTM or 
tetrahydrolipstatin (THL, Figure 3.1), an FDA-approved anti-obesity drug, were 
developed.
[58,59] 
Orlistat works primarily on pancreatic and gastric lipases within the 
gastrointestinal (GI) tract. Recently, Orlistat and other lipstatin-based natural products 
have shown promising anti-tumor activities by potently inhibiting human fatty acid 
 54 
synthase (FAS) in tumor cells.
[39,60]
 FAS is an enzyme essential for the survival of 
cancer cells.  
In our approach, extremely conservative modifications (i.e., an alkyne handle) 
were introduced in the parental Orlistat structure to provide the necessary functionality 
for target identification via Cu(I)-catalyzed 1,3-dipolar cycloaddition (click chemistry) 
or copper catalyzed azidealkyne cycloadditions (CuAAC),[16] whilst maintaining the 
native biological properties of the drug. When combined with affinity purification and 
MS/MS analysis, we were able to identify and putatively validate several previously 
unknown cellular targets of Orlistat, including GAPDH, -tubulin, Annexin A2, 
Hsp90AB1 and three ribosomal proteins (RPL7a, RPL14 & RPS9) as described in 
Chapter 2. Although some of them are highly expressed endogenously, and their 
presence might be explained primarily by their relative cellular abundance, such 
information is important to better understand the full biological effects of a drug. 
Having said this, there are still a number of challenges that prevent Orlistat 
from being considered as a potential anti-tumor drug; it has poor solubility and 
bioavailability, and, most importantly, it lacks sufficient potency and specificity. To 
begin to address some of these issues, we and others had previously focused on the 
development of highly efficient chemistry which enable facile synthesis of Orlistat 
analogues by performing various chemical modifications at the aliphatic side chains 
around the -lactone core of the drug.[41b] In our preliminary studies using different 
Orlistat-like compounds, we found a direct linkage between chemical modifications of 
Orlistat and its cellular activities.
[57b] 
However, no further studies were carried out to 
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delineate the potential cellular targets of these analogs and their biological 
consequences. Another way to achieve good in vivo efficacy of bioactive compounds is 
to deliver them into the sub-cellular compartment of cells where the target enzyme 
resides. In this way, an increase in the effective concentration of the inhibitor (i.e. 
improved potency) with a better selectivity would be expected. In fact, such 
sub-cellular targeting has recently been demonstrated successfully for several 
inhibitors and smallmolecule probes in cultured cells.
[61]
 Herein, we describe further 
chemical and cellular modifications of Orlistat with the ultimate aim to improve its 
cellular activities. By using an expanded set of new Orlistat-like probes, we 
performed in situ proteome-profiling experiments following treatment of live HepG2 
cells with our probes (Figure 3.2). Large-scale pull-down/LCMS identifications of 
potential cellular targets were subsequently conducted. From these studies, both 
common and unique protein targets of Orlistat-like analogues were identified. In order 
to further improve Orlistat’s cellular activities, we developed a “cellular modification” 
strategy to deliver our cell-permeable Orlistat variant to different sub-cellular 
organelles in living cells (Figure 3.5). This strategy was successfully implemented by 






















3.2 Results and Discussion 
3.2.1 Design of a Library of Orlistat-Like Natural Product-Based Probes 
The design of Orlistat-like probes was based on the general structure of a 
number of naturally occurring congeners of lipstatin, such as lipstatin, esterastin, 
valilactone and panclicin A-D (Figure 3.1), and our previously reported three probes 
in Chapter 2, THL-R, THL-L and THL-T, in which a terminal C-C single bond in one 
of the aliphatic chains in the parental Orlistat structure was substituted with a C-C 
triple bond. This extremely conservative modification was previously shown to enable 
full retention of the native biological activities of Orlistat, and at the same time allow 
subsequent chemical profiling/target identification by the downstream conjugation of 
reporter tags via the bio-orthogonal click chemistry. We now wish to describe the 
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synthesis, anti-proliferation evaluation and proteomic profiling results of an expanded 
list of Orlistat analogs incorporating various degrees of molecular complexities (i.e., 
changes in the position of the terminal alkyne handle, the amino ester and chirality). 
This detailed investigation has refined our present understanding of the 
anti-proliferative role played by Orlistat and established certain structure-activity 
relationships (SARs) within this drug’s structural motif from which next generations 
of designed analogs may emerge. To this end, sixteen new analogs of Orlistat were 
synthesized for the first time. Together with the three previously reported compounds 
(THL-R, THL-L & THL-R, hereafter renamed as 3-1a, 3-2a & 3-3a, respectively) and 
two key intermediates (2-13 and 2-24), all twenty-one compounds were used in this 
study. In the analogue series 3-1b-j, the left-hand aliphatic side chain remained intact, 
whilst the nature of amino ester and/or the chirality at C3, C4 and C6 positions were 
varied strategically. In the analogue series 3-2b-f, the right-hand aliphatic side chain 
was kept constant, whilst the structure of the amino ester and the chirality at C3, C4 
and C6 positions (3-2f, containing an N-formyl-L-leucine moiety) were altered. For 
the analogue series 3b, further structural changes were made at the N-formyl group by 
the introduction of either a long alkyne-containing acyl group (i.e., 3-3b). In the case 















Figure 3.2. Overall workflow of the large-scale affinity pull-down/LCMS experiments.The chemically cleavable linker, 3-13, used in study is 
shown in red. 
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3.2.2 Synthesis of Sixteen Orlistat-Like Natural Product-Based Probes 
As shown in Scheme 3.1, Scheme 3.2 and Scheme 3.3, the synthesis of these 
sixteen new compounds (3-1b-j, 3-2b-f & 3-3b-c) was based on previously described 
general strategies for the synthesis of 3-1a, 3-2a and 3-3a (THL-R, THL-L & THL-T), 
respectively. Similar to 3-1a and 3-2a, compound 3-1b-g and 3-2b-e were 
conveniently synthesized from the key intermediate 2-13 and 2-14, respectively, with 
various N-formylated amino acids (3-14a-g) under Mitsunobu conditions, thus giving 
rise to the corresponding configurationally inverted products in a single step. Synthesis 
of Orlistat analogs 3-1h-j was started with previously prepared enantiopure aldehyde 
2-8b from the commercially available dodecan-1-ol. In this context, it is noteworthy 
that this synthetic sequence, which relied on the kinetic resolution of racemic allylic 
alcohols, was chosen because of its applicability to large-scale synthesis and 
convenient variation of the chirality at C-3, C-4 and C-6 positions. Briefly, the 
aldehyde 2-8b was treated with thiopyridyl ketene acetal 2-11 under standard tandem 
Mukaiyama aldol-lactonization (TMAL) reaction conditions,
10
 thus providing the 
silyloxy--lactone intermediates as a mixture of diastereomers (ca. 9:1 anti/syn) with 
complete selectivity for the trans--lactones. Subsequently, direct O-desilylation 
allowed isolation of the enantiomerically pure -hydroxyl -lactones 3-4. Subsequent 
C-desilylation with AgNO3/2,6-lutidine gave the terminal acetylene 3-5, which was 
subjected to Mitsunobu conditions with various N-formyl amino acids, thus giving 
rise to the corresponding configurationally inverted products 3-1h-j. Synthesis of 3-2f 
commenced with the optically active aldehyde 3-6, which was obtained by 
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enantiomeric enrichment using an asymmetric allylation 
(allyltributyltin/(R)-BINOL/InCl3) reaction. Following tert-butyldimethylsilyl (TBS) 
protection and oxidative cleavage, the desired aldehyde 3-8 was obtained, which, 
following TMAL and Mitsunobu reactions, led to the desired Orlistat analogs 3-2f. 
For synthesis of 3-3b, the known hydroxyl--lactone 2-27 was first prepared as 
previously described. Subsequent treatments with 3-11 under Mitsunobu conditions 
furnished the targeted analog 3-3b. Compound 3-3c was conveniently synthesized 















































3.2.3 Biological Screening 
With these sixteen new Orlistat analogs in hand (3-1b-j, 3-2b-f & 3-3b-c), 
together with the wild-type Orlistat, the three previously reported Orlistat analogues 
(3-1a, 3-2a & 3-3a) and two key intermediates (2-13 and 2-24), a total of twenty-two 
compounds were tested for their anti-proliferative activities against the human liver 
cancer line HepG2 using the XTT assay, as described in Chapter 2,
 
followed by in situ 
proteome profiling and targeting identification using affinity pull-down/LCMS 
approaches. The overall workflow of the strategy is shown in Figure 3.2. As shown in 
Figure 3.3, nine of the compounds examined (3-1a-c, 3-1d, 3-1f, 3-2a, 3-2d, 3-3a & 
3-3c) displayed comparable activities to Orlistat in blocking the proliferation of 
HepG2 cancer cells. A closer examination of the data revealed a noteworthy 
structure-activity relationship (SAR) between the compounds tested and their 
anti-proliferative activities. In general, the chirality of the Orlistat analogs is 
important for activity. For example, in a direct head-to-head comparison, compounds 
with an inverted stereochemistry at C-3, C-4 and C-6 (S to R), i.e., 3-1b-d versus 
3-1h-j, and 3-2a versus 3-2f, were shown to have significantly lower anti-proliferative 
activities. The stereochemistry of the C- position in the N-formylated amino ester 
moiety of Orlistat also had a notable effect on its activity, as both 3-1a and 3-2a 
(which are structurally identical to Orlistat, except with a C-C to C≡C substitution at 
the left- and right-hand aliphatic chains, respectively) appeared to be more-active than 
their corresponding epimers, 3-1g, and 3-2e, respectively. The N-formylated amino 
ester moiety as a whole appeared to be essential for anti-proliferative activity, as 
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demonstrated by the lack of activity in the two hydroxyl lactone intermediates, 2-13 
and 2-24 (in which the N-formylated amino ester was deleted completely). It should 
be noted that, in a previous study, the N-formyl group of Orlistat had also shown to be 
highly sensitive to the inhibition of FAS.
[10b]
 The different anti-proliferative profiles 
displayed by Orlistat-like compounds likely have been accumulated through their 
inhibition against a multitude of cellular targets, including FAS, in HepG2 cells. 
Indeed, many drugs appear to work by synergistically targeting multiple proteins.
[63] 
 
3.2.4 In situ Proteome Profiling and Target Identification 
We then carried out in situ proteome-reactivity profiles of all probes to 
identify potential protein targets which were covalently labeled by the probes in live 
HepG2 cells. Following previously described protocols with some modifications 
(summarized in Figure 3.2), each probe (20 M) was added directly to the cell culture 
medium. After two hours of incubation, the cells were washed (to remove excessive 
probes), homogenized, incubated with rhodamine-azide (2-33) under click chemistry 
conditions, separated by SDS-PAGE gel, and analyzed by in-gel fluorescence scanning. 
As shown in part A of Figure 3.4, FAS in general was the main cellular target of these 
probes in HepG2 cells, as evident in the in-gel fluorescence scanning in which it 
showed up as the most strongly labeled band amongst all labeled bands. This is similar 
to the labeling profiles obtained from another class of Orlistat compounds previously 
reported.
[57b]
 The two key intermediates, 2-13 and 2-24, produced only weakly labeling 
profiles (including weak FAS labeling), again reinforcing the importance of 
 64 
N-formylated amino ester moiety the Orlistat structure. However, covalent labeling of 
other cellular targets could still be readily detected in the fluorescence gel, with 
different probes generating marginally but noticeably different labeling profiles. This 
indicates our probes targeted both common and unique cellular targets in HepG2 cells, 
which might have accounted for the subtle differences observed in their 



















Figure 3.3. Dose-dependent inhibition of HepG2 cell-proliferation by the 21-member orlistat analogues library using an XTT assay. The data 














































































































Figure 3.4. (A) In situ proteome-profiling of orlistat analogues against HepG2 cells. 
Probe-labeled proteins were detected by click-chemistry-mediated coupling to a 
rhodamine–azide reporter tag, followed by SDS-PAGE and in-gel fluorescence 
scanning. The arrow indicates the labeled FAS band. (B) Summary of proteins 
identified in all seventeen Orlistat-like compounds. Top: total number of proteins 
identified from each probe; Center: total number of unique proteins identified from 
each probe; Bottom: relative percentage abundance of FAS (calculated from the 
emPAI value for FAS in the experimental sample/the sum of the emPAI values for 
























































































































































































































































































































To further identify these potential cellular targets, we subsequently 
performed large-scale affinity pull-down/LCMS analysis of protein lysates obtained 
from live HepG2 cells treated with each of the probes. In Chapter 2, we used a 
standard, non-cleavable biotin reporter tag to enrich covalently captured proteins and 
eluted them by boiling in the presence of an SDS-containing buffer. However, under 
such harsh denaturing conditions, both endogenously biotinylated and highly 
expressed cellular proteins (nonspecifically bound to the avidin beads) were still 
present in the eluent even after repeated washes, resulting in an unacceptable number 
of false positives and greatly interfering with the identification of low-abundance 
cellular targets. In this study, improvement was therefore made by making use of an 
azobenzene-functionalized biotinylated linker (compound 3-13 in Figure 3.2),
[23e,64]
 
which allows selective release of probe-labeled proteins under mild elution conditions 
(25 mM Na2S2O4) that are compatible with mass spectrometric analysis. Consequently, 
fewer false positives and more reliable putative protein hits were obtained in our assay. 
Briefly as summarized in Figure 3.2, cellular lysates containing protein bands which 
have been covalently labeled by the Orlistat-like probe were treated with the cleavable 
azido-azo-biotin linker (3-13) under standard click chemistry conditions, precipitated 
with acetone, washed with methanol, solubilized with an SDS buffer, followed by 
affinity purification with Neutravidin beads and SDS-PAGE gel separation. The entire 
lane from each pull-down experiment was excised into 10 contiguous gel slices which 
were subsequently processed individually for in-gel trypsin digestion as described 
under Experimental Section. As negative controls, the entire large-scale proteomic 
 68 
experiment (from cell treatment to LCMS analysis) was repeated with DMSO. Peptides 
obtained from each gel slice were eluted and subjected to nano-LC-MS/MS analysis. 
The LC-MS/MS data were searched against the IPI (International Protein Index) human 
protein database using an in-house MASCOT server for protein identification. All 
proteins were identified with a minimum score of 40 and at least two unique peptides. 
Based on these criteria, around 200 proteins on average were identified for each of the 
seventeen Orlistat probes used (see top graph; part B of Figure 3.4).  
Details of the identified protein hits, including their accession numbers, 
emPAI values and protein masses, are listed in the Supplementary Table (in 
Appendix_CD). A total of sixty proteins were identified in all of our probes which may 
constitute the common cellular targets for these probes (for relevant references, see 
Appendix 1). These include well-known serine-type proteins, such as enolases (ENO1, 
ENO3), elongation factors (EEF2, EEF1A1 and EEF1G) and cysteine-type proteins, 
such as transferrin receptor protein (TFRC), ubiquitin-like modifier-activating enzyme 
(UBA1), and protein disulfide-isomerase (PDIA6), and several lipid metabolism 
related proteins, such as 3-hydroxyacyl-CoA dehydrogenase type-2 (HSD17B1), 
triosephosphate isomerase, and trans-2,3-enoyl-CoA reductase. Five of our previously 
identified targets against 3-1a (FASN, GAPDH, -tubulin, Annexin A2, and 
HSP90AB1), also emerged as common hits of our new probes. Not surprisingly, some 
other lipid and/or fatty acid metabolism related proteins, such as palmitoyl-protein 
thioesterase (PPT1), carnitine O-palmitoyltransferase (CPT1A), ATP-citrate synthase 
(ACLY), dihydrolipoyl dehydrogenase (DLD), acyl-CoA dehydrogenases (ACADM, 
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ACADVL), fatty aldehyde dehydrogenase (ALDH3A2), sterol O-acyltransferase 
(SOAT1), long-chain acyl-CoA synthetase (SLC27A2), acetyl-CoA acetyltransferases 
(ACAT1), lysophospholipid acyltransferase (MBOAT7), were also pulled-down by 
most (but not all) of our Orlistat probes.
[65-71]
  
Recent advances in quantitative mass spectrometry have now allowed direct 
evaluation of drug-protein interaction based on the relative peak intensity (or the 
spectra count) of proteins/peptides obtained from a mass spectrometer.
[72]
 Although 
semi-quantitative at best, this provides a very simple and quick method to evaluate the 
relative binding efficiency of a drug against its protein target.
[73]
 Specifically, the 
so-called emPAI MS quantitation approach provides an estimate of protein 
concentration from the number of peptide sequences of a protein identified by tandem 
mass spectrometry.
[73c,d]
  The abundance of an identified protein in a given pull-down 
sample relative to the abundance of the same protein in all pull-down samples was then 
calculated as the ratio of its emPAI value. These ratios where then plotted in a heat map 
for all protein/probe combinations (see Appendix Two). As shown in part B of Figure 
3.4 (bottom graph), FAS which was successfully pulled down by all seventeen Orlistat 
probes showed varied emPAI values ranging from as low as 3.0 (with probe 3-3a) to as 
high as 12.8 (with probe 3-1e), thereby indicating small but relatively significant 
differences in the relative binding affinity between this protein and the different Orlistat 
probes. It should be noted that all MS-based results obtained herein (including all the 
putative protein hits identified and their relative emPAI values) should only be used as 
preliminary data. In our current study, improvement on our previous affinity pull-down 
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procedures was made. Nevertheless, due to the highly complex cellular environment, 
the intrinsic limitation of affinity pull-down assay and mass spectrometry,
[72,73]
 false 
positives/non-specific proteins binders could be minimized but not eliminated entirely 
from our results. Consequently, proper follow-up studies and validation experiments 
will be needed before any biological conclusion is made for some of these protein hits. 
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Table 3.1. Potential unique proteins identified from MS
a
 
gene symbol protein name probe localization function 
HLA-A HLA class I histocompatibility antigen, A-68 alpha chain 3-1a membrane 
host-virus interaction, immune 
response 
PFN1 Profilin-1 3-1a cytoplasm cytoskeletal protein binding 
RPL22 60S ribosomal protein L22 3-1a cytoplasm, nucleus protein metabolism 
MIF Macrophage migration inhibitory factor 3-1a cytoplasm cell proliferation, signal transduction 
RPL12 60S ribosomal protein L12 3-1a nucleus protein metabolism 
PC Pyruvate carboxylase, mitochondrial 3-1a mitochondrion gluconeogenesis, lipid synthesis 
PGM1 Phosphoglucomutase 1 3-1a cytoplasm glucose metabolism 
BCAP31 B-cell receptor-associated protein 31 3-1a ER, nucleus transport, apoptosis 
CLTCL1 Isoform 1 of Clathrin heavy chain 2 3-1b cytoplasm receptor-mediated endocytosis 
PFKM Isoform 2 of 6-phosphofructokinase, muscle type 3-1b n/a glycolysis 
TPP2 Tripeptidyl-peptidase 2 3-1b cytoplasm, nucleus proteolysis 




PTGES2 Prostaglandin E synthase 2 3-1c membrane fatty acid biosynthesis, lipid synthesis 
ANP32A Acidic leucine-rich nuclear phosphoprotein 32 family member A 3-1c 
ER, nucleus, 
cytoplasm 
tumor suppressor,  transcriptional 
repression 
ATP1B3 Sodium/potassium-transporting ATPase subunit beta-3 3-1c membrane transport 
P4HB cDNA FLJ59430, highly similar to Protein disulfide-isomerase 3-1c ER cell redox homeostasis 
HLA-C HLA class I histocompatibility antigen, Cw02 alpha chain 3-1d membrane immune response 
EIF3E Eukaryotic translation initiation factor 3 subunit E 3-1d cytoplasm, nucleus protein biosynthesis 
NOP56 Nucleolar protein 56 3-1d nucleus ribosome biogenesis 
MYOF Isoform 5 of Myoferlin 3-1d membrane phospholipid binding 
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GNAI2 Guanine nucleotide-binding protein G(i), alpha-2 subunit 3-1e membrane signal transduction 
SCARB1 Scavenger receptor class B member 1 3-1e membrane 
receptor for phospholipids, cholesterol 
ester, lipoproteins, phosphatidylserine 
STAT3 Signal transducer and activator of transcription 3 3-1f cytoplasm, nucleus transcription regulation 
SCAMP3 Secretory carrier-associated membrane protein 3 3-1f membrane transport 
TMEM48 Isoform 3 of Nucleoporin NDC1 3-1f nucleus transport 
MYH9 Isoform 2 of Myosin-9 3-1f cytoplasm, nucleus cytokinesis 
SEC61A2 Sec61 alpha form 2 isoform b 3-1f ER transport 
LMNA Isoform C of Lamin-A/C 3-1g nucleus muscle organ development 
BZW1 Basic leucine zipper and W2 domain-containing protein 1 3-1h cytoplasm, nucleus transcription regulation 
DNAJC11 Isoform 3 of DnaJ homolog subfamily C member 11 3-1h n/a unknown 
RAB4B Ras-related protein Rab-4B 3-1h membrane vesicular trafficking 
NIT2 Omega-amidase NIT2 3-1h cytoplasm hydrolase, metabolism 
KIAA0368 KIAA0368 protein 3-1h ER, centrosome protein metabolism 
GTF2I Isoform 1 of General transcription factor II-I 3-1h cytoplasm, nucleus transcription regulation 
ARF1 ADP-ribosylation factor 1 3-1h Golgi transport, signal transduction 
TOP2B DNA topoisomerase 2-beta 3-1h nucleus transcription regulation 
LY6K Lymphocyte antigen 6K 3-1j membrane, nucleus useful as a tumor biomarker 
LYPLA2 Acyl-protein thioesterase 2 3-1j cytoplasm fatty acid biosynthesis, lipid synthesis 
GNAO1 Guanine nucleotide-binding protein G(o) subunit alpha 3-1j membrane signal transduction 
ATP2A1 SERCA1B of Sarcoplasmic/endoplasmic reticulum calcium ATPase 1 3-2a ER apoptosis in response to ER stress 
SH3KBP1 SH3 domain-containing kinase-binding protein 1 3-2a cytoplasm signal transduction 
PLEC1 Isoform 1 of Plectin 3-2b cytoplasm actin binding 
ESYT2 Isoform 4 of Extended synaptotagmin-2 3-3b membrane unknown 
a
 44 potential unique proteins were listed. References are given in Appendix 2. 
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One of the questions we were interested to address was whether subtle 
chemical modifications of the Orlistat structure leads to changes of its cellular targets, 
which was already hinted from the earlier in situ proteome profiling experiments (part 
A of Figure 3.4). If so, one would expect unique proteins targeted by each of the 
seventeen Orlistat probes could be identified form our affinity pull-down/LCMS 
experiments. Upon closer examination of our MS results, we found a total of forty-four 
unique proteins from twelve of the seventeen Orlistat probe used (bottom graph in part 
B of Figure 3.4 and Table 3.1). Among these proteins are several HLA (human 
leukocyte antigen) class I antigens which are part of the genetic region known as the 
major histocompatibility complex (MHC) class I proteins,
[74]
 and G proteins (guanine 
nucleotide-binding proteins) which belong to the larger group of enzymes called 
GTPases.
[75] 
Specifically, HLA-A, HLA-B, HLA-C were targeted uniquely by 3-1a, 
3-1c and 3-1d, and GNAI2, GNAO1 were detected only with 3-1e and 3-1j, 
respectively. Interestingly, serine exopeptidase TPP2 (tripeptidyl-peptidase 2), which 
is essential for some MHC class I antigen presentation,
[76]
 was selectively pulled-down 
by 3-1b. STAT3 (signal transducer and activator of transcription 3) which has recently 
been identified as a tumor suppressor,
[77]
 was uniquely pulled down by 3-1f. NIT2, a 
omega-amidodicarboxylate amidohydrolase and a known tumor suppressor protein,
[78]
 
was pulled down only by 3-1h. Again we caution that these MS-derived results are only 
preliminary findings, and needs to be further confirmed with suitable validation 
experiments. Nevertheless, our data concludes that subtle chemical modifications could 
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change selectivity profiles/cellular targets of Orlistat, and some of its analogs may be 
further developed into drugs targeting some of the unique proteins mentioned above. 
 
3.2.5 Design and Synthesis of AGT/SNAP-Orlistat Bioconjugates as 
Organelle-Targetable Probes 
Sub-cellular targeting of a drug, whereby the drug is delivered to a specific 
organelle inside living cells and subsequently retained there (thus greatly increasing 
the effective concentration of the drug), is expected to not only improve its in vivo 
efficacy but also minimize its off-target effects and cytotoxicity.
[79]
 A number of 
drug-delivery vehicles, including the mannose cluster for mannose-receptor 
interaction targeting the endolysosomal pathway,
[61a]
 cell-penetrating and 
cell-localization peptides,
[61b,c]
 have been successfully used for sub-cellular delivery. 
We were particularly intrigued by the AGT/SNAP-tag method, invented by Johnsson 
and coworkers, which is widely used in the bioimaging field for highly efficient in 
vivo protein labeling by making use of the alkylation of Cys
145
 of human 
O
6
-alkylguanine transferase (hAGT) with various O
6
-benzylguanine suicide substrates 
to covalently label nuclear, cytosolic, cytoskeletal, and cell-surface recombinant 
proteins with fluorophores in Escherichia coli, yeast, and hAGT-deficient mammalian 
cells.
[62, 80]
 Recently, the Johnsson group and other groups adopted this method for the 







 in cultured cells. We were 
interested to know whether the same concept could also be applied for sub-cellular 
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drug delivery. Because FAS expresses mostly in the endoplasmic reticulum (ER), 
modifying Orlistat to be delivered and retained in the ER should in principle greatly 
improve the drug’s anti-tumor activity (e.g., both in potency and selectivity).  
As shown in Figure 3.5, in a proof-of-principle study, we envisaged a 
drug-delivery system consisting of two critical components: a benzylguanine 
(BG)-derivatized Orlistat (3-4) and a model mammalian cell line over-expressing a 
SNAP protein fused to a desired protein localization sequence (PLS). 
Organelle-targetable probe 3-4 was designed on the basis of our previous findings that, 
having a terminal alkyne handle on the right-hand aliphatic chain and structural 
variations on the left-hand aliphatic chain of orlistat do not significantly interfere with 
the drug’s inhibition on FAS. Therefore, we were hopeful that once 3-4 enters the cells 
and becomes conjugated by the SNAP protein (part B of Figure 3.5), the resulting 
AGT/SNAP-Orlistat conjugate would be locally “concentrated” and retained in the 
desired sub-cellular organelle (part A of Figure 3.5). Subsequently, sub-cellular protein 
targeting may take place. Compound 3-4 was conveniently prepared via click chemistry 
between benzylguanine azide (3-16), synthesized in two steps from 6-chloroguanin, 
































Figure 3.5. Design of AGT/SNAP-orlistat bioconjugates as a organelle-targetable probe. (A) Principle of AGT/SNAP-tag fusion strategy for 
sub-celllular protein targeting using a cell-permeable, benzylguanine (BG)-containing Orlistat analogue. (B) Bioconjugation reaction of 











Scheme 3.4. Schematic showing of click chemistry-facilitated synthesis of the 
organelle-targeting, BG-containing Orlistat probe (3-4). 
 
 
Next, we confirmed that BG-containing orlistat 3-4 could indeed serve as a 
substrate of AGT/SNAP and be successfully conjugated (i.e., part B of Figure 3.5, Step 
I). As shown in Figure 3.6, recombinantly purified hexahistidine-tagged AGT protein 
(His-AGT), pre-incubated with 3-4 in PBS for 4 h at room temperature, was shown to 
completely stop the fluoresence labeling between His-AGT and its natural substrate, 
BGFL, thereby indicating the successful formation of the desired AGT/SNAP-Orlistat  
(part B of Figure 3.5). Further confirmation was obtained from ESI-Q-TOF mass 
analusis (Table 3.2); a mass shift of 535 between the untreated His-AGT and (His-AGT 
+ 3-4) labeling reaction was observed, which is consistent with the calculated mass of 
the AGT/SNAP-orlistat conjugate. The reactive -lactone ring in orlistat also remained 











Figure 3.6. Competition assay for AGT labeling with 3-4. Aliquots taken from the 
reaction mixture at the indicated time and incubated with BGFL (100 M) for 15 
minutes, followed by SDS-PAGE and in-gel fluorescence scanning. 
 
 
  Table 3.2. Observed Mass peaks for ESI-MS of His-AGT with or without 3-4
a
. 
sample MW (Da) mass difference 
His-AGT 23606  
His-AGT + 3-4 23701 535 
a
See Appendix 1 for original mass spectra. 
 
Lastly, we assessed whether the direct application of 3-4 to live mammalian 
cells leads to successful localization and retention of the Orlistat probe in the desired 
sub-cellular organelle. However, we were unable to carry out experiments directly in 
HepG2 cancer cells, because an AGT-deficient cell line is currently not available 
(AGT is endogenously expressed in most mammalian cell lines. Its presence will lead 
to interference with our assay and high background conjugation/labelling.), and the 
intrinsically low transfection efficiency of HepG2 cells also precluded the 
accumulation of a sufficient amount of transiently expressed PLS-SNAP in the cells. 
Therefore, we used an AGT-deficient CHO-9 cell line instead. Sub-cellular expression 














BGFL (100 ; 15 min)
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with mammalian DNA constructs containing the AGT-SNAP gene fused to different 
protein localization sequences (PLS; including mitochondria, ER & nucleus). 
Forty-eight hours later, after the proteins were successfully expressed and detected in 
the corresponding organelles (Figure 3.7; green channels), Compound 3-4 was 
directly applied to the media and the (SNAP + 3-4) conjugation reaction was left to 
proceed for another four hours followed by extensive washing of the cells (to remove 
excessive probe). Subsequently, in situ click chemistry was carried out in these live 
cells, as previously described in Chapter 1, to visualize the localization/retention of 
3-4 (part B of Figure 3.5, Step III). As shown in Figure 3.7 (red channels), the 
successful accumulation of 3-4 in the desired organlles (mitochondria, ER and 
nucleus), as guided by the localization of AGT-SNAP, was observed (see merged 
images of the green and red channels). Cells transfected with a control plasmid 
containing AGT/SNAP gene without a protein localization sequence displayed a 
uniform fluorescence labelling throughout the entire cell (data not shown). Taken 
together, these data show that Orlistat probe 3-4 could be successfully 
delivered/retained in sub-cellular organelles by using the AGT/SNAP-tag strategy.
12d
 
At present, owing to the lack of a suitable AGT-deficient HepG2 cell line, we were 














Figure 3.7. Images of CHO-9 cells expressing AGT-SNAP-tag in mitochondria (top), 
ER (center), or nuclei (bottom), then treated with compound 3-4, fixed, permeabilized, 
clicked with rhodamine-azide (2-33), and imaged (red channels). Cell nuclei were 
stained with Hoechst (blue channels), anti-FLAG M2 primary antibody, followed by 
FITC-conjugated antimouse IgG antibody to detect AGT/SNAP protein (green 
channels). Red and Green channels were overlaid, giving merged images shown. 




We have synthesized and evaluated an expanded set of Orlistat-like 
compounds for their anti-proliferative activities in HepG2 cancer cells. Our results 
showed some of analogs (3-1a-d, 3-1f, 3-2a, 3-2d, 3-3a & 3-3c) display comparable 
activities when compared to wild-type Orlistat, while others showed marginally weaker 
activities. Subsequent in situ proteome activity profiling, followed by large-scale 
affinity pull-down/LCMS identifications of putative protein hits enabled us to identify 
potential common and unique targets and  assess their relative binding to our probes, 
thus providing some preliminary structure-activity-relationship (SAR) information. 
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This chemical proteomics approach may be used for discovery of new cellular targets 
of Orlistat and the design of better Orlistat analogs. It may provide a general method for 
both on- and off-target identification of other suitable drugs. Finally, in order to further 
improve the cellular activity of Orlistat, we have successfully applied the 
well-established AGT/SNAP-tag technology to a benzylguanine (BG)-containing 
Orlistat variant (3-4), and in a proof-of-concept bioimaging experiment, showed the 
drug could be delivered and effectively retained in different subcellular organelles of 
living cells. We believe the AGT/SNAP-tag strategy represents an interesting and 
viable tool for sub-cellular drug delivery and organelle targeting. It might even be 
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Trypanosoma brucei is a parasite that causes African sleeping sickness in 
humans and Nagana in livestock and is transmitted by the tsetse fly. There is an urgent 
need for development of new drugs against African trypanosomiasis due to the lack of 
vaccines and effective drugs. One potentially rapid and cost-effective strategy for 
discovering new trypanocidal drugs is to extend the indication of existing drugs 
already approved for other uses. Orlistat™, also known as tetrahydrolipstatin (THL), 
is an FDA-approved anti-obesity drug with potential anti-cancer activities. Its 
trypanocidal properties have not been sufficiently explored, and possible cellular 
targets of this drug has remained completely unknown in the two proliferating stages 
of T. brucei, the blood stream form (BSF) in the mammalian hosts and the procyclic 
form (PCF) in the insect vector. In Chapter 2 and 3, we developed a novel chemical 
proteomic approach, based on Orlistat-like small molecule probes, for large-scale 
proteome-wide identification of unknown cellular targets of Orlistat in human 
hepatocytes. Herein, we describe, for the first time, their biological evaluation in both 
BSF and PCF T. brucei. Furthermore, we carried out proteomic profiling of these 
compounds, and have successfully identifies many putative cellular targets of THL-R 
(a close mimic to Orlistat) in both parasitic forms, some of which are highly 
promising drug targets, potential diagnostic markers and possible vaccine candidates. 
In addition, we demonstrated that these Orlistat-like probes, when combined with the 
bio-orthogonal click chemistry and fluorescence microscopy, provide a unique and 
highly effective chemical tool to study drug uptake and distribution in parasites. 
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Given the economic challenges of de novo drug development for neglected diseases, 
we hope our findings will stimulate other research groups to acquire additional 




Human African trypanosomiasis (HAT; commonly known as sleeping 
sickness), caused by the protozoan parasite Trypanosoma brucei, is responsible for 
50,000-70,000 deaths each year with increasing travel and migration within 
sub-Saharan Africa.
[82]
 These trypanosomes undergo a complex lifecycle in both the 
mammalian bloodstream and insect vector, the tsetse fly (Figure 4.1). After a tsetse fly 
takes a blood meal on an infected mammal, the parasites multiply in the fly, 
progressing through procyclic, epimastigote, and metacyclic developmental stages in 
the insect gut and salivary glands. When the metacyclic trypanosomes pass from the 
fly to the mammalian host, they develop into long-slender bloodstream forms which 
multiply extracellularly in the blood. After some time, the parasites cross the 
blood-brain barrier to infect the central nervous system. At high parasite densities, 
short-stumpy bloodstream forms appear and are readily transmitted to the tsetse fly. 
To survive in different hosts, considerable adaptations in parasite morphology, surface 
composition, and metabolism including lipid and energy metabolism are required. 
Both procyclic and long-slender bloodstream forms of T. b. brucei are cultured in the 
laboratory. Similar to other neglected tropical diseases (NTDs), such as Leishmania 
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spp. and Trypanosoma cruzi, limited therapeutics for HAT and related diseases (e.g. 
Nagana in cattle) are available and of the drugs currently used (four drugs have been 
used so far to treat African trypanosomiasis, Figure 4.2), most are decades old.
[82,83] 
Resistance and toxicity to current therapies make treatment increasingly problematic, 









Figure 4.1. Trypanosoma brucei life-cycle. This simplified scheme does not show 









Figure 4.2. Current drugs for African trypanosomiasis. 
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One potentially rapid and cost-effective strategy for the discovery of new 
trypanocidal drugs is to explore existing drugs which possess well-characterized 
pharmacokinetic and safety profiles, and are already approved for other uses.
[83]
 This 
‘piggy-backing’ approach has historically been proven to be quite successful in 
bringing new therapies to the anti-parasite drug discovery pipeline. A recent example 
is Miltefosine, initially developed for breast cancer but now used for treating visceral 
leishmaniasis.
[83d]
 Orlistat™ (marketed as Alli and Xenical; or THL), an 
FDA-approved anti-obesity drug which works primarily on pancreatic and gastric 
lipases within the gastrointestinal (GI) tract, was found to have potential anti-tumor 
(targeting fatty acid synthase, or FAS) and anti-mycobacterial activities.
[84]
 In a more 
recent but very preliminary study using a high-throughput screening (HTS) assay, this 
drug together with many other tested compounds was found to also exhibit some 
trypanocidal activities.
[85]
 However, no further study was carried out with live 
parasites and the molecular basis of this drug in the two replicating stages of 
Trypanosoma brucei remains completely unknown. Inspired by the concept of 
activity-based protein profiling (ABPP), which was initially coined by Cravatt and 
coworkers and further developed by others,
[5]
 we previously described a chemical 
biology strategy which makes use of natural product-like small molecule probes for in 
situ proteome-wide profiling of putative drug targets. In this approach, extremely 
conservative modifications (i.e., an alkyne handle) were introduced in the parental 
Orlistat structure to provide the necessary functionality for target identification via 




maintaining the native biological properties of the drug. Herein, we report the in situ 
proteome-wide profiling of our Orlistat-like probes in live BSF and PCF parasites for 
the first time. These compounds have been synthesized in Chapter 1 and 2 and first 
evaluated for their trypanocidal activities using a live parasite screening assay (Figure 
4.3). A distinct killing kinetics was observed, with the Orlistat-like compounds killing 
BSF more efficiently than PCF parasites. Subsequent in situ chemical proteomic 
profiling was carried out, which led to the successful identification of both common 
and unique putative drug-binding targets of Orlistat in BSF and PCF. Bioimaging 
studies using selected Orlistat probes (i.e. THL-R) in combination with the 
bio-orthogonal click chemistry and azide-containing fluorophores enabled us, for the 
first time, to accurately visualize the cellular uptake and subsequent organelle-specific 
localization of these probes as well as associated morphological changes. From these 
studies, we tentatively concluded that, with its already well-established 
pharmacokinetic and safety profiles as an FDA-approved drug, Orlistat should be 
seriously considered as one of the most promising candidates for further anti-parasite 



















Figure 4.3. Comparative parasite-based screening and proteomic profiling of PCF and 
BSF with cell-permeable Orlistat-like probes. The alkyne handle of the probes enables 
the bioorthogonal CC to be subsequently carried out, leading to both target 
identification by using pull-down and LC-MS/MS techniques and imaging-based 
uptake studies of probes by fluorescence microscopy, respectively.  
 
4.2 Results and Discussion 
4.2.1 Trypanocidal Activities of Orlistat Compounds in PCF and BSF 
We set out to consider three inter-related questions. First, does the 
introduction of a terminal alkyne handle in the Orlistat scaffold affect its trypanocidal 
activities? Second, could the relationship between the chemical structure of an Orlistat 
analogue and its trypanocidal activities (i.e., structure-activity relationship, or SAR) 
be established? Last, do these compounds have similar biological activities in both 
PCF and BSF trypanosomes? We first compared the cellular activity of THL-R (i.e., 
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3-1a) and Orlistat against the BSF of T. brucei, which is the mammal-infecting form. 
All growth/inhibition studies were performed using the Guava ViaCount FACS 
(fluorescence-activated cell sorting) assay, which allows automated, high-throughput 
quantitative analysis of the killing effect of these compounds against live parasites 
(Figure 4.4); both compounds killed cultured parasites with comparable potency in a 
dose-dependent manner (for example, ~80% killing against BSF at 125 nM). These 
results confirm the imperceptible replacement of a terminal ethyl group by an ethynyl 
group, and that potential cellular targets identified from our subsequent in situ 
proteomic profiling using selected Orlistat analogs were likely targets of Orlistat itself 










Figure 4.4. Concentration-dependent trypanocidal activities of THL and THL-R. ~1 × 
10
5
 T. brucei parasites per well were exposed to different concentrations of THL, 
THL-R and DMSO in 96-well plate format and then incubated at 37 
o
C (BSF) or 28 
o
C (PCF) for 24 h in 200 L of growth medium. The effects of compounds on T. 
brucei were determined by Guava ViaCount assay. The values represent the averages 



























































Next, we simultaneously screened a total of twenty-five potential 
trypanocidal compounds, twenty-two of which are Orlistat and its analogues/key 
intermediates (3-1a-j, 3-2a-f, 3-3a-c, 2-13 and 2-24). The other three (Figure 4.5) are 
positive controls, including two well-known trypanocidal cysteine proteinase 
inhibitors, Z-Phe-Ala-CHN2 (abbreviated as DMK)
[86]
 and N-Mpip-Phe-Hph-VSPh 
(also known as K11777),
[87]
 and a broad-spectrum lipase inhibitor MAFP.
[88]
 Both 
Z-Phe-Ala-CHN2 and K11777 are irreversible inhibitors of parasite cathepsin L and 
cathepsin B-like proteases and have shown promising trypanocidal activities. Notably, 
K11777 has passed through rodent, dog, and primate safety studies for Chagas disease 
caused by Trypanosoma cruzi. It is one of the most advanced trypanocidal agents 
known to-date and currently in late-stage preclinical development.
[87c,d]
 DMSO was 
included in the assay as a negative control. All trypanocidal assays were initially 
carried out in triplicate at a single concentration (i.e. 125 nM against BSF; 5000 nM 











As shown in Figure 4.6, Orlistat and some of its analogs (3-1a, 3-1d, 3-1e & 
3-1j; highlighted with red bars) were found to be significantly more potent than all 
three above-mentioned positive controls, especially against BSF T. brucei (empty bars; 
data for PCF are represented with filled bars, respectively). It is also interesting to 
note that the trypanocidal activity of Orlistat and its analogues, did not appear to have 
originated from its inhibitory activity against lipases alone, as one might have 
expected (since orlistat is a known lipase inhibitor). For instance, MAFP is a 
broad-spectrum lipase inhibitor but displayed one of the lowest trypanocidal activities 
amongst all the compounds tested, suggesting that Orlistat and its analogues may 
function through other targets in T. brucei, in addition to parasitic lipases. A 
noteworthy structure-activity relationship (SAR) also emerged from our 
parasitescreening studies. In general, the N-formyl group and the position of the 
terminal ethynyl group are important for activity. Three of the compounds examined, 
i.e., 3-1a (THL-R), 3-1d and 3-1e, were as potent as Orlistat, while 3-2a (THL-L) and 
3-3a (THL-T) were comparatively less potent. The N-formylated amino ester moiety 
as a whole is essential for trypanocidal activity, as demonstrated by the lack of 
activity in the two hydroxyl lactone intermediates, 2-13 and 2-24 (in which the 
N-formylated amino ester was deleted completely). Similarly, a significant drop in the 
trypanocidal activity (by ~3 folds) was observed when the amino acid group in this 
moiety was changed from glycine to -glycine (i.e. compare compounds 3-1c and 
3-1f). The overall chirality of the drug did not appear to significantly affect its 
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trypanocidal activity. For example, in a direct head-to-head comparison, compounds 
with an inverted stereochemistry at C3, C4 and C6 (S to R) positions, i.e., 3-1b-d 
versus 3-1h-j, and 3-2a versus 3-2f, appeared to retain most of their antitrypanocidal 
activities. In fact, 3-1j, together with 3-1a, 3-1d and 3-1e, was one of the four most 
potent antitrypanocidal inhibitors identified in our assay against the BSF form of the 
parasites. The stereochemistry of the C- position in the N-formylated amino ester 
moiety of Orlistat, however, had a much more notable effect on its activity, as both 
3-1a and 3-1b (which are structurally identical to orlistat, except with a C-C to C≡C 
substitution at left- and right-hand aliphatic chains, respectively) appeared to be much 
more active than their corresponding epimers, 3-1g, and 3-2e, respectively. 
Interestingly, the relocation of the terminal alkyne handle from the right- to the 
left-hand aliphatic chain, i.e., 3-1b-d versus 3-2b-d, led to a general reduction in these 
compounds’ trypanocidal activity. An increase in the chain length of the terminal 
alkyne located at the N-formyl end of Orlistat, i.e., 3-3a versus 3-3b, did not appear to 
dramatically affect the compound’s activity.  
Finally, the trypanocidal activity of all twenty-five compounds were 
examined and compared in both BSF and PCF forms of T. brucei, and our results 
clearly showed that all compounds tested were much more effective in killing BSF 
than PCF (Figure 4.6); a significantly higher dosage of the compounds (i.e., 5000 nM) 
was needed in order to achieve comparable killing effects in PCF. Further 
dose-dependent studies were carried out with selected compounds (THL and THL-R) 
against both BSF and PCF forms (Figure 4.7); results again showed that proliferation 
 93 
of both life cycle stages of the trypanosomes was efficiently inhibited by both Orlistat 
(ED50 = 49.1±1.7 nM for BSF; and ED50 = 1.55±3.65 M for PCF) and THL-R (ED50 
= 46.2±3.7 nM for BSF; and ED50 = 1.45±3.56 M for PCF). With such an effective 
trypanocidal profile, this immediately places Orlistat (as well as some of its analogues, 
i.e., THL-R) as one of the most potent drugs known to T. brucei. This, together with 
its already wellcharacterized pharmacokinetic and safety profiles (as an 
FDA-approved drug), bodes well for the argument that Orlistat should be immediately 
considered by pharmaceutical companies as one of the most promising trypanocidal 
drug candidates. It should be noted that most of the trypanocidal drugs currently under 
development focus on another highly similar parasitic protozoan Trypanosoma cruzi, 

















Figure 4.6. (A) A comparison of trypanocidal activities of the 21-member Orlistat library against BSF (white bars) and PCF (gray bars) after 24 
h, respectively. All trypanocidal assays were initially carried out in triplicate at a single concentration (i.e. 125 nM for BSF and 5000 nM for PCF, 
respectively). Four probes with the highest trypanocidal activity against BSF are shown in red (3-1a, 3-1d, 3-1e & 3-1j). BSF killing profile of 





























































































Figure 4.6. (B) A comparison of trypanocidal activitiesof the 21-member Orlistat library against BSF (white bars) and PCF (gray bars) after 48 h, 

















































































































Figure 4.7. ED50 curves of Orlistat and THL-R (3-1a) against BSF and PCF. Orlistat 
(ED50 = 49.1 ± 1.7 nM for BSF; and ED50 = 1.55 ± 3.65 M for PCF) and THL-R 
(ED50 = 46.2 ± 3.7 nM for BSF; and ED50 = 1.45 ± 3.56 M for PCF). 
 
 
4.2.2 Comparative in Situ Proteomic Profiling of T. brucei parasites 
The results above indicated that Orlistat and some of its analogs (i.e., 3-1a, 
3-1d, 3-1e & 3-1j) conferred highly potent trypanocidal activities, especially against 
the blood stream form (BSF) of parasitic protozoan Trypanosoma brucei, which lives 
in the mammalian host. Comparatively, the same compounds killed the procyclic form 
(PCF) of the parasites less effectively. The observation that the trypanocidal activity 
of Orlistat was greater than that of the general lipase inhibitor MAFP suggests that, 
the molecular basis of Orlistat inhibition against T. brucei growth might have been 
originated from multiple sources, in addition to its suspected inhibition on 
endogenous parasitic lipases (Orlistat is a well-known lipase inhibitor).
[89]
 What could 
be other possible molecular targets of this drug in T. brucei? To answer this question, 
we took advantage of the unique properties of our alkyne-containing Orlistat-like 
analogues. We had previously shown that the introduction of an alkyne handle in 
































Orlistat makes it possible for in situ proteome-wide profiling and identification of 
potential cellular targets of this drug via downstream conjugation of the protein/drug 
complex to reporter tags with the bio-orthogonal click chemistry. Although 3-1a, 3-1d, 
3-1e and 3-1j all showed similar trypanocidal profiles against BSF T. brucei, we 
chose 3-1a (THL-R) for subsequent target identification as this compound is the 
closest structural mimic to Orlistat. To study whether in situ labeling in both intact 
cells was feasible, THL-R was added to the culture medium where parasites were 
grown, either alone or in the presence of a competing Orlistat (over a concentration 
range of 10-50 M). At different time points the cells were harvested. The parasites 
were washed (to remove excessive probes), homogenized, incubated with 
rhodamine-azide (2-33) under click chemistry conditions, separated by SDS-PAGE 
gel, and analyzed by in-gel fluorescence scanning. As shown in Figure 4.8 and 4.9, 
the labeling was time- and dose-dependent. These results indicate that our probe can 
very easily enter the cellular compartments and when situated inside it selectively 
react with intracellular target(s). It is presently not clear how exactly the probe enter 
cellular compartments. Further, we compared the in situ proteome reactivity profiles 
of all twenty-one Orlistat probes against their cellular protein targets in live 
trypanosomes (Figure 4.10). In general, most probes (except 2-13 and 2-24, which are 
key intermediates of Orlistat probes and lack the N-formyl amino ester moiety), 
despite obvious differences in their trypanocidal activities, showed similar in situ 
proteome reactivity profiles, indicating they have similar cellular targets in live 
parasites. On the other hand, the in situ proteome reactivity profiles between the BSF 
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and PCF for the same probe, though appearing similar for the most part, showed 
distinguishable differences (compare the two gels in Figure 4.10), pointing to the 
likelihood of the existence of both common and unique protein targets of Orlistat in 
the two different proliferating forms of the parasites. Probes 2-13 and 2-24 managed 
to only label a handful of proteins weakly (as shown in few labeled bands in their gel 
lanes), likely a reflection of their weak trypanocidal activity as well as the need for 
full retention of the Orlistat structure in future drug development. Most labeled bands 
in both the BSF and PCF profiling gels were Orlistat-sensitive, that is, their labeling 
was inhibited by the presence of a high-concentration competing Orlistat (Figure 4.9), 
while some of the labeled bands were not inhibited by MAFP (a broad-spectrum 
lipase inhibitor) and Cerulenin (a fatty acid synthase inhibitor), indicating that most 
labeled proteins are likely specific cellular targets of Orlistat, and some of which are 

























































Figure 4.8. Dose-dependent and time course of in situ labeling/proteome profiling of 
the bloodstream forms (A), and procyclic forms (B) with THL-R (3-1a). 
Probe-labeled proteins were detected by click chemistry–mediated coupling to a 













Figure 4.9. In situ competitive labeling T. brucei parasites with THL-R (3-1a) in the 
presence of different concentrations of Orlistat, MAFP or Cerulenin. 
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4.2.3 Putative Target Identification and Validation of Both BSF and PCF 
Next, we performed large-scale proteomic analyses to identify 
Orlistat-targeted cellular proteins in both BSF and PCF parasites. Protein bands 
specifically labeled by 3-1a (that is, those bands that were sensitive to Orlistat 
competition) in both BSF and PCF were enriched (following click-chemistry 
conjugation with biotin-azide 2-34) by avidin-agarose beads, separated by 
one-dimensional SDS-PAGE and visualized by Coomassie staining or silver staining. 
The entire lane from each pull-down experiment was excised into 10 contiguous gel 
slices and each gel slice was individually processed for in-gel trypsin digestion as 
described under Experimental Section. As negative controls, the entire large-scale 
proteomic experiment (from cell treatment to LCMS analysis) was repeated with both 
BSF and PCF parasites treated with DMSO instead of 3-1a. Peptides obtained from 
each gel slice were eluted and subjected to nano-LC-MS/MS analysis. The 
LC-MS/MS data were searched against a concatenated T. brucei database using an 
in-house MASCOT server (Matrix Science, London, UK) for protein identification. 
Two independent experiments identified 160 and 161 proteins in PCF and BSF 
samples, respectively. Of these, 29 proteins for PCF and 45 for BSF (or 18% and 27%, 
respectively) were hypothetical proteins, whilst 68 proteins were observed in both 
forms. Details of the protein identification including their score values, peptide 
matches and protein masses obtained on data analysis are listed in Appendix 2. The 
most prevalent proteins identified in both PCF and BSF of T. brucei were metabolic 
enzymes which are involved in the glycolytic pathway, amino acid metabolism, fatty 
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acid metabolism and lipid biosynthesis (part A of Figure 4.12). Cytoskeletal proteins 
that are generally known to be abundantly present in cells were also detected. In 
addition, some ribosomal proteins, mitochondrial proteins, and transporter proteins 
were identified. Various isoforms of histone proteins along with other nucleic 
acid-binding proteins were detected. Proteins involved in cell defense including 
variable surface glycoproteins and peroxidases were identified. We further grouped 
the identified proteins according to their known sub-cellular localizations, either 
theoretically predicted or experimentally confirmed (based on literature data mining) 
(part B of Figure 4.11); remarkably, 31-34% of all putative targets are mitochondrial 
proteins, 14-15% are glycosomal proteins and 12% are ER proteins, suggesting a 
major effect of Orlistat (and its analogues) on these organelles in T. brucei. 
      Among the proteins identified, some were inevitably non-specific protein 
binders of Orlistat caused by their “sticky” nature as well their high endogenous 
expression level, and they therefore likely offer few potential therapeutic values. 
Consequently, we focused our attention on other “hits” which posses known 
nucleophilic serine/cysteine residues in their active sites, as they are more likely to be 
specific targets of Orlistat. We also paid special attention to proteins which are 
potential diagnostic markers, drug targets and possible vaccine candidates. A 
deliberate effort was made to categorize potential Orlistat targets into both unique and 
common targets to BSF and PCF parasites. Of the interesting proteins positively 
identified in both BSF and PCF pulldowns are glycolytic enzymes including HK, 




 Correct localization of glycosomal proteins had previously been shown 
to be essential for the survival of both BSF and PCF in T. brucei. Of the several 
mitochondrial proteins identified, alternative oxidase (AOX) is one of which 
detectable only in the BSF pull-down experiment. AOX functions as the sole terminal 
oxidase to re-oxidize NADH accumulated during glycosis,
[97]
 and is essential for the 
survival of BSF parasites in their mammalian host. There is no known human 
homologue for this protein, making it a potentially attractive drug target for the 
treatment of trypanosomiasis. As shown in Table 4.1, many proteins identified only in 
the BSF pull-down are proteins invovled in lipid and fatty acid biosynthesis, including 
including GPI-PLC, inositol phosphorylceramide synthesis (SLS1), 
phosphatidyltransferase (PIS), essential neutral sphingomyelinase (TbnSMase), 
choline/ethanolamine phosphotransferase (CEPT), GPI transamidase component 
GAA1 (TbGAA1), GPI-anchor transamidase subunit 8 (GPI8), and 
glycosylphosphatidylinositol (GPI) anchor (TbGPI16).
 [98-102]
 While it is reasonable to 
assume these lipid-related proteins are true cellular targets of Orlistat in T. brucei, 
given this drug’s well-characterized molecular targets in other biological systems. it is 
interesting to note they evaded our pull-down/target identification in PCF of T. brucei. 
We also identified proteins such as calpain,
[86a,111]
  cathepsin L-like cysteine 
peptidase (CP),
[111]





 and protein disulfide isomerase (BS2), all of which possess 
active cysteine residues and had previously been identified as targets of Orlistat and 
-lactones. Sterol 14-alpha-demethylase (CYP51, also known as 
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3-oxo-5-alpha-steroid 4-dehydrogenase), a membrane-associated enzyme identified in 
both BSF and PCF pull-downs, has recently been validated as a potential target for 
antitrypanosomal therapy.
[103]
 Among other potential drug targets, tryparedoxin 
peroxidase is a glutathione peroxiredoxin unique to trypanosomes.
[104]
 This enzyme 
detoxifies peroxynitrite radicals produced by macrophages and hence plays an 
important role in successful evasion of host defense system. Gratifyingly, we 
identified two fatty acyl CoA synthetases (i.e., ASC1 and ASC3), which are the 
parasitic homologs of mammalian fatty acid synthetases (e.g. known targets of 
Orlistat) and whose cellular activities have recently been shown to be important for 
BSF parasites in RNA interference (RNAi)-based silencing experiments. Additionally, 
we identified several proteins, including fatty acyl CoA synthetase, protein disulfide 
isomerase, pretranslocation protein, membrane-bound acid phosphatase 1 (MBAP1), 
calreticulin, UDPglucose/ glycoprotein glucosyltransferase, glycerol-3-phosphate 
dehydrogenase, and spermidine synthase,
[105-110]
 whose cellular activities have been 
shown to be important for BSF parasites in RNA interference (RNAi)-based silencing 
experiments. Nevertheless, owing to the highly complex cellular environment, the 
intrinsic limitation of affinity pull-down assay and mass spectrometry, false 
positives/non-specific proteins binders could be minimized but not eliminated entirely 
from our results. To confirm our pull-down/LC-MS/MS results, we selectively picked 
ten most likely “hits” of Orlistat from Table 4.1, and attempted to clone/express them 
in E. coli. as GST fusions. Five proteins that were successffully expressed in soluble 
forms were BS2, TbLysoPLA, MCA1, TbnSMase and GAPDH. Bacterial total lysates 
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over-expressed with these proteins, together with lysates over-expressed with GST 
only (a negative control), were directly labeled with 3-1a, and subsequently analyzed 
by in-gel fluorescnece scanning following click chemistry with rhodamine-azide (part 
of C in Figure 4.11); all five proteins were successfully labeled by THL-R specifically, 
even in the presence of other endogenous bacterial protiens. GST alone was not 
labeled by THL-R (e.g. lane 1). Taken together, these results indicate that all five 
proteins were likely true cellular targets of Orlistat in T. brucei, in addition to the two 
fatty acyl CoA synthetases. Other “hits” identified from our pull-down experiments 
were also possible targets of orlistat, but could not be further validated in the present 
study, due to our difficulty in obtaining the recombiant proteins in bacteria. 
Nevertheless, our parasite-based screening, prteome profiling, target identification and 
validation results suggest that orlistat acts as a potent trypanocidal drug in T. brucei 
by targeting essential parasitic proteins invloved in lipid and fatty acid metabolic 
pathways, including lipases, fatty acyl CoA synthetases and other proteins possessing 












Figure 4.11. Functional classifications (A) and predicted/known sub-cellular localization (B) of identified proteins in BSF, as well as in PCF 
(parentheses). (C) Target validation experiments on five recombinantly expressed “hits”. The labeling experiment was done with 3-1a against the 
proteins expreesed in the whole E. coli proteome lysates. Equal amount of protein lysates and 3-1a were used in each lane. The labeled lysates 
were subjected to click chemistry with rhodamine-azide, SDS-PAGE analysis, and in-gel fluorescence scanning (shown in grayscale). 
GST-expressing lysate (lane 1) was used as a negative control: no labeling of GST was observed. For the five “hits”, all of them showed a 
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Table 4.1. Representative proteins identified with THL-R in Trypanosoma brucei
[a]
 
T. brucei gene protein name Mw / kDa location detection 
Lipid metabolism 
Tb927.8.6390 lysophospholipase, putative,alpha/beta hydrolase, putative (LysoPLA) 30.09 n/a both 
Tb927.1.4830 phospholipase A1 (PLA1) 32.41 n/a PCF 
Tb09.211.3650 phospholipase A2-like protein, putative 49.91 n/a BSF 
Tb927.2.6000 glycosylphosphatidylinositol-specific phospholipase C (GPI-PLC)* 40.66 membrane BSF 
Tb11.01.6800 1-acyl-sn-glycerol-3-phosphate acyltransferase (GAT2) 30.36 membrane both 
Tb09.211.1030 inositol phosphorylceramide synthase (SLS1)* 37.97 golgi BSF 
Tb09.160.0530 CDP-diacylglycerol--inositol 3-phosphatidyltransferase** 24.11 ER BSF 
Tb927.5.3710 essential neutral sphingomyelinase (TbnSMase)* 65.02 ER BSF 
Tb10.6k15.1570 choline/ethanolamine phosphotransferase (CEPT)* 47.98 n/a BSF 
Tb10.100.0100 GPI transamidase component GAA1 (TbGAA1)* 51.31 membrane BSF 
Tb10.61.3060 GPI-anchor transamidase subunit 8 (GPI8)* 36.80 n/a BSF 
Tb10.70.2420 GPI inositol deacylase precursor (GPIdeAc) 61.43 membrane BSF 
Tb927.4.1920 GPI transamidase, putative (TbGPI16) 75.81 n/a BSF 
Tb11.01.4790 phospholipid:diacylglycerol acyltransferase-like protein 71.41 n/a PCF 
Tb927.6.1820 dolichyl pyrophosphate phosphatase* 22.24 ER BSF 
Tb927.3.1840 3-oxo-5-alpha-steroid 4-dehydrogenase** 33.36 membrane both 
Tb927.3.3580 lipophosphoglycan biosynthetic protein (LPG3) 87.77 cytoplasm BSF 
Fatty acid metabolism 
Tb927.7.4170 fatty acid elongase (ELO2) 30.49 ER PCF 
Tb927.7.4180 fatty acid elongase (ELO3) 33.87 ER PCF 
Tb09.160.2770 fatty acyl CoA syntetase 1 (ASC1)* 78.96 membrane BSF 
Tb09.160.2810 fatty acyl CoA synthetase 3 (ASC3)* 77.86 membrane both 
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Tb927.8.7100 acetyl-CoA carboxylase 242.92 M both 
Proteolysis 
Tb927.8.8330 calpain, putative,cysteine peptidase** 98.46 n/a both 
Tb11.02.0730 metacaspase, cysteine peptidase, Clan CD, family C13 (MCA1)** 40.18 M BSF 
Tb927.6.1000 cysteine peptidase (CP), Clan CA, family C1, Cathepsin L-like** 48.34 n/a BSF 
Tb927.4.3950 cytoskeleton-associated protein CAP5.5, cysteine peptidase, Clan CA, family C2, (CAP5.5)** 94.65 n/a PCF 
Tb10.70.7090 serine carboxypeptidase (CBP1) precursor, serine peptidase, Clan SC, Family S10 (CBP1) 51.51 n/a both 
Tb927.10.8230 protein disulfide isomerase, bloodstream-specific protein 2 precursor (BS2)* 55.58 cytoplasm BSF 
Tb927.3.4910 signal peptide peptidase, aspartic peptidase, clan AD, family A22B 38.68 n/a BSF 
Tb10.406.0290 protein tyrosine phosphatase* 25.45 membrane both 
Mitochondrial proteins 
Tb10.6k15.3640 alternative oxidase (AOX)* 37.59 M BSF 
Tb11.02.5280 glycerol-3-phosphate dehydrogenase, mitochondrial* 66.99 M both 
Tb10.389.0890 pyruvate dehydrogenase E1 alpha subunit* 42.51 M BSF 
Tb11.02.0290 succinyl-coA:3-ketoacid-coenzyme A transferase, mitochondrial precursor* 53.1 M PCF 
Miscellaneous proteins 
Tb927.4.5010 calreticulin* 45.04 ER BSF 
Tb11.01.4701 membrane-bound acid phosphatase 1 precursor (MBAP1)* 59.38 lysosome BSF 
Tb927.4.2450 thioredoxin* 44.49 n/a BSF 
Tb11.02.5450 glucose-regulated protein 78, luminal binding protein 1 (BiP)* 71.44 ER both 
Tb11.02.4100 pretranslocation protein, alpha subunit, SEC61-like (pretranslocation process) protein* 53.65 ER BSF 
Tb927.6.4280 glyceraldehyde 3-phosphate dehydrogenase (GAPDH)** 43.87 G BSF 
Tb09.v1.0380 spermidine synthase (SpSyn)** 32.93 n/a PCF 
[a]. G, M and n/a represent glycosomal, mitochondrial and not available, respectively. Symbols in the protein name column: (*) sensitive to RNA 
interference; (**) putative drug target. The five “hits” chosen for further validation experiments are highlighted (in gray).  
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4.2.4 Cellular Uptake and Morphological Changes upon Drug Treatment 
From our present studies, we have discovered a consistent trend, that is, 
Orlistat and its analogues killed BSF parasites much more effectively than PCF 
parasites. Our in situ proteomic profiling results have thus far suggested that Orlistat 
targets similar pathways/organelles in these two different parasites. Both common and 
unique molecular targets were successfully identified. While it is possible that Orlistat 
achieved much more efficient killing of BSF over PCF by selectively inhibiting some 
of the unique proteins present only in BSF (the investigation of this hypothesis is 
on-going), we wonder whether the difference in trypanocidal activity might also be 
due to differential cellular uptakes of this drug in the two different forms of parasites. 
With the alkyne-containing 3-1a, which is an Orlistat mimic containing a extremely 
conservative C-C to C≡C structural mutation and possessing full antitrypanocidal 
activity, we were able to use it to accurately assess the cellular uptake and sub-cellular 
localization of Orlistat in both BSF and PCF parasites by fluorescence microscopy. In 
our bioimaging experiments, 3-1a-treated live parasites were fixed, treated with the 
rhodamine-azide reporter tag under the bio-orthogonal click chemistry conditions then 
imaged. Immunofluorescence (IF) experiments were carried out, where applicable, to 
determine the sub-cellular localization of the drug, as well as subsequent 
morphological changes on the parasites (Figure 4.12 and 4.13). In a typical 
experiment, trypanosomes (1×10
5
 cells/mL for either forms) were treated with 1-10 
M of 3-1a for 2 hours. As shown in Figure 4.12 (3-1a was colored in Red and 
DAPI-stained nucleus and kinetoplast were colored in Blue), PCF parasites displayed 
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poor cellular uptakes of the drug - up to 10 M of 3-1a was needed in order to be 
sufficiently detected inside the parasites (e.g., right panels in Figure 4.12). On the 
other hand, the cellular uptake of the drug could be readily detected in BSF parasites 
even with only 1 M of 3-1a (left panels in Figure 4.12). Previous studies had 
suggested that BSF parasites exhibit much more rapid rates of endocytosis of 
lowdensity lipoproteins (LDLs), which carry phospholipids and cholesteryl esters, as 
compared to PCF parasites.
[114]
 It is therefore intriguing to speculate that our 
Orlistat-like probes (i.e., 3-1a), given their lipid-like chemical structure, may also 
enter the BSF parasites effectively via receptor–mediated endocytosis pathways. The 
same reason may also explain why our Orlistat-like compounds are much more potent 
trypanocidal agents in BSF than in PCF parasites. It should be highlighted that with 
the unique properties of these probes in bioimaging experiments (cell permeability, 
“click-able”fluorescence tagging), they allow convenient, rapid and highly sensitive 
monitoring of drug action in cells, and may be further developed into novel probes for 
positron emission tomography (PET) by clicking with reporter tags containing 
suitable radioisotopes (e.g., 
18
F). 
We further analyzed the morphological changes of different sub-cellular 
organelles in BSF and PCF T. brucei upon treatment with 3-1a (125 nM and 2.5M 






 antibodies were used to fluorescently stain the endoplasmic 
reticulum (ER), lysosomes, and glycosomes of the parasites, respectively. 
MitoTracker was used as the mitochondrion fluorescence marker. DAPI (2 g/mL) 
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was used to stain the kinetoplast and nuclear DNA of the parasites. As shown in 
Figure 4.14, the normal network of the mitochondrion visualized with MitoTracker 
collapsed into a flattened sheet with a series of fenestrations upon drug treatments. 
The ER, glycosomes and lysosomes were barely visible compared with control cells 
(treated with DMSO only). These observations confirm that Orlistat has clear effects 
on the morphology of mitochondria, glycosomes, ER and lysosomes in both BSF and 
PCF cells, indicative of specific targeting of proteins localized to these organelles by 
the drug. These results correlate reasonably well with our above-described proteomic 

























Figure 4.12. Cellular uptake of THL-R (3-1a) within the BSF and PCF T. brucei. Parasites (2 × 10
5
 cells) were incubated with THL-R (3-1a) (at 
0, 1 and 5 M for BSF and 0, 5, and 10 M for PCF, respectively) for 2 h, reacted with 10 M of rhodamine–azide (2-33) under CuAAC 
conditions, and then imaged. (Top) DAPI stained, drug-treated parasites (with nucleus and kinetoplast colored in blue). (Bottom) Rhodamine 



































Figure 4.13. Morphological changes in BSF and PCF T. brucei treated with THL-R 
(3-1a) for 24 h (DMSO as negative controls). Immunofluorescence galleries of T. 
brucei parasites labeled with different sub-cellular organelle markers. MitoTracker 
Red CMXRos (Invitrogen) was used to stain the mitochondrion; anti-TbSKL was 
used to label glycosomes; anti-TbBiP was used to label ER; anti-TbTrypanopain was 
used to label lysosomes.All cells were counter-stained with DAPI to visualize 
kinetoplast and nucleus (colored in blue). Phase contrast images and merged 
fluorescence images are shown as labels indicate. Scale bar represents 10 m.  
 
4.3 Conclusion 
We have evaluated our orlistat-like probes for their antitrypanocidal activities 
against both the bloodstream form (BSF) and procyclic form (PCF) of protozoan 
parasite Trypanosoma brucei. Our results showed Orlistat and some of its analogs 
(3-1a, 3-1d, 3-1e & 3-1j) possess one of the most potent trypanocidal profiles known 
to T. brucei, especially against the BSF parasites. This, together with its already 
well-characterized pharmacokinetic and safety profiles as an FDA-approved drug, 
indicates that Orlistat should be immediately considered by pharmaceutical 
companies as one of the most promising trypanocidal drug candidates. Subsequent in 
situ proteomic profiling of the Orlistat-like probes enabled us to identify, for the first 
time, putative cellular targets of Orlistat in both BSF and PCF parasites, indicating 
organelle-specific targeting of the drug. Some of which were further validated by 
labeling of recombinantly expressed enzymes in E. coli lysate. Our results suggest 
that orlistat acts as a potent trypanocidal drug in T. brucei by targeting essential 
parasitic proteins invloved in lipid and fatty acid metabolic pathways, including 
lipases, fatty acyl CoA synthetases and other proteins possessing acitve 
serine/cysteine residues. With the unique design and properties of these Orlista-like 
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probes (e.g. cell permeability and click-ability), they allowed convenient, rapid and 
highly sensitive imaging-based experiments to be carried out with live parasites to 
study drug uptake and morphological changes. Our results confirmed much more 
efficient cellular uptakes of Orlistat-like compounds by BSF over PCF parasites. 
Clearly, in order to depict a better understanding of possible mechanisms and 
pharmacological effects of Orlistat in T. brucei, additional studies will be required for 
validation of other putative targets identified from our present study, and to further 
understand the biological consequency of some of these already-validated targets. 
Notwithstanding, from our current results, we concluded that Orlistat should be 
seriously considered as one of the most promising candidates for further anti-parasitic 
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Abstract 
K11777 is a potent, irreversible inhibitor of parasite and mammalian cysteine 
protease. Its direct intracellular target proteins and potential side effects as a 
antiparasitic agent, however, have remained largely elusive to date. We report the 
design, synthesis and application of K11777-derived activity-based probes (ABPs) 




More than a billion people suffer from neglected tropical diseases (NTDs), 
including malaria (caused by Plasmodium falciparum), sleeping sickness (aka Human 
African trypanosomiasis; caused by Trypanosoma brucei), Chagas’ disease (aka 
American trypanosomiasis; caused by Trypanosoma cruzi), leishmaniasis, 
onchocerciasis, lymphatic filariasis and schistosomiasis.
[83b,118]
 Most drugs available 
to date however are limited by parasite resistance and marked host toxicity. New 
strategies and targets that can effectively combat these parasitic diseases are therefore 
needed urgently. Equally important, from the standpoint of drug efficacy and safety, 
comprehensive cellular target profiling of a given drug candidate is becoming an 
integral step in the process of drug discovery. The knowledge of potential on- and 
off-targets of a drug at the earliest stages of its development will not only shed light 
on its potential success (or failure) during the clinical trials, but also provide 
invaluable insights into its mode of action and further optimizations.  
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One promising strategy for discovering small-molecule therapeutics for 
parasitic diseases has been to target the cathepsin L subfamily of the papain-like (clan 
CA, family C1) cysteine proteases such as cruzain, rhodesain (also called brucipain or 
trypanopain) and falcipains (FP-2 and -3).
[119,120]
 Among various pharmacophores, 
vinyl sulfones have been widely studied as potential cysteine protease inhibitors and 
are entering the development pipeline as anti-parasitics (Figure 5.1).
[121]
 One of these, 
K11777, which was developed from the predecessor K11002 by replacing the 
morpholine-urea ring in K11002 with an N-methylpiperazine (N-Mpip) for increased 
oral bioavailability and solubility in intestinal fluids, is currently in late-stage 
preclinical trials for Chagas disease.
[122-124] 
Although it is clear that K11777 also 
demonstrated efficacy against other parasites as diverse as trypanosomes (i.e., T. 
brucei, L. major, T. gondii, E. histolytica) and schistosome bloodflukes (i.e., S. 
mansoni),
[125-127
 its mechanism of action is not well understood except for inhibition 
of the cathepsin L and/or B-like cysteine proteases in vitro. Little information is 
available concerning its other potential cellular targets and distribution.  
I previously described a chemical profiling approach that makes use of 
drug-like probes for proteome-wide profiling of cellular targets in living cells. This 
method is based on activity-based protein profiling (ABPP), and large-scale 
LC-MS/MS analysis, allowing rapid determination of potential cellular targets of 
bioactive small molecules. Herein, I describe the first application of this method in 
live parasites. Several cell-permeable probes based on K11777 were designed, 












Figure 5.1. Structures of representative, anti-cruzain (K11002, K11777, WRR-483, & 




5.2 Results and Discussion 
5.2.1 Design of K11777-like Probes 
The design of K11777-like probes was based on the general structure of 
several trypanocidal vinyl sulfones (e.g., K11777, K11002 & 
Cbz-Phe-Hph-VSCH2Ph) and our previous experience with Orlistat-like probes. We 
took advantage of key properties of vinyl sulfones in our rational design of ABPs: (1) 
vinyl sulfones inhibit cysteine proteases via a Michael addition to form a covalent 
bond with the active-site cysteine residue (e.g., Cys 25 in the crystal structures of 
cruzain•K11777, rhodesain•K11777, & rhodesain•K11002; Cys 51 in 
FP-3•K11017);[121,128] (2) recent crystal structures of rhodesain with K11777 and 
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K11002 have shown that the N-Mpip /morpholine-urea ring didn’t form any specific 
polar interactions with rhodesain and thus was assumed non-essential for inhibitor 
binding.
[121,128]
 Accordingly, probes 5-1 and 5-2, in which an C-C triple bond was 
introduced at the P3 position, were synthesized. We also synthesized probe 5-3 by 
introducing an C-C triple bond at the P1’ position. Our experience was that such 
extremely conservative modifications would not compromise the native biological 
properties of mother compounds, whilst allowing subsequent target identification by 













Figure 5.2. Structures of K11777-like probes (5-1, 5-2, & 5-3) and applications in T. 
brucei proteome profiling. Cell-permeable probes are directly incubated with living 
cells and covalently bind to the active sites of dedicated target proteins via a Michael 
addition. The cells are subsequently lysed, and the labeled proteins are “clicked” to a 
fluorescent rhodamine-azide dye for visualization/imaging or a biotin-azide for target 




Superimposition of the rhodesain•K11777 and rhodesain•K11002 structures 
highlights structural differences that cause rhodesain to provide room for the branched 
N-Mpip. Molecular docking experiments were also carried out to ensure extra groups 
introduced in three analogues did not affect K11777 binding to its targets. As shown 
in Figure 5.3, the K11777 core binds expectedly to the enzyme pockets, with 
interactions closely matching those reported in the rhodesain•K11777 x-ray structure. 
The extra handles in the probes appeared to be projected toward the solvent-exposed 





















Figure 5.3. Superimposition of rhodesain•K11777 and rhodesain•K11002 (A). 
Surface representation of the docking of K11777 (in red) and VS-1 (in green, part B), 
VS-2 (in blue, part C) & VS-3 (in cyan, part D) in the binding pockets of rhodesain 
(the structure of rhodesain•K11777 has been described in the Protein Data Bank (PDB 























5.2.2 Synthesis of K11777-like Probes 
The three analogues were synthesized by using appropriate modifications of 
previously described methods.
[129]
 Reduction of the Weinreb amide 5-6 derived from 
commercially available Boc-homophenylalanine gave the corresponding aldehyde 5-7 
in excellent yields. HornerWadsworthEmmons olefination with phosphonate 5-5 
(prepared in two steps involving alkylation of benzenethiol with diethyl 
iodomethylphosphonate and oxidation of sulfides 5-4 to sulfone 5-5 using m-CPBA) 
provided the vinyl sulfone 5-8 in 71% yield. Deprotection of the Boc group afforded 
amine 5-9 as a TFA salt. This material was coupled to 5-16 or 5-23 under standard 
peptide coupling conditions giving 5-1 (VS-1), and 5-2 (VS-2), repectively (K11777 
and K11002 were also synthesized in parallel, see Scheme 5.2). Compound 5-16 was 
prepared from piperazine in five steps (only two purification steps), including 
monoBoc protection of piperazine, Nalkylation with propargyl bromide, Boc 
deprotection, urea 5-15 formation via reaction of an intermediate isocyanate 5-11 
(prepared in two steps involving methyl esterification of phenylalanine and generation 
of amino acid ester isocyanate using triphosgene) with 5-14, methyl ester deprotection. 
Similar to 5-16, compound 5-23 was conveniently synthesized from the intermediate 
isocyanate 5-11 with commercially available (4-ethynylphenyl)methanol, thus giving 
rise to the corresponding carbamate 5-22, followed by the deprotection of methyl ester. 
For the synthesis of 5-3, the known phosphonate 5-24 was first prepared as previously 
described.
[130]
 Subsequent Oalkylation with propargyl bromide gave 5-25. Following 
HornerWadsworthEmmons reaction with aldehyde 6-7, Boc deprotection, coupling 
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with 5-19, which was obtained in three steps in 82% overall yield, furnished the 


























































5.2.3 Effects on Trypanocidal Activities
We first evaluated the anti-trypanocidal activities of vinyl sulfones VS-1, 
VS-2 & VS-3 (i.e., 5-1, 5-2 & 5-3), together with K11002 and K11777 in cell culture 
of both the bloodstream form (BSF) and the procyclic form (PCF) of T. brucei using 
the Guava ViaCount assay as described in Chapter 4, which represent two distinct 
stages of T. brucei during its complex life cycle alteration between mammalian hosts 
and insect vectors. In this context, it is worth noting that the BSF and PCF parasites 
differ extensively in morphology and metabolism. All vinyl sulfones blocked the 
parasite growth to a similar extent in a dose-dependent manner with ED50 values 
between 4 and 8 M (Figure 5.4). Additionally, there was no noticeable difference in 
inhibition between BSF and PCF trypanosomes by all five compounds. These data 
show the introduction of a terminal alkyne handle at the indicated positions did not 
noticeably affect its trypanocidal activity. Therefore, all three probes should be 
suitable chemical probes for proteome profiling and cellular target identification of 
K11777. Only VS-1, however, was chosen for further comprehensive proteome 
profiling, LC-MS/MS and cellular bioimaging experiments based on its closest 
resemblance to K11777. The result was somewhat surprising since recent studies for 
cysteine proteases in the T. brucei show that cathepsin B like protease known as 
TbCatB, which is more abundantly expressed in the bloodstream versus the procyclic 
form of the parasite, is essential for parasite survival in both in vitro
[131]
 and in vivo
[132]
 
models. In contrast, knockdown of brucipain by RNAi in vitro produced no detectable 
phenotypic changes.
[131]
 As referenced above, the phenotypes associated with 
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interference of TbCatB are similar to those observed in the earlier study in which the 
cysteine protease inhibitor Z-Phe-Ala-CHN2 (where Z is benzyloxycarbonyl) was 
used to kill the parasites. Thus, results from these in vitro RNAi studies of these two 
cathepsin-like proteases in T. brucei support the hypothesis that Z-Phe-Ala-CHN2 
kills the bloodstream form T. brucei by inhibiting TbCatB rather than brucipain. 
However, it remains to be clarified whether inhibition of the bloodstream form T. 
brucei development by vinyl sulfones (e.g., K11777) also might have been originated 







Figure 5.4. Dose-dependent trypanocidal effects of K11002, K11777 and three 
analogues (VS-1, VS-2 & VS-3) against bloodstream form (top) and procyclic form of 




5.2.4 In situ Proteome Profiling and Target Identification 
Next, we compared the in situ proteome reactivity profiles of our probes 
against their cellular targets in live BSF and PCF (Figure 5.5). Generally, the three 
probes showed comparable in situ proteome reactivity profiles, thereby indicating 
they have similar cellular targets in the parasites. However, the reactivity profiles 
 







K11777 (3.9  ± 0.3 M)
VS-2  (4.1  ± 0.4 M)
VS-3  (4.8  ± 0.5 M)
VS-1  (4.6  ± 0.2 M)
BSF


























VS-2  (7.0  ±  0.6 M)
VS-3  (5.1  ±  0.5 M)
K11777 (5.8  ±  0.4 M)
VS-1  (6.7  ±  0.4 M)
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between BSF and PCF for VS-1 (lanes 1 and 5 in part A of Figure 5.5), though similar, 
showed noticeable differences, suggesting the existence of both common and unique 
targets in the two forms. In addition to the expected rhodesain and TbCatB bands (~41 
kDa and ~31 kDa indicated by arrows, respectively), which were subsequently 
verified by affinity pull-down/western blotting with the corresponding antibodies 
(part B of Figure 5.5), a number of other proteins were also covalently labeled by the 
three probes. These labeled bands were K11777-sensitive, that is, their labeling was 
blocked by the presence of a competing K11777 (lanes 2 and 6). Also evident in 
Figure 5.5A & 5.5B was that, VS-1 labeled only the mature active enzyme form of 
rhodesain (~41 kDa), but not its proform (~48 kDa).
[140]
 In addition, TbCatB labeled 
by VS-1 was mostly detected in BSF, which is consistent with previous findings that 
TbCatB was up-regulated in BSF.
[141]
 Subsequently, we performed large-scale 
proteomic analyses using VS-1 to identify potential cellular targets of K11777 in both 
parasite forms by affinity pull-down/LC-MS/MS experiments; all proteins were 
identified with a minimum protein score of 40 as well as at least two unique peptides, 
and results are summarized in Figure 5.5C, Table 5.1 and in Appendix 2. In total, 49 
and 111 proteins were identified from BSF and PCF, respectively, 20 of which were 
from both parasite forms (see Appendix 2 for detailed protein ID). Among these 
proteins, some were inevitably non-specific protein binders caused by their “sticky” 
nature as well as their high endogenous expression level (e.g. cytoskeletal proteins 
and carbohydrate-metabolism-related proteins). We focused our attention on other 
candidates which possess known nucleophilic cysteine residues, because they are 
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more likely true cellular targets of K11777 (Table 5.1); in addition to the expected 
rhodesain and TbCatB, other proteins such as BS2, MCA4, AOX and two proteasome 
subunits were identified. It is worth noting that vinyl sulfones had previously been 
identified as potent and irreversible inhibitors of proteasomes (through modifications 
of their active-site threonine).
[133,134]
 Thus, it is not surprising that two proteasome 
subunits were detected in PCF. It is also interesting to note that many more proteins 
were identified from PCF alone (91) than from BSF (29), and many of them were 
cytosolic. 
We also confirmed that our probes were capable of labeling active cathepsin 
L in intact HepG2 cells. In doing so, we performed pull-down and Western blotting 
experiments with anti-cathepsin L antibody. Notably, cathepsin L is a lysosomal 
proteinase which is significantly involved in all stages of cancer progression, 
including growth, antigiogenesis, invasion, and and metastasis.
[135,136]
 Recent interest 
in cathepsin L show that proteolysis by this enzyme is required for the entry and 
replication of the SARS and Ebola viruses in human cells.
[137-139]
 Thus cathepsin L 
inhibitors have potential as novel anti-viral agents. As shown (Figure 5.6), cathepsin L 
labeled by VS-1 in HepG2 is the mature active enzymes (~30 kDa), as no labeling of 














Figure 5.5. (A) In situ proteome profiling of probes (25 M) against T. brucei BSF 
and PCF. K11777 was added to selected lanes in competition experiments. Putative 
bands of labeled rhodesain and TbCatB were indicated (with arrows). (B) Western 
blotting validation of rhodesain and TbCatB labeled with VS-1 (25 M), following in 
situ labeling and affinity pull-down/WB experiments. Null pull-down experiments 
(with DMSO) were used as negative controls. (C) Venn diagram illustrating the 











Figure 5.6. In situ proteome-profiling of VS-1 against HepG2 live cells and Western 
blotting analysis of pulled-down fractions treated with VS-1 (25 M), or DMSO as 















































































29       20          91







Table 5.2. Representative proteins identified with VS-1 in Trypanosoma brucei
[a]
 
T. brucei gene protein name Mw / kDa location detection 
Tb927.6.1000 cysteine peptidase precursor (CP), Clan CA, family C1, cathepsin L-like* 48.34 lysosome both 
Tb927.6.560 cysteine peptidase C (CPC), Clan CA, family C1, cathepsin B-like (TbCatB)** 37.22 lysosome BSF 
Tb927.10.8230 protein disulfide isomerase, bloodstream-specific protein 2 precursor (BS2)* 55.58 cytoplasm BSF 
Tb927.5.1810 lysosomal/endosomal membrane protein p67 (p67)* 72.73 lysosome BSF 
Tb10.70.5250 metacaspase MCA4, cysteine peptidase, Clan CD, family C13 (MCA4)** 38.97 nucleus BSF 
Tb927.10.7090 alternative oxidase (AOX)** 37.59 mitochondrion BSF 
Tb927.10.290 proteasome alpha 2 subunit* 25.36 cytoplasm PCF 
Tb927.10.6080 proteasome beta 5 subunit (PRCE)* 34.42 cytoplasm PCF 
Tb09.160.4250 tryparedoxin peroxidase (TRYP1)** 22.43 cytoplasm PCF 
Tb927.5.3350 iron superoxide dismutase** 26.82 mitochondrion PCF 
Tb927.10.7410 succinyl-CoA ligase [GDP-forming] beta-chain* 44.91 mitochondrion PCF 
Tb10.70.4740 enolase** 46.59 glycosome PCF 
[a]




5.2.5 Cellular Imaging 
To visualize cellular localization of VS-1 and potential cellular targets of 
K11777, live parasites were directly treated with VS-1, fixed, and reacted in situ with 
the rho-azide reporter, then imaged. Overall, no noticeable difference was observed in 
the probe uptake between BSF and PCF (Figure 5.7). As shown in Figure 5.8, VS-1 
signals were detected mostly in the lysosome of BSF, where endogenous rhodesain 
resides. This lysosoal colocalization is important given that K11777 had little or no 
toxicity on mammalian presumably because vinyl sulfones become concentrated 
within the parasite,
[143]
 and/or human cathepsins’ redundancy and activation within 
other subcellular compartments.
[144,145]
 In contrast, the probe was shown to be evenly 
distributed throughout PCF parasites with no specific subcellular localization. Similar 
results were obtained with HepG2 mammalian cells as shown in Figure 5.9. This 
result could be due to the fact that K11777 is a broad-spectrum cysteine protease 
inhibitor.
[142] 
Our results correlate well with our above-described proteome profiling 
and affinity pull-down/LC-MS/MS data where different cellular targets were labeled 
in the two parasite forms, and many more cytosolic proteins were identified in PCF. 
The partial colocalization observed between VS-1 and rhodesain in BSF presumably 
also reflected the presence of other side targets of K11777. Collectively, these results 
established that VS-1 not only can be used for in situ proteome profiling and 
identification of potential cellular targets of K11777 in live parasites, it may also be 













Figure 5.7. Cellular uptake of VS-1 within BSF and PCF T. brucei. Parasites (2 × 10
5
 cells) were incubated with VS-1 (at 0, 10 & 25 M, 
respectively) for 2 h, reacted with 10 M of rhodamine–azide 2-33 under CuAAC conditions, and then imaged. DAPI stained (with nucleus 













Figure 5.8. Confocal microscopy of VS-1 localization in BSF (top) and PCF (bottom). 
Live parasites were treated with VS-1 (25 M) followed by imaging as described in 
ESI. Panels (a) and (e): bright-field images. Panels (b) and (f): 554 nm channel 
(pseudocolored in red) detecting cellular localization of VS-1. Panels (c) and (g): 
Immunofluorescence (IF) staining at 488 nm channel (pseudocolored in green) to 
detect cellular localization of rhodesain. Anti-rhodesain primary antibody and 
FITC-conjugated anti-rabbit IgG secondary antibody were used. Panels (d) and (h): 
merged images of panels (b) and (c), (f) and (g) together with nuclei (stained with 
DAPI; pseudocolored in blue). All images were acquired under the same settings. 









Figure 5.9. Immunofluorescence analysis of active cathepsin L in HepG2 cells 






In conclusion, we have successfully synthesized and evaluated K11777-like 
probes for their anti-trypanocidal activities against both BSF and PCF T. brucei. 
Subsequent in situ proteome profiling of VS-1 enabled us to tentatively identify 
previously unknown cellular targets of K11777 in both parasite forms. Furthermore, 
we demonstrated the utility of our probe for live-parasite labeling and visualization of 
potential K11777-responsive targets (e.g. rhodesain). We believe that our 
observations may provide important information for investigating K11777 as a 
antiparasitic drug candidate other than T. brucei. Further studies are underway to 







Design, Synthesis and Biological Evaluation of Potent 
Azadipeptide Nitrile Inhibitors and Activity-Based Probes as 
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Trypanosoma cruzi and Trypanosoma brucei are parasites that cause Chagas 
disease and African sleeping sickness, respectively. There is an urgent need for 
development of new drugs against both diseases due to the lack of adequate cures and 
emerging drug resistance. One promising strategy for the discovery of small-molecule 
therapeutics against parasitic diseases has been to target the major cysteine proteases 
such as cruzain for T. cruzi, and rhodesain/TbCatB for T. brucei. Azadipeptide nitriles 
belong to a novel class of extremely potent cysteine protease inhibitors against 
papain-like proteases. We herein report the design, synthesis, and evaluation of a 
inhibit both recombinant cruzain and rhodesain at low nanomolar/picomolar ranges. A 
strong correlation between the potency of rhodesain inhibition (i.e. target-based 
screening) and the trypanocidal activity (i.e., whole organism-based screening) of the 
compounds was observed. To facilitate detailed studies of this important class of 
inhibitors, selected hit compounds from our screenings were chemically converted to 
activity-based probes (ABPs), which were subsequently used for in situ proteome 
profiling and cellular localization studies to further elucidate potential cellular targets 
(on and off) in both the disease-relevant bloodstream form (BSF) and the 
insect-residing procyclic form (PCF) of Trypanosoma brucei. Overall, the inhibitors 
presented herein show great promises as a new class of anti-trypanosome agents that 
possess better activities than existing drugs. The activity-based probes generated from 
this study could also serve as valuable tools for parasite-based proteome profiling 
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studies, as well as bioimaging agents for studies of cellular uptake and distribution of 
these drug candidates. Our studies therefore provide a good starting point for further 





Chagas disease (or American trypanosomiasis) is caused by Trypanosoma 
cruzi and affects around 12 million people in Latin America, resulting in ~14,000 
deaths per year.
[146]
 More recently, due to immigrant carriers or infections from 
contaminated transfusions and organ transplants, Chagas disease has been reported in 
areas where it normally doesn’t exist.[147] Human African trypanosomiasis (HAT, 
sleeping sickness) is caused by tsetse fly transmitted parasites of Trypanosoma brucei. 
Over 60 million people in sub-Saharan Africa are at risk of this disease, of which 
there are already 50,000-70,000 confirmed cases.
[83e]
 Existing drugs used to treat 
these diseases are generally highly toxic and often ineffective, and drug resistance has 
developed in some cases.
[148]
 With no immediate prospect of vaccines, there is a dire 
need to develop new trypanocidal agents with acceptable efficacy and safety profiles. 
One encouraging approach to novel anti-parasitic agents is the development of small 
molecule inhibitors targeting parasitic cysteine proteases such as cruzain (an essential 
protease for the survival of T. cruzi
[149]





 Cysteine proteases are fundamental to the metabolism of many parasites, 
and their inhibitors have been shown to kill protozoan parasites in both culture and 


















Figure 6.1. (A) Representative structures of anti-parasitic cysteine protease inhibitors. 
(B) Proposed inhibitory mechanism of cysteine proteases by azanitriles (top) and 
diazomethyl ketones (bottom). 
 
One such inhibitor, N-Mpip-Phe-Hph-VSPh (also known as K11777; in 
Chapter 5) is currently in late-stage preclinical trials for Chagas disease.
[124]
  K11777 
was also shown to have potent in vitro and in vivo (mice were cured of infection) 
bioactivities against T. brucei,
[126,150]
 presumably by targeting rhodesain, TbCatB, or 





Z-Phe-Ala-CHN2 (6-6a; Figure 6.1A), has also been shown to be lethal to T. brucei in 
both in vitro and in vivo studies.
[85,151]
 Vinyl sulfones, tetrafluorophenoxymethyl 
ketones, and diazomethyl ketones, all of which contain an electrophilic “warhead” 
that can covalently and irreversibly inactivate cruzain as a result of nucleophilic attack 
by the active-site cysteine (a representative example is shown in the bottom scheme of 
Figure 6.1B), are also known parasiticidal agents. Vinyl sulfones, however, are also 
well-known proteasome inhibitors.
[133,134]
 Previous work in developing anti-malarial 
compounds showed that synthetic peptidyl aldehydes were potent reversible inhibitors 
of the cysteine protease hemoglobinases, falcipain-2 and falcipain-3. One such 
compound, Mu-CO-Leu-hPhe-al (Figure 6.1A), which exhibited strong inhibitory 
activity on falcipains and cultured Plasmodium falciparum parasites, was tested in a 
murine malaria model. Recently, Gütschow and co-workers reported proteolytically 
stable azadipeptide nitriles as a novel class of cysteine protease inhibitors that form 
covalent but reversible isothiosemicarbazide adducts with the active-site cysteine 
(Figure 6.1B; top).
[152,153]
 Using cathepsin K as an example, the authors further 
demonstrated that structural optimizations of azadipeptide nitriles could result in 
selective cathepsin inhibitors. A subsequent study clearly demonstrated that 
azadipeptide nitriles also possessed potent anti-malarial activities.
[154]
 In the current 
study, we have taken efforts to further optimize this class of inhibitors as potential 
agents against trypanosome parasites, with the ultimate aim to generate highly potent 
inhibitors that possess fewer off-targets and side effects (which are often associated 
with irreversible enzyme inhibitors).
[155]
 Herein, we report the chemical synthesis and 
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biological evaluation of a series of aza-nitrile-containing inhibitors, as well as some 
activity-based probes derived from selected compounds. By first screening these 
compounds against purified recombinant cruzain and rhodesain (i.e., target-based 
screening), we found most of them were indeed highly potent inhibitors, with IC50 
values in the low nanomolar/picomolar ranges. Since inhibitor sensitivities are often 
affected by assay conditions such as pH, ionic strength, and the presence of lipids or 
other proteins, we subsequently carried out whole organism-based screening and 
quantitatively verified the potencies of some of these compounds. A good correlation 
between the potency of rhodesain inhibition and the trypanocidal activity of these 
compounds was observed. Next, by combining the whole organism-based screening 
with activity-based protein profiling (ABPP) coupled with the bio-orthogonal click 
chemistry, we carried out comprehensive proteome profiling experiments against 
selected hit compounds in an effort to identify both on- and off-targets, which 
provided invaluable insights into the mode-of-action and further optimizations. 
Finally, fluorescence imaging experiments with the probes provided further 
information on the compound’s cellular uptake and sub-cellular distribution (Figure 
6.1C). Overall, the inhibitors presented have promise as trypanocidal agents with 
improved activity, and the probes can serve as valuable tools for assessing the uptake 
and distribution of the drug candidate and for examining the potential for drug 













Figure 6.2. Overall workflow of chemical screens and characterizations of azanitriles 
that were screened with target-based (cruzain & rhodesain) and organism-based 
assays, and conversion of hit molecules into activity-based probes (ABPs). Putative 
identification of cellular targets (on and off) was done via in situ parasite-based 
proteome profiling. Reaction of the alkyne handle on the probe with rhodamine-azide 
via click chemistry allows visualization of target proteins by SDS-PAGE gel or 
fluorescence microscopy. Alternatively, with biotin-azide, the probe-labeled parasite 
proteome could be pulled-down/LC-MS/MS for target identification. 
 
 
6.2 Results and Discussion 
6.2.1 Design and Synthesis of Azadipeptide Nitriles 
The isoelectronic replacement of the CH group by a nitrogen atom to yield 
azapeptides is a common structural modification in the chemistry of peptides and 
peptidomimetics.
[156]
 This structural modification was first applied to the P1 position 
of peptide nitriles in 2008.
[152]
 The resulting azadipeptide nitriles were characterized 







































compounds possess a methylated P2-P1 peptide bond, which accounts for their 
stability towards proteolytic cleavage. Such azadipeptide nitriles also showed 
time-dependent inhibition, and the reversible formation of adducts with the active site 
cysteine was proposed (part B of Figure 6.1; top). The strategy we had undertaken in 
the current work was to build on these initial results to further demonstrate potent 
enzymes are structurally homologous to cathepsin L. Previous studies showed that 
cruzain was effectively inhibited by vinyl sulfones bearing Leu or Phe residues at the 
P2 position (e.g. K11777/K11002). However, the P1 and P3 groups were considered to 
be less important, due to their solvent exposure as seen in the protein 
structure.
[121,128,157]
 In other words, the urea group at the P3 position in 
K11777/K11002 did not actively participate in binding interactions with the enzyme; 
therefore this moiety could be replaced by a carbamate group, or an amide 
group.
[140,158]
 The designed library was based on the scaffold presented in Scheme 6.1, 
in which R
3
 was either 2,3-dihydro-1,4-benzodioxin-6-yl (resulting in an amide group 





 could be either phenyl, isopropyl or isobutyl, so that the amino acid at 
the P2 position was either Phe, Val or Leu, respectively. The highest variability was 
introduced at the P1 position with five different groups (i.e., Me, Bn, CH2Bn, 
CH2CH2Bn, n-butyl), thereby enabling a systematic evaluation of the 
structure-activity relationship (SAR) between members of this library and their 
inhibitory property against cruzain/rhodesain. In this context, it is noteworthy that the 
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structural diversity of this library can be easily increased by further variations at P1, P2 
and P3 positions using the same chemistry developed herein.  
As shown in Scheme 6.1, the synthesis of our library was accomplished by 
modifications of previously reported procedures for the preparation of 6-3b and its 
derivatives (Scheme 6.2).
[16]
 Starting from commercially available Boc-protected 
amino acids, we  prepared the corresponding benzyl esters and then removed the 
amine protecting group using standard methods. Next, the coupling with 
1,4-benzodioxane-6-carboxylic acid to give 6-8ac, whereupon the deprotection was 
carried out hydrogenolytically. The hydrazones 6-10ac were subjected to the 
reductive amination of various aldehydes using dimethylamine-borane complex as 





Upon treatment with cyanogen bromide finished the desired aza-nitriles 6-1ao 





-alkylhydrazide 6-15 was prepared by using sodium cyanoborohydride 
in the presence of acetic acid,
[159]
 instead of dimethylamineborane complex. 
Attempts to prepare the aldehyde 6-4 by oxidation of the corresponding primary 
alcohol with Dess-Martin periodinane (DMP) resulted in a complex mixture of 
products. Therefore, the Weinreb amide 6-22 was prepared and subsequently reduced 
























































6.2.2 Biological Screening 
With twenty-one aza-nitriles (6-1ao, 6-2 & 6-3ae), the aldehyde 6-4 in 
hand, we next evaluated the inhibitory activity of the library against cruzain and 
rhodesain in fluorometric microplate assays using the substrate Z-Phe-Arg-AMC. For 
comparison, K11002 was also assayed under conditions. All compounds exhibited 
greater inhibitory capacity toward rhodesain than cruzain (Table 6.1). The anti-cruzain 
and anti-rhodesain activities were well correlated. This phenomenon is not surprising 
given the structural homology of these two enzymes. In general, compounds with Phe 
(6-1ae) and Leu (6-1ko) in P2 were more active than compounds with Val (6-1fj), 
whilst Leu compounds (6-1ko) exhibited higher potency for cruzain. In P1, methyl 
(6-1a, 6-1f & 6-1k) group yielded better results than others. Finally, the changes with 
P3 confer a subtle effect on enzyme selectivity, arguing that P3 may be a recognition 
element for other enzymes in the papain class than initially assumed. Indeed, a study 
in which a combination of optimized P2 and P3 substituents in azadipeptide nitriles led 
to a picomolar cathepsin K inhibitor with remarkable selectivity over other cathepsins 
was recently published.
[153]
 Compound 6-2 (Figure 6.2), bearing a Phe side chain in P2 
and Boc group in P3, respectively, was not only one of the strongest inhibitors of 
rhodesain (IC50 = 60 pM), but it also presented the highest selectivity toward this 
protease (IC50 Cuzi/IC50 Rhod = 193). Compound 6-1a was also a potent inhibitor of 
rhodesain (IC50 = 140 pM, IC50 Cuzi/IC50 Rhod = 60). Another inhibitor with highest 
activity toward rhodesain was compound 6-1k (IC50 = 60 pM), although this 
compound did not demonstrate selectivity (IC50 Cuzi/IC50 Rhod = 5). As a control, IC50 
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values of K11002 were calculated for rhodesain (IC50 = 0.36 nM) and cruzain (IC50 = 
6.6 nM). Interestingly, compound 6-4, with an incorporated aldehyde “warhead”, 
displayed comparable potency as K11002/K11777 against both enzymes (IC50 values 
of 0.55 nM and 3.6 nM, respectively, against rhodesain and cruzain). Although we did 
not further evaluate the inhibitory activity of our compounds against TbCatB due to 
the unavailability of this enzyme, we were encouraged by the observation that some 
compounds show low picomolar IC50 values against rhodesain, thereby decided to 
investigate their activities against live parasites (i.e. whole organism-based screening). 
In this context, it is noteworthy that TbCatB has been shown to be essential for T. 
brucei survival based on RNA interference studies in vitro
[131]
 and in mice
[132]
. 
Whether rhodesain is essential was unclear due to a lack of complete silencing (via 
RNAi) of target transcript, either in vitro
[131]
 or in vivo
[132]
 (40% proteolytic activity 
remained). Yet, even with the limited gene knockdown, rhodesain’s importance to 
parasite survival was clear in that parasites exposed to RNAi were less efficient in 
penetrating an in vitro model of the blood-brain barrier and blocked by the cysteine 
protease inhibitor K11777.
[150]
 As such, the combined data, to some extent, perhaps 
support rhodesain as a valuable drug target.
[120] 
We next evaluated the trypanocidal activities of these compounds in cell 
cultures of both BSF and PCF of T. brucei using a growth assay on a Guava PCA-96 
system (Guava Technologies, USA) following the manufacturer’s instructions. As 
shown in Figure 6.3 & 6.4, all compounds induced a potent, dose-dependent 
inhibition on parasite replication. As expected, most azanitriles were found to be 
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significantly more potent than the two positive controls, i.e., K11002 and compound 
6-4. Overall, there were similarities in the structure-activity relationship (SAR) in this 
series of compounds between the recombinant enzymes, particularly rhodesain, and T. 
brucei. Compounds 6-3a-e with Phe at the P2 position and Cbz at the P3 position 
displayed the best parasite-killing activity against T. brucei. Similar to data obtained 
from rhodesain inhibition experiments, compounds having Phe (6-1a-e) and Leu 
(6-1k-o) at the P2 position inhibited parasite growth better than compounds having Val 
(6-1f-j) at the same position. When compounds 6-1a-e (with Phe at the P2 position) 
and 6-1k-o (with Leu at the P2 position) were compared, no significant difference in 
anti-parasitic activity was observed. Notably, compound 6-2 which has a Boc group at 
the P3 position and exhibited an IC50 value of 60 pM against rhodesain, was 
comparatively less potent in its anti-parasitic activity than compounds 6-1a and 6-3a 
(which bear an aromatic amide and a Cbz group at the P3 position, respectively). This 
suggests that the P3 residue is important for the trypanocidal activity of these 
aza-nitriles. For all compounds tested, there was no obvious difference in trypanocidal 
activity when the P1 position was changed from a methyl group to other groups. This 
series of compounds, however, were able to block parasite growth much more 
effectively than K11002. These results did not entirely correlate with inhibition results 
obtained using recombinant rhodesain (Table 6.1), which might be due to differences 
in their cell permeability and/or the mechanism-of-action among these compounds. 
The exact reason is still under our active investigation. In order to quantitatively 
confirm the above screening results against some of the compounds tested across a 
 150 
wider range of inhibitor concentrations, we subsequently obtained the ED50 values of 
selected compounds (6-3b, 6-3d, 6-3e and K11777/K11002) against both life cycle 
stages of T. brucei (Table 6.2). Interestingly, our results clearly showed that these 
azanitriles (e.g. 6-3b, 6-3d and 6-3e) were ~2-fold more active in blocking PCF 
parasite growth (ED50 values of 0.4, 0.7 and 0.7 M, respectively, after 24 h) than 
BSF parasite growth (ED50 values of 1.1, 1.1, and 1.4 M, respectively). Importantly, 
all of them displayed stronger trypanocidal activity than K11777 and K11002 in both 
PCF and BSF of T. brucei. On the contrary, both K11777 and K11002 displayed a 
slightly stronger trypanocidal activity in BSF (ED50 = 0.9 and 5.6 M) than in PCF 
(ED50 = 5.8 and 7.3 M). In this context, it is worth noting that the T. brucei life 
cycles alternate between mammalian host stages and insect vector stages, which are 
coupled to extensive alterations in morphology and metabolism. Although the precise 
underlying mechanism for above differences is presently unclear, they appear again to 
be related to these compounds’ differences in the cell permeability and/or cellular 
targets. Therefore, as described in the next sections, we had made an attempt to 
identify potential cellular targets (on and off) of some of the most potent compounds 
in T. brucei using activity-based protein profiling (ABPP) coupled with the 
bio-orthogonal click chemistry. To this end, we have successfully made 
cell-permeable activity-based probes (ABPs) and used them for parasite-based 
proteome profiling and bioimaging experiments (vide infra). It should also be noted 
that, due to the high similarity between T. cruzi and T. brucei, these 
compounds/probes are possibly effective againts T. cruzi as well. 
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Table 6.1. Inhibition cruzain and rhodesain by aza-nitriles 6-1ao, 6-2, 6-3ae, 6-4 & K11002. 
Compd. 6-1a 6-1b 6-1c 6-1d 6-1e 6-1f 6-1g 6-1h 6-1i 6-1j 6-1k 6-1l 
Rhodesain 
(IC50/nM) 
0.14±0.06 0.51±0.01 1.86±0.01 0.24±0.004 1.34±0.02 5.4±0.01 15.8±0.001 35.1±0.002 54.0±0.01 54.6±0.001 0.06±0.001 0.33±0.04 
Cruzain 
(IC50/nM) 
8.5±0.002 19.5±0.01 101.6±0.005 8.1±0.008 52.2±0.02 18.8±0.003 133.6±0.02 396.9±0.003 410.6±0.001 410.6±0.01 0.34±0.004 4.2±0.02 
Compd. 6-1m 6-1n 6-1o 6-2 6-3a 6-3b 6-3c 6-3d 6-3e 6-4 K11002  
Rhodesain 
(IC50/nM) 
0.71±0.001 0.14±0.02 0.33±0.02 0.06±0.008 0.4±0.01 0.19±0.02 0.81±0.009 2.0±0.002 0.06±0.008 0.55±0.005 0.36±0.02  
Cruzain 
(IC50/nM) 
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Figure 6.4. (A) Dose-dependent trypanocidal effects of aza-nitriles (6-1ao, 6-2 & 6-3ae), the aldehyde 6-4 and vinyl sulfone K11002 against 





































































































Figure 6.4. (B) Dose-dependent trypanocidal effects of aza-nitriles (6-1a1o, 6-2 & 6-3ae), the aldehyde 6-4 and K11002 against bloodstream 












































































  Table 6.2. ED50 values of compounds used in this study. 
Compound BSF (M) PCF (M) 
K11002 5.6 7.3 
6-3b 1.1  0.4  
6-3d 1.2  0.7  
6-3e 1.4  0.7  
 
 
6.2.3 Design and Synthesis of Activity-based Probes (ABPs) 
  Our screening results thus far showed some of the azanitriles were highly 
potent inhibitors of cruzain/rhodesain, and possessed excellent trypanocidal activity in 
T. brucei likely through inhibition of endogenous rhodesain/TbCatB activities, but 
they fell short in addressing the possibility that these compounds might also target 
other cellular proteins present in the parasite proteome (e.g. off-targets). To facilitate a 
more detailed understanding of this novel class of inhibitors, we converted two hit 
compounds identified from our screening results, 6-3b, and Z-Phe-Ala-CHN2 (6-6a) 
into activity-based probes (ABPs), which would enable parasite-based proteome 
profiling and large-scale pull-down/LC-MS/MS analysis to identify potential cellular 
targets (on and off) based on our previously established protocols. Briefly, two probes, 
6-5 and 6-6b, were designed and chemically synthesized (Scheme 6.5). In both probes, 
a small terminal alkyne was introduced at a suitable position (e.g. near the P3 position) 
for subsequent click chemistry, followed by in-gel fluorescence and 
bioimaging/pull-down experiments. We had previously found, from an independent 
study with natural product-like probes, that such an extremely conservative 
modification was critical to ensure full retention of the native biological properties of 
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the parental compounds (e.g. 6-3b and 6-6a). Probes 6-5 and 6-6b were conveniently 
prepared from the key intermediate 5-23, which was obtained in four steps from 
phenylalanine. The subsequent transformations leading to 6-5 were similarly 
performed as in the case of 6-3b. Similarly, compound 5-23 was coupled with 
L-alanine methyl ester hydrochloride (6-27) to give the corresponding dipeptide, 
whereupon subsequent hydrolysis was carried out under basic conditions, giving 
6-29b. Its activation with isobutyl chloroformate in the presence of 
N-methylmorpholine and the subsequent reaction of the mixed anhydride with 













Scheme 6.5. Synthesis of Cbz-Phe-Ala-CHN2 (6-6a) and two activity-based probes 





6.2.4 In Situ Proteome Profiling 
We first confirmed that compounds 6-5 and 6-6b retained the full biological 
activities as their parental compounds (part A & B of Figure 6.5); both the IC50 against 
recombinant rhodesain and dose-dependent inhibitory profiles against the growth of 
BSF/PCF of T. brucei were comparable to 6-3b and 6-6a, respectively. For example, 
probe 6-5 and compound 6-3b displayed nearly identical IC50 values against 
rhodesain (0.21 and 0.19 nM, respectively; part A of Figure 6.5) and inhibitory 
profiles against T. brucei growth. Similar results were obtained for probe 6-6b and 
compound 6-6a (IC50 = 2.9 and 3.1 nM, respectively; for parasite inhibition profiles, 
compare part A of Figure 6.4 and part B of Figure 6.5). Taken together, these data 
showed that the introduction of a terminal alkyne handle in both 6-3b and 6-6a did 
not noticeably affect their trypanocidal activities, and confirmed 6-5 and 6-6b were 
suitable ABPs for subsequent target identification/profiling studies. We next compared 
the in situ proteome reactivity profiles of two probes using live BSF and PCF by 
following a previously optimized procedure. Briefly, probes were directly added to 
the cell medium where parasites were grown. After two hours, the parasites were 
washed (to remove excessive probes), homogenized, incubated with rhodamine-azide 
under click chemistry conditions, separated by SDS-PAGE gel, and analyzed by in-gel 
fluorescence scanning (part C of Figure 6.5); the two probes in general showed 
comparable in situ proteome reactivity profiles in both forms of T. brucei, albeit with 
significant differences in relative reactivity (compare lanes 1 & 3 for BSF and lanes 5 
& 7 for PCF). For example, 1 M of 6-5 was able to give stronger 
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fluorescence-labeling profiles than 10 M of 6-6b. These results correlated well with 
the relative potency their trypanocidal activities. This observation, together with the 
fact that the fluorescence labeling of these two probes were efficiently inhibited by the 
addition of excessive 6-3b and 6-6a (lanes 2, 4, 6 & 8), indicates all the labeled 
proteins were likely true cellular targets of the probes, and both probes had similar 
cellular targets in the parasites. On a related note, as seen in lanes 1/5 (for probe 6-5) 
and lanes 3/7 (for probe 6-6b), the in situ proteome reactivity profiles between BSF 
and PCF of the parasites, though similar, showed noticeable differences, suggesting 














Figure 6.5. Biological evaluation of two ABPs (6-5 and 6-6b) in living T. brucei. (A) 
IC50 curves of probes and their parental compounds against rhodesain. (B) 
Dose-dependent, anti-trypanocidal effects of the probes against bloodstream forms of 
T. brucei after 24 h. Results represent the average standard deviation for duplicated 
independent trials. (C) In situ proteome-profiling of probes (6-5, 1M; 6-6b, 10 M) 
against BSF and PCF of T. brucei. 6-3b (10 M) or 6-6a (100 M) was added to 




TbCatB were indicated (with arrows). (D) Western blotting validation of rhodesain 
and TbCatB labeled with 6-5 (1 M) or 6-6b (10 M), following in situ labeling and 
affinity pull-down experiments. (E) Venn diagram illustrating the numbers of proteins 
identified from T. brucei with probe 6-5 (1 M) and 6-6b (10 M), after in situ 




The covalent labeling of the two expected cellular targets, rhodesain and 
TbCatB (~41 kDa and ~31 kDa; part C of Figure 6.5), were unequivocally verified by 
affinity pull-down/western blotting with the corresponding antibodies (part D of 
Figure 6.5). The two probes labeled only the mature active enzyme form of rhodesain 
(~41 kDa), but not its proform (~48 kDa). In addition, the fluorescent TbCatB bands 
labeled by the two probes were detected more prominently in BSF than in PCF. This 
is consistent with previous findings that TbCatB was up-regulated in BSF. We also 
confirmed that our two newly synthesized activity-based probes were capable of 
labeling active cathepsin L in living HepG2 cells (Figure 6.6). As expected, only the 
mature active form of cathepsin L (~30 kDa) was labeled by both probes, whilst no 
labeling of its proforms (~41 kDa).  
Finally, to identify other proteins that were also covalently labeled by the two 
probes, we performed large-scale proteomic analyses using 6-5 and 6-6b in both 
parasite forms by affinity pull-down followed by LC-MS/MS experiments (Table 6.3). 
All proteins were identified with a minimum protein score of 30 as well as at least 
four unique peptides, and results are summarized in part E of Figure 6.5. In total, 59 
& 95 proteins were identified with probe 6-5 from BSF and PCF, respectively, of 
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which 35 were detected in both parasitic forms. For probe 6-6b, 34 and 92 proteins 
were identified in BSF and PCF, respectively, with 24 detected in both forms. When 
all proteins identified from both forms were pooled together, 133 and 105 of them 
were uniquely identified in BSF and PCF, respectively, and 21 were present in both 
forms. Among these proteins, some were non-specific protein binders caused by their 
“sticky” nature as well as their high endogenous expression level, such as 
carbohydrate-metabolism-related glycosomal proteins, although correct localization 
of glycosomal proteins has been shown to be essential for the survival of the 
bloodstream form as well as of the procyclic form of T. brucei. We therefore focused 
our attention on other candidate proteins having previously known nucleopholic 
cysteine residues in their active sites, as they are likely reactive towards both 6-5 and 
6-6b, and therefore may be true cellular targets of the corresponding parental 
compounds (6-3b and 6-6a). As shown in Table 6.3, in addition to the expected 
rhodesain and TbCatB, other proteins such as CAP5.5, calpain-like cysteine peptidase, 
BS2, MCA4 and one proteosome subunit were identified only in BSF with either 6-5 
or 6-6b. Of note, sterol 14-alpha-demethylase (CYP51), which has been recently 
validated as a potential target for anti-trypanosomal therapy, was identified only with 
6-6b in both forms. Additionally, we have identified several proteins, including 
3-ketoacyl-CoA thiolase, BILBO1, and succinyl-CoA synthetase alpha, all of which 
were previously reported to be essential for parasite survival from RNAi experiments. 
Finally, it should be noted that all LC-MS/MS-based results obtained above should 
only be used as preliminary data. Owing to the highly complex cellular environment 
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and the intrinsic limitation of affinity pull-down/mass spectrometric experiments, 
false positives/non-specific proteins binders could be minimized but not eliminated. 
Consequently, proper follow-up studies and validation experiments will be needed 










Figure 6.6. (A) Comparative studies of in situ labeling of HepG2 cells by 6-6b & 6-5. 
(B) Western blotting analysis of pulled-down fractions of HepG2 cells treated with 


















































T. brucei gene Protein name Location 
Detection 
6-5 6-6b 
Tb927.6.1000 cysteine peptidase precursor (CP), Clan CA, family C1, Cathepsin L-like** L both both 
Tb927.6.560 cysteine peptidase C (CPC), Clan CA, family C1, Cathepsin B-like** L BSF BSF 
Tb927.4.3950 
cytoskeleton-associated protein CAP5.5, putative,cysteine peptidase, Clan CA, 
family C2, putative (CAP5.5)** 
n/a both / 
Tb11.47.0035 
calpain-like cysteine peptidase, cysteine peptidase, Clan CA, family C2, 
putative** 
n/a BSF / 
Tb927.3.3410 aspartyl aminopeptidase n/a BSF / 
Tb927.5.1810 lysosomal/endosomal membrane protein p67 (p67) L BSF / 
Tb11.01.1350 S-adenosylhomocysteine hydrolase n/a PCF / 
Tb927.6.950 cysteinyl-tRNA synthetase C PCF / 
Tb927.8.2540 3-ketoacyl-CoA thiolase* M PCF / 
Tb927.8.1990 tryparedoxin peroxidase (TRYP2) M PCF / 
Tb10.6k15.2290 protein disulfide isomerase, bloodstream- specific protein 2 precursor (BS2)* C / BSF 
Tb10.70.5250 metacaspase MCA4, cysteine peptidase, Clan CD, family C13 (MCA4)** N / BSF 
Tb927.6.1260 proteasome beta-1 subunit (TbPSB1)* n/a / BSF 
Tb11.02.0100 carboxypeptidase n/a / PCF 
Tb11.01.3960 flagellar protein essential for flagellar pocket biogenesis (BILBO1)* F / PCF 
Tb927.3.2230 succinyl-CoA synthetase alpha subunit* M / PCF 
Tb11.02.4080 sterol 14-alpha-demethylase (CYP51)** n/a / PCF 
 
                    [a]
 Symbols in the protein name column: (*) sensitive to RNA interference; (**) putative drug target.
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6.2.5 Cellular Imaging Using Activity-based Probes 
Having accomplished putative target identification using the corresponding 
ABPs, 6-5 and 6-6b, we next investigated whether these probes could be used for 
drug uptake studies, as well as visualization of their sub-cellular distribution and 
potential cellular targets in live parasites (both BSF and PCF). To do this, live 
parasites were treated with probe 6-5 or 6-6b, fixed, and reacted in situ with 
rhodamine-azide (Figure 6.7); consistent with in situ labeling profiles, as low as 0.1 
M of probe 6-5 was sufficient to stain the parasites strongly, rendering them visible 
under a confocal fluorescence microscope (panels b & f in part A of Figure 6.7), 
whereas 10 M of 6-6b was needed in order to produce fluorescent images with 
comparable probe labelling intensity (panels d & h in part A of Figure 6.7). There was 
no other noticeable difference in the cellular uptake of the two probes between BSF 
and PCF parasites. The sub-cellular distribution of the two probes, however, were 
notably different (part B of Figure 6.7); probe 6-6b stained mostly lysosomal 
compartments of the BSF parasites, which was expected for a probe designed to target 
the endocytic cysteine proteases, rhodesain/TbCatB (panel j). This result was further 
confirmed by immunofluorescence (IF) experiments with the anti-rhodesain antibody 
(panel k). Interestingly, the same probe showed mostly cytosolic distribution in PCF 
parasites (panel n). Probe 6-5, on the other hand, did not appear to entirely colocalize 
with rhodesain (panels d & h), and showed both lysosomal and cytosolic distribution 
in both BSF and PCF parasites (panels b & f). Surprisingly, staining of HepG2 cells 
(Human hepatocellular liver carcinoma) with the probes revealed that 6-5 (at l M) 
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resided mostly in lysosomal compartments and colocalized with cathepsin L (Figure 
6.8). On the other hand, even as high as 50 M of 6-6b only weakly stained HepG2 
cells under similar conditions. Collectively, these results demonstrate that our newly 
synthesized ABPs could be used as potential cell-permeable bioimaging agents to 





































Figure 6.7. Fluorescence microscopy of cellular uptake (A) and sub-cellular 
localization (B) of the probes in in BSF and PCF of T. brucei. Live parasites were 
treated with 5 (0.1 M) or 6b (10 M) for 2 h, in situ reacted with rhodamine-azide (10 
M) under click chemistry conditions, and then imaged. (A) Panels a, c, e & g: 
merged images of bright-field with stained nuclei (DAPI; in blue); Panels b, d, f & h: 
554 nm channel (pseudocolored in red) detecting cellular uptake of the probe. (B) 
Panels a, e, i & m: bright-field images; Panels b, f, j & n: 554 nm channel 




Immunofluorescence (IF) staining at 488 nm channel (pseudocolored in green) to 
detect cellular localization of rhodesain. Anti-rhodesain primary antibody and 
FITC-conjugated anti-rabbit IgG secondary antibody were used; Panels d, h, l & p: 
merged images of panels b & c, f & g, j & k, n & o together with stained nuclei 


















Figure 6.8. (A) Confocal microscope images of cellular uptake of 5 and 6b within 
HepG2 live cells. (B) Confocal microscope images of cathepsin L in HepG2 cells 
treated with DMSO (top), 5 or 6b and immunofluorescence staining. Panel (a), (e) and 
(i): Bright field images of the corresponding cells. Panel (b), (f) and (j): 554 nm 






probe. Panel (c), (g) and (k): immunofluorescence staining at 488 nm channel 
(pseudocolored in green) using anti-cathepsin L primary antibody and 
FITC-conjugated anti-rabbit IgG secondary antibody detecting cellular localization of 
cathepsin L. Panel (d), (h) and (l): merged images of panels (b), (f) and (j), (c), (g) and 
(k) together with stained nuclei (with Hoechest; pseudocolored in blue). All images 




In conclusion, we have synthesized a focused library of azanitrile-containing 
compounds and screened them for inhibitory activities against recombinant cruzain 
and rhodesain, as well as for their trypanocidal activities in both BSF and PCF of T. 
brucei. All compound exhibited excellent activities and showed promises as potential 
anti-parasitic agents. By comparing the structure-activity relationship (SAR) of these 
compounds, inhibition of rhodesain protease activity and trypanocidal activities were 
well correlated. The rational approach taken to design this novel class of compounds 
may provide a starting point for future development of compounds suitable for 
therapeutic applications, and be used to address selectivity profiles of different class 
of cysteine protease inhibitors (i.e., aza-nitriles vs diazomethylketones). Furthermore, 
based on the most potent hits from our screening results, two activity-based probes, 
6-5 and 6-6b, were subsequently developed. These cell-permeable probes enabled 
parasite-based proteome profiling/identification of potential cellular targets (on and 
off) of the parental compounds, and unequivocally confirmed that both rhodesain and 
TbCatB were targets of our compounds. The probes could be used in cell imaging 
experiments for further assessment of the drugs’ uptake and their sub-cellular 
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distribution. Clearly, additional studies will be required for further target validation, as 
well as to determine drug efficacy and toxicity in animal models. Furthermore, we 
expect the azadipeptide nitrile inhibitors reported in this study will likely be potent 
against human cathepsins, due to the high sequence homology of these enzymes with 
rhodesain/cruzain. This, however, should not deter them from being considered as 
potential anti-parasitic agents. Previous studies had clearly indicated that preferential 
inhibition of parasite cysteine proteases over human cathespins is possible in infected 
human cells due to parasite localization, e.g. parasites reside in the cytoplasm of host 





Chapter 7: Concluding Remarks 
 
In this thesis, I have described the synthesis and biological characterization 
of orlistat-like natural product-based probes, K11777-like drug candidate-based 
probes and drug-like azadipeptide nitrile-based small molecules, determination of 
structure-activity relationships of these compounds, target identification and 
validation in subsequent molecular biology as well as cell biological experiments in 
both mammalian cells and Trypanosoma brucei parasites. It is hoped that the findings 
of this thesis would not only enable a more holistic understanding of orlistat from 
from antiobesity drug to new anticancer and trypanocidal agent as well as of K11777 
as a drug candidate for parasitic infection, but also provide further directions on 
conversion of drugs (and drug candidates) or bioactive natural products to activity- or 
affinity-based probes in conjunction with mass spectrometry to comprehensively 
identify their direct binding targets (and off targets) on a proteome scale, thereby 
accelerating the clinical validation of drug candidates (drug activity and toxicity) and 
the discovery of the novel targets of hit compounds from, for instance, phenotypic 




























All chemicals were purchased from commercial vendors and used without 
further purification, unless otherwise noted. Tetrahydrofuran (THF) and diether ether 
were distilled under an N2 atmosphere over sodium benzophenone and used 
immediately. Dichloromethane (CH2Cl2) was distilled over CaH2. Unless otherwise 
stated, all non-aqueous reactions were carried out under an atmosphere of dry argon 
or nitrogen in oven-dried glassware. Indictated reaction temperatures refer to those of 
the reaction bath, while room temperature (rt) is noted as 25 
o
C. Liquids and solutions 
were transferred via syringe. Reaction progress was monitored by TLC on pre-coated 
silica plates (Merck 60 F254, 250 m thickness) and spots were visualized by ceric 




C NMR spectra 
were recorded on a Bruker model Avance 300 MHz or DPX-300 MHz or DPX-500 
MHz NMR spectrometer. Chemical shifts are reported in ppm relative to internal 
standard tetramethylsilane (Si(CH3)4 = 0.00 ppm) or the solvent resonance (CDCl3 




C, respectively). Data 
for 
1
H NMR spectra are reported in terms of chemical shift (δ ppm), multiplicity, 
coupling constant (Hz), and number of protons. 
1
H NMR coupling constants (J) are 
reported in Hertz (Hz) and multiplicity is indicated as follows: s (singlet), d (doublet), 
t (triplet), q (quartet), m (multiplet), br s (broad singlet), dd (doublet of doublet). Mass 
spectra were obtained on Shimadzu IT-TOF-MS or Shimadzu ESI-MS system. If need, 
products were purified via a Waters semipreparative HPLC equipped with a 
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Phenomenex Luna C18 reverse phase (5 m, 30 mm × 75 mm) column. The mobile 
phase was a mixture of acetonitrile and H2O each containing 0.1% trifluoroacetic 
acid. 
 
8.1.2 Biological Assays 
Cell-culture Conditions 
HepG2 and HEK-293T  cells were grown in DMEM (Invitrogen, Carlsbad, 
CA) containing 10% heat-inactivated fetal bovine serum (FBS; Gibco Invitrogen), 
100 U/mL penicillin and 100 g/mL streptomycin (Thermo Scientific, Rockford, IL) 
and maintained in a humidified 37 
o
C incubator with 5% CO2. MCF-7 and PC-3 cells 
were maintained in RPMI 1640 medium supplemented with 10% FBS and 100 U/mL 
penicillin and 100 g/mL streptomycin. CHO-9 cells were maintained in F12-Nutrient 
Mixture (Invitrogen) supplemented with 5% fetal bovine serum and 100 U/mL 
penicillin and 100 g/mL streptomycin. The bloodstream forms of T. brucei were 
grown at 37 °C and 5% CO2 in HMI-9 medium supplemented with 20% 
heat-inactivated fetal bovine serum (FBS). Procyclic forms YTAT 1.1 were grown at 
28 °C and 5% CO2 in Cunningham's medium supplemented with 15% 
heat-inactivated fetal bovine serum (FBS). 
 
Cell Proliferation Assay (XTT) 
Cell viability was determined using the XTT colorimetric cell proliferation 
kit (Roche) following manufacturer’s guidelines. Briefly, cells were grown to 20-30% 
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confluence (since they will reach ~ 90% confluence within 48 to 72 h in the absence 
of drugs) in 96-well plates under the conditions described above. The medium was 
aspirated, and then washed with PBS, and then treated, in duplicate, with 0.1 mL of 
the medium containing different concentrations of tested compounds. Compounds 
were applied from DMSO stocks whereby DMSO never exceeded 1% in the final 
solution. The same volume of DMSO was used as a negative control. Fresh medium, 
along with the compounds, were added every 24 h. After a total treatment time of 72 h, 
proliferation was assayed using the XTT colorimetric cell proliferation kit (Roche) 
following manufacturer’s guidelines (read at 450 nm). Data represent the average ± 
s.d. for two trials.  
 
Guava ViaCount Assay 
Parasite number and percentage viability were determined in 96-well plate 
format using the Guava ViaCount assay on a Guava PCA-96 system (Guava 
Technologies, USA) following the manufacturer's instructions. Briefly, BSF and PCF 
trypanosomes were harvested in exponential growth phase and adjusted to a 
concentration of 1 × 10
5
 parasites/mL in complete growth medium. For larger screens, 
the diluted trypanosomes were aliquoted (200 L) in sterile 96-well flat white opaque 
culture plates (Greiner, Germany) using a Sciclone ALH 3000 Liquid Handling 
Workstation (Caliper Life Sciences, USA). For small-scale screens, diluted 
trypanosomes were dispensed manually using a multichannel pipette (BrandTech, 
USA). Compounds to be tested were serially diluted in DMSO by a Multidrop Combi 
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reagent dispenser (Thermo Scientific) for large screens requiring automation, or by a 
multichannel pipette for small screens conducted manually. Negative controls were 
performed using 1.25% DMSO. After 24 or 48 h of incubation, cell density and 
viability were evaluated using ViaCount assay on the Guava PCA-96 system. ED50 
values were calculated by sigmoid curve fitting with GraphPad Prism 5.0 software 
(San Diego, USA). All data were collected in duplicate. 
 
In Vitro Proteomic Profiling and In-Gel Fluorescence Scanning 
To generate protein lysates, cells were washed twice with cold 
phosphate-buffered saline (PBS), and harvested, and collected by centrifugation. Cell 
pellets were resuspended in PBS and lysed by sonication. Protein concentration was 
determined by the Bradford assay. Cell lysates were diluted with PBS to achieve final 
concentration of ~ 1 mg/mL for labeling reactions. For in vitro proteomic profiling, 
probes were added to cell lysates (50 g) in 50 L PBS in the presence or absence of 
competitors. Unless indicated otherwise, samples were incubated for 2 h with varying 
concentrations of probe at room temperature. After incubation, 10 L freshly 
premixed click chemistry reaction cocktail in PBS [rho-azide 2-33  (100 M, 10 mM 
stock solution in DMSO), tris(2-carboxyethyl)phosphine hydrochloride (TCEP) (1 
mM, 50 mM freshly prepared stock solution in deionized water), 
tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl] amine (TBTA) (100 M, 10 mM stock 
solution in DMSO) and CuSO4 (1 mM, 50 mM freshly prepared stock solution in 
deionized water)] was added and vortexed, then incubated for 2 h at room temperature 
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with gentle mixing. The reactions were terminated by the addition of pre-chilled 
acetone (0.5 mL), placed at -20 °C for 30 min and centrifuged at 13000 rpm for 10 
min at 4 °C to precipitate proteins. The supernatant was discarded and the pellet 
washed two times with 200 L of pre-chilled methanol. The protein pellets were 
allowed to air-dry for 10 min, resuspended in 25 L 1standard reducing SDS-loading 
buffer and heated for 10 min at 95 °C; ~ 20 g of protein was loaded per gel lane for 
separation by SDS-PAGE, then visualized by in-gel fluorescent scanning using a 
Typhoon 9410 Variable Mode Imager (Amersham) and images were 
analysed/quantitated with the ImageQuant
TM
 software (Amersham). 
 
In Situ Proteomic Profiling and In-Gel Fluorescence Scanning 
For mammalian cells, cells were grown to 80-90% confluence in 24-well 
plates under the conditions described above. The medium was removed, and then cells 
were washed twice with cold PBS, and treated with 0.5 mL of 
growth-medium-containing probe, with or without competitors. For T. brucei 
trypanosomes, parasites were plated into 6-well plates (PCF, 2 mL at ~1 × 10
7 
cells/mL) or 25-mL cell culture flasks (BSF, 10 mL at ~2 × 10
6 
cells/mL). Probes 
were applied from DMSO stocks whereby DMSO never exceeded 1% in the final 
solution. The same volume of DMSO was used as a negative control. After 2 h of 
incubation at 5% CO2, the growth medium was aspirated, and cells were washed 
twice with PBS to remove the excessive probe, harvested, and pelleted by 
centrifugation. The cell pellet was resuspended in PBS (50 L), homogenized by 
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sonication, and diluted to ~1 mg/mL with PBS. Probe targets were detected by click 
chemistry with a rho-azide 2-33, SDS/PAGE analysis, and in-gel fluorescence 
scanning.   
 
In Situ Pull-Down and Mass Spectrometry Identification 
For in situ proteomic experiments, living mammalian cells or T. brucei 
parasites (T75 culturing flask) labeled in growth media with probe or DMSO 
(negative control) were harvested, washed, and homogenized in PBS. Fresh CuAAC 
reagents were added at the same concentrations as described above, except that 
biotin–azide 2-34 was substituted for rho–azide 2-33. Acetone-precipitated and 
methanol-washed protein pellets were solubilized in PBS containing 0.1% (w/v) SDS 
by brief sonication. Insoluble materials were precipitated by centrifugation (13,000 g 
× 10 min) at 4 
o
C. The supernatants were then incubated with gentle shaking at 4
 o
C or 
overnight with Neutravidin agarose beads (50 L/mg protein, Prod # 29204, Thermo 
Scientific, USA) which have been pre-washed twice with PBS. After centrifugation, 
the bead/complexes were washed extensively 4 times with 1% (w/v) SDS in PBS, 
three times with PBS, and twice with 250 mm ammonium bicarbonate (ABC). If need, 
beads were re-suspended in 500 L of 8 M urea, and then 25 L of 200 mM TCEP 
and 25 L of 400 mM iodoacetamide were added for capping of the reactive cysteine 
residues. After 30 min, the beads were washed twice with 250 mm of ABC. Elution of 
bound proteins from beads was then performed twice using the boiling buffer (200 
mM Tris pH 6.8, 400 mM DTT, 8% (w/v) SDS), then pooled. Protein samples were 
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concentrated using an YM-10 Centricon spin column (Millipore, USA). Following 
SDS-PAGE separation, protein bands were visualized by Coomassie blue/silver 
staining. Gel lanes corresponding to both DMSO-treataed and probe-treated samples 
were then each cut into 10 slices. Subsequent trypsin digestion (using In-Gel Trypsin 
Digestion Kit, Pierce Co., USA) and peptide extraction (with 50% acetonitrile and 1% 
formic acid) generated a total of 10 LCMS samples for each pull-down experiment. 
All samples were dried in vacuo and stored at -20 
o
C until LCMS analysis. Where 
necessary, each pull-down/LCMS experiment was performed in triplicate to ensure 
the high quality of MS hits obtained. 
Each LCMS sample was re-suspended in 0.1% formic acid for mass 
spectrometry analysis as previously described. Briefly, peptides were separated and 
analyzed on a Shimadzu UFLC system (Shimadzu, Kyoto, Japan) coupled to an 
LTQ-FT Ultra (Thermo Electron, Germany). Mobile phase A (0.1% formic acid in 
H2O) and mobile phase B (0.1% formic acid in acetonitrile) were used to establish the 
60 min gradient comprised of 45 min of 5–35% B, 8 min of 35–50% B, and 2 min of 
80% B, followed by reequilibrating at 5% B for 5 min. Peptides were then analyzed 




 Source (Michrom BioResources, 
USA) at an electrospray potential of 1.5 kV. A gas-flow of 2 L/min, ion-transfer tube 
temperature of 180 
o
C and collision-gas pressure of 0.85 mTorr were used. The 
LTQ-FT was set to perform data acquisition in the positive ion mode as previously 
described except that the m/z range of 350–1600 was used in the full MS scan.[160a] 




database (76708 sequences, 33362815 residues) used for the Mascot search was a 
concatenated IPI protein database (or a concatenated T. brucei protein database). The 
database search was performed using an in-house Mascot server (version 2.2.07, 
Matrix Science, UK) with an MS tolerance of 10 ppm and MS/MS tolerance of 0.8 Da. 
Two missed cleavage sites of trypsin were allowed. Carbamidomethylation (C) was 
set as a fixed modification, and oxidation (M) and phosphorylation (S, T, and Y) were 
set as variable modifications. 
 
Fluorescence Microscopy 
For mammalian cells, cells were seeded on sterile 12-mm glass coverslips 
contained in 24-well plates and grown for 24 h until ~ 60-70% confluence under 
culture conditions. After removing the medium and washing twice with PBS, cells 
were incubated in the growth medium containing probe at culture temperature and 5% 
CO2 for 2 h. The cells were then washed twice with PBS, and fixed with 4% 
paraformaldehyde in PBS for 15 min at room temperature, washed with PBS (2 × 5 
min with gentle agitation). For T. brucei parasites, trypanosomes (1 × 10
5
 cells/mL for 
both forms) were incubated in growth medium containing probe at culture 
temperature and 5% CO2 for 2 h. The parasites were then washed twice with PBS, and 
fixed with 4% paraformaldehyde in PBS for 15 min at room temperature and washed 
with PBS (2 × 5 min with gentle agitation), and then sedimented to 
poly-L-lysine-coated coverslips. In both cases, medium containing 1% DMSO was 
used as a negative control. Fixed cells were permeabilized with Triton-X 100 (0.1% 
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and 0.25% Triton-X 100 for mammalian cells and T. brucei parasites, respectively) in 
PBS for 15 min at room temperature, and washed with PBS (2 × 5 min with gentle 
agitation). The cells were blocked with 3% BSA in PBS for 30 min at room 
temperature, and washed with PBS (2 × 5 min with gentle agitation). The cells were 
then treated with a freshly pre-mixed click chemistry reaction solution [rho-azide 2-33 
(10 M final concentration from a 10 mM stock solution in DMSO), TCEP (1 mM 
final concentration from a 50 mM freshly prepared stock solution in deionized water), 
TBTA (100 M final concentration from a 10 mM stock solution in DMSO), and 
CuSO4 (1 mM final concentration from a 100 mM freshly prepared stock solution in 
deionized water)] in PBS for 1 h at room temperature. The cells were washed with 
PBS (1 × 5 min with gentle agitation), and cold methanol (1 × 5 min with gentle 
agitation), followed by 1% Tween-20 and 0.5 mM of EDTA in PBS (3 × 2 min with 
gentle agitation), and with PBS (2 × 5 min with gentle agitation). The cells were then 
incubated in PBS containing 0.25 g/mL Hoechst or 2 g/mL DAPI (DNA stain) for 
15 min at room temperature, and washed with PBS (2 × 5 min with gentle agitation) 
and a final wash with deionized water (1 × 5 min with gentle agitation) before being 
mounted onto the Fluoromount G (Emsdiasum, USA). For immunofluorescence (IF) 
analysis, cells were then incubated with the corresponding primary antibodies and 
washed with PBS (3 × 5 min with gentle agitation), followed labeled with the 
corresponding secondary antibodies and a final wash with PBS (3 × 5 min with gentle 
agitation) before mounting.  
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8.2 Chapter 2 
8.2.1 Chemical Syntheis 
Dodecanal (2-4) 
To a cooled (0 °C) and stirred suspension of PCC (16.2 g, 75 mmol) 
in DCM (100 mL) was added dodecan-1-ol (11.2 mL, 50 mmol) in 
one lot. After being stirred for 3 h, when the reaction was complete, the reaction was 
quenched with anhydrous ether (100 mL). The mixture was stirred vigorously and the 
supernatant passed through a small pad of silica gel. The eluent was concentrated in 
vacuo to obtain 2-4 (8.3 g, 90%), which was purified by column chromatography on 
silica gel (5% EtOAc/hexanes). 
1
H NMR (300 MHz, CDCl3): δ 9.76 (t, J = 1.9 Hz, 
1H), 2.41 (td, J = 1.8, 7.4 Hz, 2H), 1.58-1.65 (m, 2H), 1.27 (br s, 16H), 0.88 (t-like, 
3H). 
 
Synthesis of 2-5a and 2-5b 
To a stirred solution of 2-4 (5.18 g, 
23.48 mmol) in dry THF (40 mL) 
cooled at -10 
o
C was added a 1 M 
solution of allylmagnesium bromide 
(35.2 mL, 35.2 mmol) in ether dropwise via syringe. The reaction mixture was stirred 
for 1 h at -10 
o
C, saturated aqueous NH4Cl (50 mL) was added, and the mixture was 
partitioned between ether (300 mL) and water (30 mL). The organic layer was washed 
once with water (16 mL) and brine (30 mL) and dried (Na2SO4) and the solvent 
 180 
removed in vacuo. Flash chromatography on silica gel (hexanes/EtOAc (24:1-16:1)) 





H NMR (300 MHz, CDCl3): δ 5.76-5.90 (m, 1H), 5.15 (br d, J = 2.9 Hz, 
1H), 5.12 (s, 1H), 3.63-3.66 (m, 1H), 2.11-2.34 (m, 2H), 2.09 (br s, 1H), 1.63 (br s, 
3H), 1.26 (s, 17H), 0.88 (t-like, 3H);
 l3
C NMR (75 MHz, CDCl3): δ 135.0, 118.0, 70.7, 
42.0, 36.9, 31.9, 29.7, 29.6, 29.4, 25.7, 22.7, 14.1. 
To a stirred solution of (R)-(-)-O-acetylmandelic acid (4.97 g, 25.6 mmol) and 
DMAP (1.24 g, 10.15 mmol) in dry DCM (46 mL) cooled at 0 
o
C was added dropwise 
a solution of the above homoallylic alcohol (4.6 g, 20.33 mmol) in DCM (46 mL) 
followed by a solution of DCC (5.25 g, 25.45 mmol) in DCM (40 mL) via cannula. 
The reaction mixture was stirred at 0 
o
C for 30 min, warmed to room temperature, and 
stirred for 1 h. The white precipitate was removed by filtration through a small pad of 
Silica gel and the pad washed with DCM (5 × 70 mL). The filtrate chromatography on 
silica gel (hexanes/benzene (1:9)) yielded 7.8 g (94%) of the mandelate esters 2-5a 




H NMR (300 MHz, CDCl3): δ 7.45-7.48 (m, 2H), 7.35-7.37 
(m, 3H), 5.88 (s, 1H), 5.36-5.49 (m, 1H), 4.93 (app quint. J = 
6.2 Hz, 1H), 4.75-4.81 (m, 2H), 2.15-2.19 (m, 5H), 1.54 (br s, 
2H), 1.25 (br s, 18H), 0.88 (t-like, 3H); 
l3
C NMR (75 MHz, CDCl3): δ 170.2, 168.5, 
134.0, 132.9, 129.1, 128.6, 127.6, 117.6, 75.0, 74.7, 38.3, 33.5, 31.9, 29.6, 29.5, 29.4 
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(2), 25.1, 22.7, 20.7, 14.1.  
 
(R)-(S)-pentadec-1-en-4-yl 2-acetoxy-2-phenylacetate (2-5b) 
1
H NMR (300 MHz, CDCl3): δ 7.45-7.49 (m, 2H), 7.35-7.37 
(m, 3H), 5.88 (s, 1H), 5.66-5.80 (m, 1H), 5.08 (d, J = 6.4 Hz, 
1H), 5.04 (s, 1H), 4.91 (quint., J = 6.2 Hz, 1H), 2.32 (t, J = 6.7 
Hz, 2H), 2.17 (s, 3H), 1.07-1.45 (br m, 20H), 0.89 (t-like, 3H); 
l3
C NMR (75 MHz, 
CDCl3): δ 170.3, 168.6, 134.1, 132.9, 129.1, 128.6, 127.6, 117.9, 75.0, 74.7, 38.5, 
33.2, 31.9, 29.6, 29.4, 29.3, 29.2, 24.7, 22.7, 20.7, 14.1. 
 
(R)-4-Hydroxypentadec-1-en (2-6a) 
To a stirred solution of 2-5a (3.15 g, 7.84 mmol) in MeOH (50 
mL) was added dropwise 2 N KOH (19.6 mL, 39.21 mmol). 
The reaction mixture was heated at 75 
o
C for 6 h, cooled, and concentrated in vacuo. 
The residue was diluted with water (10 mL), acidified in cold 1 N HCl, and extracted 
with ether (3 × 100 mL). The combined organic extracts were washed with water (20 
mL) and brine (20 mL) and dried (Na2SO4) and the solvent was removed in vacuo. 
Flash chromatography on silica gel (hexanes/EtOAc (16:1-12:l)) afforded 1.7 g (99%) 
of 2-6a as a colorless oil, [a]D + 5.78
o
 (c 2.89, CHCl3). The absolute configurations of 





Prepared according to the method of 2-6a using 2-5b (0.511 g, 
1.27 mmol), and 2 N KOH (3.18 mL, 6.35 mmol) in MeOH (8 
mL). Purification by flash chromatography on silica gel (hexanes/EtOAc (16:l- 12:l)) 
afforded 0.28 g (99%) of 2-6b as a colorless oil, [a]D -6.63
o
 (c 1.69, CHCl3). 
 
Synthesis of 2-6a from 2-6b 
To a stirred solution of 2-6b (1.13 g, 5.0 mmol) and Ph3P (6.56 
g, 25.0 mmol) in dry ether/toluene (3:l) was added 
p-nitrobenzoic acid (3.76 g, 22.5 mmol) followed by dropwise 
addition of DEAD (3.94 mL, 25 mmol) at room temperature. 
The reaction mixture was stirred for 30 min and the solvent was removed in vacuo to 
afford a residue, which after flash chromatograhy on silica gel (hexanes/EtOAc 
(49:l-39:1)) yielded 1.62 g (86%) of the p-nitrobenzoate ester as a colorless oil. 
1
H 
NMR (300 MHz, CDCl3): δ 8.28 (quint. J = 2.0 Hz, 2H), 8.20 (dd, J = 2.1, 6.9 Hz, 
2H), 5.74-5.89 (m, 1H), 5.06-5.23 (m, 3H), 2.45-2.49 (m, 2H), 1.68-1.77 (m, 2H), 
1.25 (br s, 18H), 0.87 (t-like, 3H); 
l3
C NMR (75 MHz, CDCl3): δ 164.3, 150.5, 136.1, 
133.3, 130.6, 123.5, 118.1, 75.4, 38.6, 33.6, 31.9, 29.6, 29.5 (2), 29.4, 29.3, 25.3, 22.7, 
14.1. 
Treatment of the above ester with K2CO3 in methanol afforded 2-6a in 
quantitative yield. Briefly, to a stirred solution of the p-nitrobenzoate ester (1.61 g, 4.3 




reaction mixture was stirred at room temperature for 12 h, filtered and concentrated in 
vacuo. The residue was diluted with water (40 mL), acidified in cold HOAc, and 
extracted with ethyl acetate (3 × 40 mL). The combined organic extracts were washed 
with water and brine and dried (Na2SO4), and the solvent was removed in vacuo. 
Flash chromatography on silica gel (hexanes/EtOAc (16:l- 12:l)) afforded 0.96 g (99%) 
of 2-6a as a colorless oil. 
 
(R)-tert-butyldimethyl(pentadec-1-en-4-yloxy)silane (2-7a) 
To a solution of (R)-2-6b (1.62 g, 7.16 mmol) and imidazole 
(0.54 g, 7.85 mmol) in DMF (3.7 mL) was added TBSCl (1.19 
g, 7.82mmol) as a solution of 4 mL of DMF at room temperature. The resulting 
mixture was stirred overnight, diluted with ether (50 mL), washed with brine, dried 
over MgSO4, filtered, concentrated in vacuo, and finally purified by flash 
chromatography on silica gel (hexanes) to give 2.32 g (95%) of (R)-silyl ether 2-7a as 
a colorless oil. 
1
H NMR (300 MHz, CDCl3): δ 5.76-5.90 (m, 1H), 5.11-5.16 (m, 2H), 
3.64 (br s, 1H), 2.09-2.34 (m, 2H), 1.46-1.65 (br s, 3H), 1.26 (s, 17H), 0.88 (br m, 
12H), 0.06 (d, J = 5.0 Hz, 6H). 
 
(R)-3-(tert-butyldimethylsilyloxy)tetradecanal (2-8a) 
Ozone was bubbled into a stirred MeOH-DCM (1:1, 35 mL) 
solution of 1.1 g of (R)-silyl ether 2-7a (3.2 mmol) at -78 
o
C 
until the blue color persisted for ~4 min. methyl sulfide (7.0 mL, 94.4 mmol) and 
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triethylamine (0.7 mL, 4.97 mmol) were added and the cooling bath was removed. 
The reaction mixture was warmed to room temperature, stirred overnight, 
concentrated in vacuo. Purification by flash chromatography on silica gel 
(EtOAc/hexanes 1:29) afforded 1.0 g (93%) of (R)-aldehyde 2-8a as a colorless oil. 
l
H 
NMR (300 MHz, CDCl3): δ 9.81 (t, J = 2.4 Hz, 1H), 4.17 (q, J = 5.8 Hz, 1H), 2.51 
(dd, J = 2.4, 5.6 Hz, 2H), 1.51 (br m, 4H), 1.26 (br s, 18H), 0.88 (br m, 12H), 0.06 (d, 
J = 5.0 Hz, 6H);
 l3
C NMR (75 MHz, CDCl3): δ 202.5, 68.3, 50.8, 37.9, 31.9, 29.6, 
29.5, 29.3, 25.8, 25.1, 22.7, 14.1, - 4.4, -4.7. 
 
8-(trimethylsilyl)-oct-7-ynoic acid (2-9) 
To a solution (trimethylsilyl)acethylene (3.4 mL, 24 mmol) 
in THF (20 mL) was added n-BuLi (16.5 mL, 26.4 mmol, 
1.6M soln in hexanes) at –78 oC. After the mixture was stirred for 20 min, a solution 
of 6-bromohexanoic acid (2.6 g, 13.4 mmol) in dry THF (60 mL) and anhydrous 
HMPA (40 mL) was added via syringe over 10 min at –78 oC. The reaction mixture 
was stirred for 2 h, then quenched with saturated NH4Cl solution, and diluted with 
ether, washed with brine, dried over Na2SO4, filtered, and concentrated in vacuo. The 
resulting residue was purified by flash column chromatography on silica gel (50% 
EtOAc/hexanes) to give 2-9 (2.32 g, 82%) as a colorless oil. 
1
H NMR (300 MHz, 
CDCl3): δ 2.37 (t, J = 7.4 Hz, 2H), 2.23 (t, J = 6.72 Hz, 2H), 1.44-1.68 (m, 6H), 0.14 
(s, 9H); 
13




S-pyridin-2-yl 8-(trimethylsilyl)-oct-7-ynethioate (2-10) 
To a stirred solution of acid 2-9 (2.27 g, 10.7 mmol) 
in DCM (30 mL) was added oxalyl chloride (1.4 mL, 
16.0 mmol) at 0 
o
C. The reaction mixture was stirred 
for 2 h at ambient temperature. The solvent was evaporated under reduced pressure. 
To a stirred solution of the oil residue was added 2-thiopyridine (1.42 g, 12.8 mmol) 
in DCM (30 mL), followed by Et3N (3.0 mL, 21.3 mmol) at 0 
o
C. The reaction 
mixture was stirred for 2 h at ambient temperature and then quenched with 1N HCl 
(30 mL) and neutralized by washing with saturated NaHCO3 solution. The organic 
layers were combined and evaporated, then resulting yellow oil was purified by flash 
chromatography on silica gel (20% EtOAc/hexanes) to afford thiopyridyl ester 2-10 
(2.55 g, 78%) as a yellow oil. 
1
H NMR (300 MHz, CDCl3): δ 8.61-8.63 (m, 1H), 
7.71-7.77 (m, 1H), 7.61 (d, J = 7.9 Hz, 1H), 7.28-7.31 (m, 1H), 2.72 (t, J = 7.6 Hz, 
2H), 2.32 (t, J = 6.9 Hz, 2H), 1.70-1.80 (m, 1H), 1.44-1.57 (m, 4H), 0.14 (s, 9H); 
13
C 
NMR (75 MHz, CDCl3): δ 196.5, 151.6, 150.3, 137.0, 130.1, 123.4, 107.5, 84.3, 44.1, 




Thiopyridyl ester 2-10 (5.42 g, 17.9 mmol) was 
dried azeotropically with xylenes. After purging with 
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N2, anhydrous DMF (1.57 g, 21.5 mmol) and anhydrous Et3N (3.02 g, 21.5 mmol) in 
dry DCM (120 mL) was added and the mixture was cooled to −78 οC. After 10 min, 
LiHMDS (1.0 M, 41.3 mL, 41.3 mmol) was added dropwise. The reaction mixture 
was stirred for 30 min and then TBSCl (5.4 g, 35.8 mmol) was added dropwise to the 
reaction mixture at −78 οC. The reaction mixture was stirred for 2 h at −78 οC and 
then quenched with pH 7 phosphate buffer (20 mL × 2). The organic layer was 
separated, dried over Na2SO4 and evaporated. The resulting yellowish oil was purified 
by flash chromatography on silica gel (10% EtOAc/hexanes) to afford ketene acetal 
2-11 (5.6 g, 74 %) as a yellow oil. 
1
H NMR (500 MHz, CDCl3): δ 8.40-8.50 (m, 1H), 
7.54 (dt, J = 1.9, 7.6, Hz, 1H), 7.31-7.33 (d, J = 8.2 Hz, 1H), 6.98-7.01 (m, 1H), 5.39 
(t, J = 7.0 Hz, 1H), 2.34 (dd, J = 6.9, 13.8 Hz, 2H), 2.20 (dd, J = 5.7, 12.6 Hz, 2H), 
1.50-1.56 (m, 4H), 0.88 (s, 9H), 0.14 (s, 9H), 0.08(s, 6H); 
13
C NMR (126 MHz, 
CDCl3): δ 174.1, 160.4, 149.4, 139.7, 136.5, 123.4, 121.5, 119.6, 107.3, 84.5, 35.9, 
28.4, 28.3, 26.3, 25.7, 25.6, 25.0, 19.7, 18.1, 17.6, 0.2. -4.8; ESI-MS: (m/z) calcd for 
C22H37NOSSi2 [M+H]
+





TMAL reaction:  
ZnCl2 (796 mg, 5.84 
mmol) was fused under 
vacuum and then 
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allowed to cool to room temperature under a flow of nitrogen. 15 mL of dry DCM 
was then added via syringe followed by a solution of 2-8a (547 mg, 2.92 mmol) in 5 
mL of DCM and ketene acetal 2-11 (1.72 g, 4.08 mmol). The reaction mixture was 
stirred for 72 h at ambient temperature. 10 mL of pH 7 phosphate buffer were then 
added and the mixture was stirred vigorously for 45 min, filtered through a pad of 
celite, and washed with DCM. The organic filtrate was dried over Na2SO4, filtered, 
and concentrated. The residue was purified by flash chromatography on silica gel 
(10% EtOAc/hexanes) to provide the mixture of silyloxy--lactone diastereomers as 
white solids. 
1
H NMR (500 MHz) analysis of the mixture of diastereomers indicated a 
diastereomeric ratio of 8.5:1. Without further purification, the mixture was used 
directly in the next step. 
 
O-desilylation:  
To a stirred solution of the mixture of 
silyloxy--lactones in 48 mL of CH3CN cooled to 0 °C, 
4.8 mL of HF (48%) was added dropwise. The mixture 
was stirred at 0 °C for 2 h, then allowed to warm to ambient temperature and stirred 
for an additional 8 h. The reaction mixture was diluted with 150 mL of Et2O, 
quenched carefully with cold saturated NaHCO3 solution, and washed with brine. The 
organic layer was dried over Na2SO4, filtered, and concentrated. The residue was 
purified by flash chromatography on silica gel (10% EtOAc/hexane) to provide the 
hydroxy--lactone 2-12 (360 mg, 46%) and a mixture of the two diastereomers (90 
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mg, 12%) as white solids (58% overall two steps). Spectroscopic data are reported for 
the major diastereomeric--lactone 2-12. 1H NMR (500 MHz, CDCl3): δ 4.50 (app 
quint., J = 4.4 Hz, 1H), 3.78-3.83 (m, 1H), 3.27 (dt, J = 3.8, 7.6 Hz, 1H), 2.24 (t, J = 
7.0 Hz, 2H), 1.77-1.96 (m, 4H), 1.49-1.57 (m, 8H), 1.26 (br s, 18H), 0.88 (t, J = 7.0 
Hz, 3H), 0.15 (s, 9H); 
13
C-NMR (126 MHz, CDCl3): δ 171.3, 106.7, 85.0, 75.6, 68.5, 
56.5, 41.8, 38.2, 31.9, 29.6, 29.5, 29.3, 28.1, 27.3, 26.9, 25.9, 25.4, 22.7, 19.6, 14.1; 
ESI-MS: (m/z) calcd for C25H46O3Si [M+H]
+
 423.32, found 423.25. 
 
(3S,4S)-3-(hex-5-yn-1-yl)-4-((R)-2-hydroxytridecyl)oxetan-2-one (2-13) 
C-desilylation: To a solution of 
(trimethylsily1)-acetylene 2-12 (134 mg, 0.5 mmol) in 
20 mL of a mixture of acetone/H2O/2,6-lutidine (v/v/v 1: 
1: 0.l) was added solid AgNO3 (850 mg, 5 mmol, 10 equiv.). The white suspension 
was stirred vigorously for 4 h, and then 5 mL of a 1.0 M aqueous KH2PO4 solution 
was added. The resulting yellow slurry was stirred for an additional 30 min. Filtration 
of the reaction mixture through Celite removed most of the yellow precipitate. The 
filtrate was extracted with Et2O, and the combined organic extracts were washed once 
with brine and dried over Na2SO4. Evaporation of the solvent under reduced pressure 
afforded a pale yellow oil. Purification by chromatography on silica gel (15:l 
hexanes/EtOAc) gave 81 mg of 2-13 (83%) as a sticky, colorless oil. 
1
H NMR (500 
MHz, CDCl3): δ 4.50 (app quint., J = 4.4 Hz, 1H), 3.78-3.83 (m, 1H), 3.28 (dt, J = 3.8, 
8.2 Hz, 1H), 2.19-2.23 (m, 2H), 1.91-1.97 (m, 2H), 1.77-1.87 (m, 2H), 1.47-1.62 (m, 
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8H), 1.26 (br s, 18H) 0.88 (t, J = 6.3 Hz, 3H); 
13
C-NMR (126 MHz, CDCl3): δ 171.4, 
84.0, 75.6, 68.7, 68.5, 56.4, 41.8, 38.2, 31.9, 29.6(2), 29.5(2), 29.3, 28.0, 27.2, 25.8, 
25.4, 22.7, 18.1, 14.1; IT-TOF-MS: (m/z) calcd for C22H38O3 [M+H]
+




2-formamido-4-methylpentanoate (2-1, THL-R) 
Mitsunobu reaction: -lactone 2-13 (70 mg, 0.2 mmol), 
PPh3 (79 mg, 0.3 mmol), and N-formyl-L-leucine (128 
mg, 0.8 mmol) were placed in a RB-flask and 
azeotroped under vacuum with 0.5 mL of xylene for 30 
min. Addition of 5.0 mL of dry THF was followed by cooling to 0 °C, DIAD (60 L, 
0.3 mmol) was then added via syringe. The mixture was stirred at 0 °C for 10 min, 
allowed to warm to ambient temperature. The reaction was monitored by TLC. After 
the reaction was complete, the mixture was then concentrated in vacuo and polar 
impurities were separated by flash chromatography on silica gel (60:40, 
hexanes/EtOAc). Further purification of the residue by flash chromatography on silica 
gel (20% EtOAc/hexanes) yielded -lactone 2-1. (74 mg, 75%). 1H NMR (500 MHz, 
CDCl3): δ 8.22 (s, 1H), 5.92 (d, J = 8.2 Hz, 1H), 5.01-5.06 (m, 1H), 4.68 (dt, J = 4.4, 
8.8 Hz, 1H), 4.30 (q, J = 4.4 Hz, 1H), 3.23 (dt, J = 3.8, 7.6 Hz, 1H), 2.14-2.23 (m, 
3H), 1.96 (t, J = 2.5 Hz, 1H), 1.95-2.04 (m, 1H), 1.55-1.82 (m, 11H), 1.25-1.27 (m, 
18H), 0.96-0.98 (m, 6H), 0.88 (t, J = 7.0 Hz, 3H); 
13
C NMR (126 MHz, CDCl3): δ 
171.9, 170.5, 160.6, 83.9, 74.7, 72.7, 68.8, 56.9, 49.7, 41.5, 38.7, 34.1, 31.9, 29.6, 
29.5, 29.4, 29.3(2), 28.0, 27.1, 25.7, 25.1, 24.9, 22.9, 22.7, 21.9, 21.7, 18.1, 14.1; 
ESI-MS: (m/z) calcd for C29H49NO5 [M+H]
+
 492.4, found 492.3. 
 
(S)-(+)-N-Formyl leucine (2-14) 
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To a stirred solution of L-leucine (1.31 g, 10 mmol) in formic acid 
(50 mL) was added dropwise acetic anhydride (28 mL, 300 mmol) 
at 0 
o
C. After addition of the acetic anhydride, the solution was 
stirred at room temperature overnight. The solution was treated with water (40 mL). 
The solvent was removed under reduced pressure to yield a white residue. This 
residue was recrystallized from water to yield (S)-(+)-N-formyl leucine 2-14 (82%). 
1
H NMR (300 MHz, DMSO-d6) δ: 8.23 (s, 1H), 5.95 (d, J = 8.0 Hz, 1H), 4.10 (m, 
1H), 1.70–1.92 (m, 3H), 0.97 (d, J = 6.2 Hz, 6H). 
 
(10-Bromodecyloxy)(tert-butyl)dimethylsilane (2-15) 
Imidazole (2.15 g, 31.6 mmol), DMAP (258 mg, 2.11 mmol) 
and TBSCl (3.81 g, 25.3 mmol) was added to a solution of 
10-bromodecan-1-ol (5.0 g, 21.1 mmol) in DCM (60 mL) at 0 °C. The reaction 
mixture was warmed to room temperature and stirred for 5 h. The organic phase was 
washed with water, brine, dried over anhydrous Na2SO4 and concentrated in vacuo. 
The crude product was then purified by flash column chromatography on silica gel 
(2% EtOAc/hexanes) to provide 2-15 (7.31 g, 99%) as a colourless oil.
 1
H NMR (300 
MHz, CDCl3): δ 3.60 (t, J = 6.6 Hz, 2H), 3.40 (t, J = 6.9 Hz, 2H), 1.85 (q, J = 6.9 Hz, 
2H), 1.53-1.40 (m, 4H), 1.29 (br s, 10H), 0,89 (s, 9H), 0.05 (s, 6H); 
13
C NMR (75 
MHz, CDCl3): δ 63.3, 34.0, 32.9, 32.8, 29.5, 29.4, 28.7, 28.2, 26.0, 25.8, 18.4, -5.3; 
IT-TOF-MS: (m/z) calcd for C16H35BrOSi [M+1]
+




To a stirred solution of 2-15 (6.0 g, 17.1 mmol) in THF (15 
mL) was added dropwise a suspension of lithium acetylene 
(3.14 g, 34.1 mmol) in DMSO-THF (35 mL, 5:2) at 0 °C. 
The reaction mixture was warmed to room temperature and stirred for 4.5 h, then 
quenched with saturated NH4Cl solution (50 mL). The mixture was diluted with water 
and extracted with Et2O. The combined organic layers were washed with brine, dried 
over anhydrous Na2SO4 and concentrated in vacuo. The crude alkyne was purified by 
flash column chromatography on silica gel (2% EtOAc/hexanes) to give 2-16 (2.38 g, 
47%) as a colourless oil.
 1
H NMR (500 MHz, CDCl3): δ 3.59 (t, J = 7.0 Hz, 2H), 2.18 
(dt, J = 6.9, 2.5 Hz, 2H), 1.93 (t, J = 2.5 Hz, 1H), 1.55-1.37 (m, 6H), 1.28 (br s, 10H), 
0.89 (s, 9H), 0.04 (s, 6H); 
13
C NMR (126 MHz, CDCl3): δ 84.8, 68.0, 63.3, 41.0, 32.9, 
29.6, 29.44, 29.41, 29.1, 28.8, 28.5, 26.0, 25.8, 18.4, -5.25; ESI-MS: (m/z) calcd for 
C18H36OSi [M+H]
+
 297.3, found 297.2.  
 
Dodec-11-yn-1-ol (2-17) 
PPTS (510 mg, 2.0 mmol) was added to a solution of 2-16 (3.0 
g, 10.1 mmol) in 95% EtOH (30 mL) and stirred at room 
temperature for 38 h. The reaction mixture was quenched with 
brine (30 mL) and extracted with Et2O. The combined organic layers were washed 
with brine, dried over anhydrous Na2SO4 and concentrated in vacuo. The crude 
alcohol was purified by column chromatography on silica gel (10% EtOAc/hexanes) 
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to yield 2-17 (1.619 g, 88%) as a colourless oil. 
1
H NMR (500 MHz, CDCl3): δ 3.61 (t, 
J = 6.95, 2H), 2.16 (dt, J = 7.0, 2.5 Hz, 2H), 1.92 (s, 1H), 1.52 (m, 5H), 1.27 (br s, 
11H); 
13
C NMR (126 MHz, CDCl3): δ 84.7, 68.0, 63.0, 32.7, 29.5, 29.4, 29.3, 29.0, 
28.7, 28.4, 25.7, 18.3. 
 
Dodec-11-ynal (2-18) 
To a solution of alcohol 2-17 (1.0 g, 5.5 mmol) in DCM (10 mL) 
was added a suspension of PCC (1.78 g, 8.3 mmol) in DCM (25 
mL) at 0 °C. The reaction mixture was warmed to room 
temperature and stirred for 3.5 h and then filtered through a pad of celite. The filtrate 
was concentrated under reduced pressure and the crude aldehyde was purified by 
column chromatography on silica gel (hexanes/EtOAc, 100:0 to 96:4) to provide 
aldehyde 2-18 (735 mg, 74%) as a colourless oil.
 1
H NMR (500 MHz, CDCl3): δ 9.76 
(t, J = 1.25 Hz, 1H), 2.42 (t, J = 7.6 Hz, 2H), 2.18 (dt, J = 7.0, 2.5 Hz, 2H), 1.93 (t, J 
= 2.5 Hz, 1H), 1.62 (quin, J = 7.0 Hz, 2H), 1.52 (q, J = 7.0 Hz, 2H), 1.38 (m, 2H), 
1.30 (br s, 8H); 
13
C NMR (126 MHz, CDCl3): δ 202.9, 84.7, 68.1, 43.9, 29.3, 29.2, 
29.1, 29.0, 28.7, 28.4, 22.0, 18.4. 
 
(R)-Pentadec-1-en-14-yn-4-ol (2-19) 
(S)-BINOL (415 mg, 1.45 mmol) was added to a suspension 
of InCl3 (292 mg, 1.32 mmol, azeotropically dried over 
THF (2 × 3 mL)) in DCM (15 mL) and stirred for 2 h at 
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room temperature. Allyltributyltin (4.37 g, 13.2 mmol) was added and stirred for 5 
min, then the reaction mixture was cooled to -78 °C and stirred for 10 min. Aldehyde 
2-18 (1.19 g, 6.6 mmol) in DCM (10 mL) was added dropwise and stirred at -78 °C 
for 4 h then warmed to room temperature overnight. Saturated NaHCO3 solution (25 
mL) was added to the reaction mixture and stirred for 30 min. The aqueous phase was 
extracted with DCM. The combined organic layers were washed with brine, dried 
over anhydrous Na2SO4 and concentrated under reduced pressure. The crude product 
was purified by column chromatography on silica gel (hexanes/EtOAc, 95:5) to give 
homoallylic alcohol 2-19 (1.06 g, 71%, 62.4% ee) as a colourless oil. 
1
H NMR (500 
MHz, CDCl3): δ 5.79-5.87 (m, 1H), 5.15 (br d, J = 3.2 Hz, 1H), 5.12 (s, 1H), 
3.62-3.67 (m, 1H), 2.28-2.33 (m, 1H), 2.11-2.19 (m, 3H), 1.93 (t, J = 2.5 Hz, 1H), 
1.29-1.57 (m, 16H); 
13
C NMR (126 MHz, CDCl3): δ 134.9, 118.1, 84.8, 70.7, 68.0, 
42.0, 36.8, 29.6, 29.5, 29.4, 29.1, 28.7, 28.5, 25.6, 18.4. 
 
(R)-tert-Butyldimethyl(pentadec-1-en-14-yn-4-yloxy)silane (2-20) 
Imidazole (848 mg, 12.5 mmol), DMAP (51 mg, 0.42 mmol) 
and TBSCl (1.13 g, 1.47 mmol) was added to a solution of 
alcohol 2-19 (980 mg, 4.15 mmol) in DCM (20 mL) at 0 °C. 
The reaction mixture was warmed to room temperture and stirred for 7.5 h. The 
organic phase was washed with water, brine, dried over anhydrous Na2SO4 and 
concentrated in vacuo. The crude product was then purified by flash column 




H NMR (500 MHz, CDCl3): δ 5.77-5.85 (m, 1H), 5.03 (br d, J = 8.8 
Hz, 1H), 5.01 (s, 1H), 3.67 (quint., J = 5.7 Hz, 1H), 2.16-2.22 (m, 4H), 1.94 (t, J = 2.5 
Hz, 1H), 1.54 (q, J = 7.6 Hz, 1H), 1.26-1.41 (m, 15H), 0.89 (s. 9H), 0.04 (s, 6H); 
13
C 
NMR (126 MHz, CDCl3): δ 135.5, 116.5, 84.8, 72.0, 68.0, 41.9, 36.8, 29.7, 29.6, 29.4, 
29.1, 28.8, 28.5, 25.9, 25.7(2), 25.3, 18.4, 18.2, 18.1, -2.9. 
 
(R)-3-(tert-Butyldimethylsilyloxy)tetradec-13-ynal (2-21) 
Ozone was bubbled through a solution of 2-20 (900 mg, 
2.67 mmol) and Et3N (0.77 mL, 5.34 mmol) in DCM (25 
mL) cooled at -78 °C. After reaction was complete 
(monitored by TLC), Me2S (332 mg, 5.34 mmol) was added to the reaction mixture 
and warmed to room temperature. After stirring for 2 h, the solvent was removed 
under reduced pressure. The crude aldehyde was then purified by column 
chromatography on silica gel (hexanes/EtOAc, 100:0 to 9:1) to furnish aldehyde 2-21 
(720 mg, 80%) as a colourless oil.
 1
H NMR (500 MHz, CDCl3): δ 9.81 (t, J = 2.6 Hz, 
1H), 4.17 (quint., J = 5.7 Hz, 1H), 2.51 (dd, J = 2.6, 5.0 Hz, 2H), 2.18 (dt, J = 2.5, 6.9 
Hz, 2H), 1.93 (t, J = 2.5 Hz, 1H), 1.29-1.55 (m, 16H), 0.88 (s, 9H), 0.07 (s, 3H), 0.06 
(s, 3H); 
13
C NMR (126 MHz, CDCl3): δ 202.4, 84.8, 68.3, 68.0, 50.8, 37.8, 29.6, 29.5, 
29.4, 29.0, 28.7, 28.5, 25.8, 25.1, 18.4, 18.0, -4.4, -4.7. 
 
(3S,4S)-3-hexyl-4-((R)-2-hydroxytridec-12-ynyl)oxetan-2-one (2-24) 
TMAL reaction:  
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Prepared according to 
the general TMAL 
reaction procedure using 
aldehyde 2-21 (544 mg, 1.61 mmol), ZnCl2 (438 mg, 3.22 mmol), and ketene acetal 
2-23 (740 mg, 2.42 mmol) in DCM (10 mL). The crude mixture was purified by 
column chromatography on silica gel (hexanes/EtOAc: 100:0 to 97:3) to provide a 
mixture of silyloxy--lactone diastereomers as a colourless oil. 1H NMR (500 MHz) 
analysis of the mixture of diastereomers indicated that a diastereomeric ratio of 11:1. 
Without further purification, the mixture was used directly in the next step. 
1
H NMR 
(500 MHz, CDCl3): δ 4.41-4.44 (m, 1H), 3.83-3.85 (m, 1H), 3.16-3.24 (m, 1H), 2.18 
(dt, J = 2.5, 6.9 Hz, 3H), 1.94 (t, J = 2.5 Hz, 1H), 1.28-1.85 (m, 27H), 0.90 (s, 9H), 
0.89 (t, J = 7.0 Hz, 3H), 0.07 (s, 6H). 
 
O-desilylation:  
Prepared according to the general O-desilylation 
procedure using the above silyloxy--lactone (409 mg, 
0.9 mmol), and 40% HF (780 L) in CH3CN (12 mL). 
The crude mixture was purified by flash chromatography on silica gel 
(hexanes/EtOAc, 100:0 to 9:1) to provide the hydroxy--lactone 2-24 (173 mg, 32%) 
and a mixture of the two diastereomers (42 mg, 8%) as a colourless oil (40% overall 
two steps). Spectroscopic data are reported for the major diastereomeric -lactone 
2-24: 
1
H NMR (500 MHz, CDCl3): δ 4.49 (dt, J = 4.4, 8.8 Hz, 1H), 3.78-3.83 (m, 1H), 
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3.24-3.27 (m, 1H), 2.18 (dt, J = 2.5, 7.0 Hz, 2H), 1.93 (t, J = 2.5 Hz, 1H), 1.72-1.92 
(m, 4H), 1.29-1.53 (m, 25H), 0.88 (t, J = 7.0 Hz, 3H); 
13
C NMR (126 MHz, CDCl3): δ 
171.6, 84.7, 75.6, 68.5, 68.0, 56.6, 41.8, 38.1, 31.5, 29.4, 29.0, 28.9, 28.7, 28.4, 27.7, 






hylpentanoate (2-2, THL-L) 
Prepared according to the general Mitsunobu reaction 
procedure using -lactone 2-24 (11 mg, 0.03 mmol), 
DIAD (23 L, 0.12 mmol), N-formyl-L-leucine 2-14 (20 
mg, 0.13 mmol), and triphenylphosphine (33 mg, 0.13 mmol) and in THF (1.0 mL). 
Purified by flash chromatography on silica gel (hexanes/EtOAc, 9:1 to 4:1) to give 
-lactone 2-2 as a colourless oil (44%). 1H NMR (500 MHz, CDCl3): δ 8.22 (s, 1H), 
5.91 (br d, J = 8.2 Hz, 1H), 5.00-5.03 (m, 1H), 4.66-4.71 (m, 1H), 4.27-4.34 (m, 1H), 
3.22 (dt, J = 4.4, 7.6 Hz, 1H), 2.18 (dt, J = 2.5, 6.9 Hz, 2H), 2.00 (dt, J = 4.4, 14.5 Hz, 
1H), 1.93 (t, J = 2.5 Hz, 1H), 1.28-1.85 (m, 30H), 0.96-0.99 (m, 6H), 0.89 (t, J = 7.6 
Hz, 3H); IT-TOF-MS: (m/z) calcd for C29H49NO5 [M+H]
+





To a stirred solution of ocanoic acid (1.54 g, 10.7 mmol) in dry 
DCM (30 mL) was added oxalyl chloride (1.4 mL, 16.0 mmol), 
and a catalytic amount of anhydrous DMF at 0 
ο
C. The reaction mixture was stirred 
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for 2 h at 25 
ο
C. The solvent was evaporated under reduced pressure. To a stirred 
solution of the oil residue was added 2-thiopyridine (1.42 g, 12.8 mmol) in DCM (30 
mL) followed by Et3N (3.0 mL, 21.3 mmol) at 0 
ο
C. The reaction mixture was stirred 
for 2 h at 25 
ο
C and then quenched with 1N HCl (30 mL) and neutralized by washing 
with saturated NaHCO3 solution (30 mL × 2). The organic layers were combined and 
evaporated, then resulting yellow oil was purified by flash chromatography on silica 





Anhydrous DMF was added to a solution of freshly prepared 
LiHMDS (5.05 mmol) in THF (10 mL) cooled at -78 °C 
followed by a solution of TBSCl (635 mg, 4.21 mmol) in THF (4 mL). After 10 min, a 
solution of thiol ester 2-22 (1.0 g, 4.21 mmol) in THF (4 mL) was added to the 
reaction mixture. The mixture was stirred at -78 °C for 20 min, then quenced with 
saturated NH4Cl solution (10 mL). The crude was extracted with Et2O (3 × 20 mL), 
the combined organic layers was washed with brine (30 mL), dried over anhydrous 
Na2SO4, and concentrated in vacuo. The residue was purified by flash 
chromatography on silica gel (5% EtOAc/hexanes) to provide thioketene acetal 2-23 
(1.12 g, 74%) as a pale yellow oil. 
1
H NMR (300 MHz, CDCl3): δ 8.41 (d, J = 3.8 Hz, 
1H), 7.54 (dt, J = 8.2, 1.7 Hz, 1H), 7.32 (d, J = 7.9 Hz, 1H), 6.99 (m, 1H), 5.40 (t, J = 
7.0 Hz, 1H), 2.18 (t, J = 7.0 Hz, 2H), 1.31 (br s, 10H), 0.87 (s, 12H), 0.06 (s, 6H); 
IT-TOF-MS: (m/z) calcd for C19H33NOSSi [M+H]
+





DCC (13 mg, 0.063 mmol) was added to a solution of 
(S)-MTPA (7.5 mg, 0.032 mmol) and DMAP (0.5 mg, 
0.0042 mmol) in DCM (1.0 mL). After 5 min, homoallylic 
alcohol 2-19 (5.0 mg, 0.021 mmol) in DCM (0.5 mL) was 
added and the reaction mixture was left to stir at room temperature overnight. The 
reaction mixture was filtered through a pad of celite and the filtrate was concentrated 
under reduced pressure. The resulting crude product was purified by flash 
chromatography on silica gel (2% EtOAc/hexanes) to give (S)-Mosher ester 2-25 (1.2 
mg, 43%) as a colourless oil. 
1
H NMR (500 MHz, CDCl3): δ 7.54 (m, 2H), 7.39 (m, 
3H), 5.60-5.68 (m, 1H), 5.14 (m, 1H), 5.03 (br d, J = 5.7 Hz, 1H), 5.00 (s, 1H), 3.54 
(s, 3H), 2.35 (m, 2H), 2.18 (dt, J = 7.0, 2.5 Hz, 2H), 1.94 (t, J = 2.5 Hz, 1H), 1.52 
(quin, J = 7.6 Hz, 2H), 1.26-1.37 (m, 14H); ESI-MS: (m/z) calcd for C25H33F2O3 
[M+Na]
+
 461.2, found 461.1. The ee of homoallylic alcohol 2-19 was 62.4% as 
determined by 
1




Prepared according to the method of (S)-MTPA ester using 
homoallylic alcohol 2-19 (5.3 mg, 0.023 mmol), (R)-MTPA 
(11 mg, 0.046 mmol), DCC (14 mg, 0.069 mmol), and 
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DMAP (0.6 mg, 0.0046 mmol). Purification by flash chromatography on silica gel  
(2% EtOAc/hexanes) afforded (R)-MTPA ester 2-26 (6.7 mg, 67%) as a colourless oil. 
1
H NMR (500 MHz, CDCl3): δ 7.54-7.56 (m, 2H), 7.38-7.40 (m, 3H), 5.72-5.80 (m, 
1H), 5.15-5.18 (m, 1H), 5.11 (br d, J = 7.0 Hz, 1H), 5.09 (br s, 1H), 3.56 (s, 3H), 2.42 
(t, J = 6.3 Hz, 2H), 2.18 (dt, J = 7.0, 2.5 Hz, 2H), 1.94 (t, J = 2.5 Hz, 1H), 1.52 (quin, 
J = 7.6 Hz, 2H), 1.20-1.37 (m, 14H); ESI-MS: (m/z) calcd for C25H33F2O3 [M+Na]
+
 
461.2, found 461.1. 
 
(3S, 4S)-3-hexyl-4-((R)-2-hydroxytridecyl)oxetan-2-one (2-27) 
TMAL reaction: Prepared according to the general 
TMAL reaction procedure using aldehyde 2-8a (432 mg, 
1.27 mmol), ZnCl2 (346 mg, 2.54 mmol) and ketene 
acetal 2-23 (652 mg, 1.85 mmol). Purification by flash chromatrography on silica gel 
(hexanes/EtOAc, 100:0 to 95:5) gave a mixture of silyloxy--lactone diastereomers as 
colourless oils, which was used directly in the next O-desilylation step. 
O-desilylation: Prepared according to the general O-desilylation reaction 
procedure using silyloxy--lactone (500 mg, 1.07 mmol) and 40% HF (2.5 mL). 
Purification by flash chromatrography on silica gel (hexanes/EtOAc, 100:0 to 96:4) 
gave the hydroxy--lactone 2-27 (174 mg, 38%) and a mixture of the two 
diastereomers (47 mg, 10%) as white solids (48% overall, 2 steps): 
1
H NMR (500 
MHz, CDCl3): δ 4.50 (m, 1H), 3.81 (m, 1H), 3.26 (dt, J = 7.6, 3.8 Hz, 1H), 1.95-1.26 
(m, 35H), 0.88 (t, J = 6.9 Hz, 6H); 
13
C NMR (126 MHz, CDCl3): δ 171.6, 75.6, 68.5, 
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56.6, 41.8, 38.1, 31.9, 31.5, 29.63, 29.61, 29.55, 29.5, 29.3, 29.0, 27.7, 26.8, 25.4, 
22.7, 14.1, 14.0; ESI-MS: (m/z) calcd for C22H42O3 [M+Na]
+





POCl3 (695 mg, 4.53 mmol) was added to a solution of 
Fmoc-Leu-OH (1.0 g, 2.83 mmol), tert-butanol (2.1 g, 28.3 
mmol) and pyridine (1.2 mL, 14.2 mmol) in anhydrous DCM (5 
mL) at 0 °C. The reaction mixture was warmed to room temperture and stirred for 4 h. 
The reaction mixture was washed with 1N HCl (10 mL), saturated NaHCO3 solution 
(10 mL), brine (10 mL), dried over Na2SO4 and concentrated under reduced pressure. 
The residue was purified by flash chromatography on silica gel (25% EtOAc/hexanes) 
to provide ester 2-28 (931 mg, 80%) as a colourless oil.
 1
H NMR (500 MHz, CDCl3): 
δ 7.76 (d, J = 7.6 Hz, 2H), 7.60 (d, J = 7.0 Hz, 2H), 7.40 (t, J = 7.6 Hz, 2H), 7.31 (t, J 
= 7.6 Hz, 2H), 5.16 (br d, J = 8.2 Hz, 1H), 4,39 (d, J = 7.0 Hz, 2H), 4.28 (m, 1H), 
4.23 (t, J = 7.0 Hz, 1H), 1.72-1.60 (m, 2H), 1.27 (br s, 10H), 0.96 (d, J = 6.3 Hz, 6H); 
13
C NMR (126 MHz, CDCl3): δ 172.4, 155.9, 144.0, 143.9, 141.3, 127.7, 127.0, 125.1, 
120.0, 81.9, 66.9, 53.1, 47.3, 42.1, 28.0, 24.8, 22.8, 22.0. 
 
(S)-tert-butyl 4-methyl-2-propiolamidopentanoate (2-29) 
Et2NH (1.1 mL, 11 mmol) was added to a solution of ester 2-28 
(900 mg, 2.2 mmol) in CH3CN (5 mL). The reaction mixture 
was stirred at room temperture overnight. The solvent was 
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evaporated under reduced pressure and the crude product was used without futher 
purification. 
DCC (144 mg, 0.7 mmol) was added to a solution of propiolic acid (49 mg, 0.7 
mmol) in DCM (1.0 mL) at 0 °C and stirred for 10 min. The unpurified 
H2N-Leu-O
t
Bu (144 mg, 0.7 mmol) in DCM (1.0 mL) was added dropwise to the 
reaction mixture. The reaction mixture was warmed to room temperture and stirred for 
1 h. Then the reaction mixture was filtered through a pad of celite and the filtrate was 
concentrated under reduced pressure. The crude product was purified by flash 
chromatography on silica gel (25% EtOAc/hexanes) to provide amide 2-29 (70 mg, 
42%) as a colourless oil.
 1
H NMR (300 MHz, CDCl3): δ 6.47 (br s, 1H), 4.53 (m, 1H), 
2.81 (s, 1H), 1.67-1.46 (m, 9H), 1.45 (s, 9H), 0.93 (d, J = 5.3 Hz, 6H); 
13
C NMR (75 
MHz, CDCl3): δ 171.4, 151.5, 82.4, 73.7, 51.6, 41.6, 27.9, 24.8, 22.7, 22.0. 
 
(S)-4-methyl-2-propiolamidopentanoic acid (2-30) 
TFA (0.5 mL) was added to a solution of amide 2-29 (70 mg, 
0.29 mmol) in DCM (0.5 mL) cooled at 0 °C. The reaction 
mixture was warmed to room temperture and left to stir for 5 h. 
The solvent was evaporated under reduced pressure and the crude product was used 
without further purification.
 1
H NMR (500 MHz, CDCl3): δ 6.26 (br d, J = 7.6 Hz, 
1H), 4.70 (m, 1H), 3.96 (br s, 1H), 2.87 (s, 1H), 1.74 (m, 2H), 1.63 (m, 1H), 0.97 (d, J 





Prepared according to the general Mitsunobu reaction 
procedure using -lactone 2-27 (71 mg, 0.20 mmol), 
PPh3 (68 mg, 0.26 mmol), acid 2-30 (46 mg, 0.25 mmol) 
and DIAD (52 μL, 0.26 mmol) in THF (3.0 mL). Purification by flash 
chromatrography on silica gel (hexanes/EtOAc, 100:0 to 85:15) afforded 2-3 (54 mg, 
52%) as a colourless oil. 
1
H NMR (500 MHz, CDCl3): δ 6.31 (br d, J = 7.6 Hz, 1H), 
5.01-5.04 (m, 1H), 4.60 (dt, J = 4.4, 8.8 Hz, 1H), 4.26-4.30 (m, 1H), 3.21 (dt, J = 3.8, 
7.6 Hz, 1H), 2.84 (s, 1H), 2.15 (dt, J = 7.6, 15.1 Hz, 1H), 1.99 (dt, J = 4.5, 15.7 Hz, 
1H), 1.54-1.80 (m, 8H), 1.25 (br s, 25H), 0.96 (d, J = 6.3 Hz, 3H), 0.95 (d, J = 6.3 Hz, 
3H), 0.874 (t, J = 7.0 Hz, 3H), 0.867 (t, J = 7.0 Hz, 3H); 
13
C NMR (126 MHz, CDCl3): 
δ 171.4, 170.7, 151.7, 83.3, 74.7, 74.1, 72.9, 57.0, 51.4, 41.2, 38.6, 34.0, 31.9, 31.4, 
29.6, 29.5, 29.4, 29.3, 29.2, 28.9, 27.6, 26.7, 25.1, 24.9, 22.8, 22.6, 22.5, 21.7 14.1, 
14.0; IT-TOF-MS: (m/z) calcd for C31H53NO5 [M+H]
+
































In a previously flame-dried under an argon atmosphere round-bottom flask 
equipped with a magnetic stir bar, was dissolved rhodamine B acid 2-32
[161]
 (31 mg, 
0.05 mmol), HBTU (38 mg, 0.1 mmol), HOBt (14 mg, 0.1 mmol) in dry DMF (0.5 
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mL). DIEA (30 L, 0.2 mmol) was added in one portion, and the reaction mixture was 
stirred at room temperature for 10 min. Amino azide linker 2-31
[162]
 (27 mg, 0.2 mmol) 
in DMF (0.5 mL) was then added in one portion and the reaction mixture was stirred 
at room temperature overnight. The solvent was evaporated under reduced pressure 
and the crude mixture was poured into 5% HCl (5 mL, saturated with brine), and 
extracted with DCM (3 × 5 mL). The combined organic phase was washed with 
saturated NaHCO3 solution (2 × 5 mL), 5% HCl (2 × 5 mL, saturated with brine), and 
brine (10 mL), then dried over anhydrous Na2SO4, and concentrated to yield rho-N3 




H-thieno[3,4-d]imidazol-4-yl)pentanamide (2-34, biotin-N3) 
Triethylamine (0.1 mL, 0.71 mmol) was added to a solution of amino azide 
linker 2-31 (200 mg, 0.92 mmol) in dry DMF (5 mL). After the solution was stirred 
for 15 min, N-hydroxsuccinimidobiotin (biotin-NHS, 375 mg, 1.10 mmol) was added 
in one portion. The reaction mixture was stirred for 12 h at room temperature and then 
concentrated in vacuo to give a gel-like residue, which was purified by flash 
chromatography on silica gel (acetone/hexane-4:1) to afford 345 mg of biotin-N3 2-34 







carbonyl)phenyl)-3H-xanthen-3-ylidene)-N-ethylethanaminium (2-35, rho-alk) 
Prepared according to the above similar procedure using rhodamine B acid 
2-32 (31 mg, 0.05 mmol), propargylamine (15 L, 0.2 mmol), HBTU (38 mg, 0.1 
mmol), HOBt (14 mg, 0.1 mmol) and DIEA (30 L, 0.2 mmol) in dry DMF (0.5 mL). 
IT-TOF-MS: (m/z) calcd for C39H46N5O4 648.354, found 648.342. 
 
8.2.2 Cell Biological Assays 
Cell-culture conditions, cell-proliferation assay, in situ proteomic profiling, 
pull-down assay, and fluorescence microscopy were carried out using the general 
protocols as described in 8.1.2. 
 
8.2.2.1 Chemicals and Antibodies 
Orlistat (98%), Tris(2-carboxyethyl) phosphine (TCEP), and the click 
chemistry ligand, tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine (TBTA) were 
purchased from Sigma-Aldrich. Antibody against FAS (Cat No. 610963) was from 
BD Transduction Labs (San Diego, CA). Antibodies against eIF2(#9722), 
phospho-eIF2(#9721), and cleaved caspase-8 (#9746) were from Cell Signaling 
Technologies (Beverly, MA). Antibodies against HSP90b (sc-1057), Annexin A2 
(sc-1492) and RPL14 (KQ-16; sc-100826) were from Santa Cruz Biotechnology, Inc.. 
Antibodies against RPL7a (ab70753) and RPS9 (ab74711) were from Abcam. 




8.2.2.2 Western Blotting 
To monitor the effects of THL analogues on inducing phosphorylation of 
eIF2, PC-3 cells were treated with indicated concentrations of Orlistat and THL 
analogues for 16 h. Samples from treated cells were then separated on 12% 
SDS-PAGE gel and further transferred to PVDF membranes. Membranes were 
blocked with 5% BSA in TBS. After blocking, membranes were incubated with 
anti-eIF2(#9722 from cell signaling, 1/5000) or anti-phospho-eIF2(#9721 from 
Cell Signaling, 1/2000). After incubation, membranes were washed with TBST for 
three times and then incubated with an appropriate secondary antibody [anti-mouse 
conjugated HRP (1/5000) or anti-rabbit conjugated HRP (1/5000)]. After secondary 
incubation, blots were washed again with TBST before the development with 
SuperSignal West Pico kit (Pierce).  
To monitor the effects of THL analogues on inducing activation of caspase-8 
pathway, MCF-7 cells were treated with indicated concentrations of Orlistat and THL 
analogues for 36 h. Samples from treated cells were then separated on a 12% 
SDS-PAGE gel and further transferred to PVDF membranes. Membranes were 
blocked with 5% BSA in TBS. After blocking, membranes were incubated with 
anti-caspase 8 (#9746 from Cell Signaling, 1/2000). After incubation, membranes 
were washed with TBST for three times, and then incubated with anti-mouse 
conjugated HRP (1/5000). After secondary incubation, blots were washed again with 
TBST before the development with SuperSignal West Pico kit (Pierce). 
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8.2.2.3 Measurement of Protein Synthesis 
Live HepG2 cells were treated with the indicated concentrations of Orlistat, 
THL-R or CHX (cycloheximide, an inhibitor of protein biosynthesis) for 12 h, washed 
twice with PBS, and then pulsed with AHA (L-azidohomoalanine, 20 M) for 4 h. 
Cells were collected, washed, and cell lysates were prepared and subjected to click 
chemistry with rhodamine-alkyne 2-35, SDS-PAGE analysis, and in-gel fluorescence 
scanning. 
 
8.2.2.4 Hydroxylamine Treatment of Gels 
After the proteins were separated by SDS-PAGE gel, the gel was soaked in 
40% MeOH, 10% acetic acid, shaking overnight at room temperature, washed with 
deionized water (2 × 5 min), and scanned for the prehydroxylamine treatment 
fluorescence. The gel was then soaked in PBS, shaking 1 h at room temperature, 
followed by boiling in neutralized hydroxylamine (Alfa Aesar) (2.5% final 
concentration) for 5 min, washing with deionized water (2 × 5 min), and soaking in 
40% MeOH, 10% acetic acid, shaking overnight at room temperature. The gel was 
washed with deionized water (2 × 5 min) and scanned for the posthydroxylamine 
fluorescence. 
 
8.2.2.5 Mass spectrometry Identification 
After digestion, digested peptides were then extracted from the gel with 50% 
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acetonitrile and 1% formic acid. Tryptic peptide extracts were evaporated by speedvac 
and reconstituted with 10 L 0.1% TFA, a volume of 2 L of the peptide extracts 
were manually spotted onto a Prespotted AnchorChip MALDI target plate for 
MALDI-TOF Mass step with 10 L of 10 mM ammonium phosphate in 0.1% TFA, 
and allowed to dry at ambient temperature. MALDI TOF mass spectra were recorded 
using Ultraflex III TOF/TOF mass spectrometer (Bruker Daltonics) with the compass 
1.2 software package including flexControl 3.0 and flexAnalysis 3.0, calibrated with 
PAC peptide calibration standards. MS/MS analysis for the major peaks in PMF 
spectra were carried out by autoLIFT on the MALDI-TOF/TOF instrument. MS and 
MS/MS Peak lists with intensity value were submitted to Matrix Science Mascot 
server (http://www.matrixscience.com/) through BioTools 3.0 (Bruker Daltonics) 
using database NCBInr 090202 version, variable modifications of carbamidometyl on 
cysteine (C) and oxidation on methione (M), allowing maxium of trypsin missed 
cleavage, peptide mass tolerance at 200 ppm; MS/MS mass tolerance of 0.7 Da. 
 
8.2.2.6 Target Validation by Western Blotting 
Pull-down sample from labeled lysates was separated on 12% SDS-PAGE 
gel together with pull-down sample from DMSO-treated, unlabeled lysates (negative 
controls). After SDS-PAGE gel separation, proteins were then transferred to a PVDF 
membrane and subsequently blocked with 2.5% (w/v) BSA/PBST. Membranes were 
incubated for 1 h at room temperature with the respective antibodies (i.e., anti-FAS, 
anti-RPL7a, anti-Annexin A2, anti-HSP90b, anti-RPS9, anti-GAPDH, and 
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anti--tubulin). After three times of washing with PBST, blots were further incubated 
with the appropriate secondary antibody for 1 h at room temperature. After incubation, 
the blot was washed again with PBST for 3 times and the SuperSignal West Pico kit 
(Pierce) was used to develop the blot. 
 
8.2.2.7 Target Validation by Recombinant Protein Expression in HEK-293T Cells  
Mammalian expression vectors overexpressing each of the four targets were 
purchased from Origene (USA). Vectors were transfected with Lipofectamine reagent 
(Qiagen) at 80% confluence. After 24 h of transfection, either nontransfected and 
transfected cell were incubated with THL-R. After incubation, small fractions of the 
samples were analyzed by Western blotting with 1/2000 anti-c-Myc antibody (Santa 
Cruz). The rest of the cells were lysed and immunopurified with c-Myc agarose beads 
(Santa Cruz). Eluted fractions were clicked with rho-azide 2-33 as previously 
described. After click chemistry, samples were concentrated, separated on a 
SDS-PAGE gel and scanned by in-gel fluorescence. 
 
8.2.2.8 Identification of GAPDH Labeling Site 
The mammalian expression vector overexpressing GAPDH was used as 
template for generating the GAPDH active-site mutant, using the Site-Direceted 
Mutagenesis System provided by Invitrogen (USA). Cys
151
 was mutated to Ala. 
Primers used for site-directed mutagenesis were designed following the vendor’s 




Vectors overexpressing both wild-type and mutant GAPDH were transfected to 
HEK-293T cell lines. Recombinant protein was purified, labeled with THL-R and 
clicked with rho-azide 2-33 as previously described. Further, samples were separated 
on SDS-PAGE gel and fluorescently scanned with Typhoon Scanner. After scanning, 
gel was fixed and silver stained to visualize the total protein bands. 
 
8.2.2.9 Cellular Imaging 
For colocalizing in situ targets of THL analogues with FAS, cells were 
further incubated with anti-FASN primary antibodies (1:200) for 1 h at room 
temperature (or overnight at 4 °C), and washed twice with PBS. The cells were 
incubated with FITC-conjugated antimouse IgG (1:500) for 1 h, washed again. Cells 
were stained with 1 g/mL Hoechst for 10 min at room temperature, washed again 
before mounting. For colocalizing in situ targets of THL-R with ER, cells were further 
incubated with ER-Tracker Green (glibenclamide BODIPY FL) for 1 h at room 
temperature (or overnight at 4 °C), and washed twice with PBS. Cells were stained 
with 1 g/mL Hoechst for 10 min at room temperature, washed again before 
mounting. 
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8.3 Chapter 3 
8.3.1 Chemical Syntheis 
(S)-(S)-1-[(2S,3S)-3-(hex-5-yn-1-yl)-4-oxooxetan-2-yl]tridecan-2-yl 
2-formamidopropanoate (3-1b) 
Prepared according to the representative Mitsunobu 
reaction procedure using -lactone 2-13 (18 mg, 0.05 
mmol), triphenylphosphine (20 mg, 0.075 mmol), PPh3 
(79 mg, 0.3 mmol), N-formyl-L-alanine (23 mg, 0.2 
mmol) and  DIAD (15 L, 0.075 mmol) in 1.0 mL of THF. Purification by flash 
chromatography on silica gel (20% EtOAc/hexanes) gave 3-1b (20 mg, 89%) as a 
colorless oil. 
1
H NMR (500 MHz, CDCl3): δ 8.19 (s, 1H), 6.16 (br s, 1H), 5.07 (m, 1H), 
4.64 (quin., J = 7.6 Hz, 1H), 4.32 (dt, J = 8.9, 4.4 Hz, 1H), 3.23 (dt, J = 7.6, 3.8 Hz, 1H), 
2.72 (dt, J = 6.3, 2.5 Hz, 2H), 7.16 (dt, J = 14.5, 4.4 Hz, 1H), 2.01 (dt, J = 14.5, 4.4 Hz, 
1H), 1.95 (t, J = 2.5 Hz, 1H), 1.54-1.62 (m, 8H), 1.45 (d, J = 7.0 Hz, 3H), 1.25 (br s, 
18H), 0.88 (t, J = 7.6 Hz, 3H);
 13
C NMR (126 MHz, CDCl3): δ 172.1, 170.4, 160.4, 
83.8, 74.8, 72.9, 68.8, 60.4, 56.9, 47.1, 38.9, 34.2, 31.9, 29.6, 29.5, 29.4, 29.31. 29.27, 
27.9, 27.1, 25.7, 25.1, 22.7, 21.0, 18.3, 18.1, 14.2, 14.1; ESI-MS: (m/z) calcd for 
C26H43NO5 [M+H]
+ 







Prepared according to the representative Mitsunobu 
reaction procedure using -lactone 2-13 (26 mg, 0.075 
mmol), triphenylphosphine (30 mg, 0.113 mmol), 
N-formyl-glycine (31 mg, 0.3 mmol), and DIAD (23 L, 
0.113 mmol) in 1.0 mL of THF. Purification by flash chromatography on silica gel 
(20% EtOAc/hexanes) gave 3-1c (24 mg, 73%) as a colorless oil. 
1
H NMR (500 MHz, 
CDCl3): δ 8.24 (s, 1H), 6.23 (br s, 1H), 4.34 (dt, J = 8.8, 4.4 Hz, 1H), 4.10 (dd, J = 18.3, 
5.7 Hz, 1H), 4.02 (dd, J = 18.3, 5.7 Hz, 1H), 3.22 (dt, J = 7.6, 3.8 Hz, 1H), 2.20 (dt, J = 
6.3, 2.5 Hz, 2H), 2.18 (t, J = 8.2 Hz, 1H), 2.01 (dt, J = 14.1, 4.4 Hz, 1H), 1.95 (t, J = 2.5 
Hz, 1H), 1.73-1.85 (m, 4H), 1.52-1.59 (m, 8H), 1.24 (br s, 18H), 0.86 (t, J = 6.9 Hz, 3H); 
13
C NMR (126 MHz, CDCl3): δ 170.5, 169.2, 161.0, 83.8, 74.9, 72.9, 68.8, 56.8, 40.1, 
38.8, 34.0, 31.8, 29.54, 29.48, 29.37, 29.27, 29.24, 27.9, 27.0, 25.7, 25.1, 22.6, 18.0, 








Prepared according to the representative Mitsunobu 
reaction procedure using -lactone 2-13 (28 mg, 0.08 
mmol), triphenylphosphine (31 mg, 0.12 mmol), 
N-formyl-L-isoleucine (51 mg, 0.32 mmol), and DIAD 
(24 L, 0.12 mmol) in 1.0 mL of THF. Purification by flash chromatography on silica 
gel (20% EtOAc/hexanes) gave 3-1d (21 mg, 54%) as a colorless oil. 
1
H NMR (500 
MHz, CDCl3): δ 8.23 (s, 1H), 6.10 (br d, J = 8.2 Hz, 1H), 5.02 (m, 1H), 4.64 (dd, J = 8.9, 
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5.1 Hz, 1H), 4.29 (dt, J = 8.9, 5.1 Hz, 1H), 3.24 (dt, J = 7.6, 4.5 Hz, 1H), 2.21 (dt, J = 
6.3, 2.5 Hz, 2H), 2.18 (t, J = 7.6 Hz, 1H), 2.01 (dt, J = 10.1, 5.0 Hz, 1H), 1.95 (t, J = 2.5 
Hz, 1H), 1.55-1.85 (m, 12H), 1.26 (br s, 17H), 0.96 (d, J = 6.9 Hz, 3H), 0.94 (t, J = 7.6 
Hz, 3H), 0.87 (t, J = 7.6 Hz, 3H); 
13
C NMR (126 MHz, CDCl3): δ 170.9, 170.5, 160.7, 
83.7, 74.4, 72.8, 68.7, 56.9, 55.4, 38.6, 37.6, 33.9, 31.9, 29.6, 29.5, 29.4, 29.29, 29.28, 
27.9, 27.1, 25.7, 25.1, 24.9, 22.6, 18.1, 15.6, 14.1, 11.5; ESI-MS: (m/z) calcd for 
C29H46NO5 [M+H]
+




Prepared according to the representative Mitsunobu 
reaction procedure using -lactone 2-13 (18 mg, 0.05 
mmol), triphenylphosphine (20 mg, 0.075 mmol), 
N-formyl-L-phenylalanine (19 mg, 0.1 mmol), and DIAD 
(15 L, 0.075 mmol) in 1.0 mL of THF. Purification by flash chromatography on silica 
gel (20% EtOAc/hexane) gave 3-1e (12 mg, 46%) as white solids. 
1
H NMR (500 MHz, 
CDCl3): δ 8.17 (s, 1H), 7.26-7.32 (m, 3H), 7.17-7.19 (m, 2H), 6.10 (br d, J = 6.9 Hz, 
1H), 4.99 (m, 1H), 4.90 (dd, J = 13.9, 7.3 Hz, 1H), 4.16-4.24 (m, 1H), 3.08-3.20 (m, 
3H), 2.21 (dt, J = 6.3, 2.5 Hz, 2H), 2.18 (t, J = 7.6 Hz, 1H), 2.01 (dt, J = 10.1, 5.0 Hz, 
1H), 1.95 (t, J = 2.5 Hz, 1H), 1.55-1.85 (m, 6H), 1.26 (br s, 20H), 0.88 (t, J = 6.95 Hz, 
3H); 
13
C NMR (126 MHz, CDCl3): δ 170.8, 170.5, 160.5, 139.6, 129.3, 129.2, 128.7, 
128.6, 127.3 (2), 83.9, 74.5, 72.9, 68.7, 56.8, 52.1, 38.5, 37.8, 33.9, 31.9, 29.6, 29.5, 








Prepared according to the representative Mitsunobu 
reaction procedure using -lactone 2-13 (35 mg, 0.1 
mmol), triphenylphosphine (40 mg, 0.15 mmol), 
N-formyl--glycine (23 mg, 0.2 mmol), and DIAD (30 
L, 0.15 mmol) in 2.0 mL of THF. Purification by flash chromatography on silica gel 
(20% EtOAc/hexane) gave 3-1f (30 mg, 67%) as a colorless oil.
 1
H NMR (500 MHz, 
CDCl3): δ 8.15 (s, 1H), 6.24 (br s, 1H), 5.09 (dt, J = 6.3, 3.2 Hz, 1H), 4.36 (dt, J = 8.8, 
4.4 Hz, 1H), 3.57 (quin., J = 5.6 Hz, 1H), 3.22 (dt, J = 6.9, 3.8 Hz, 1H), 2.55 (dd, J = 6.3, 
5.0 Hz, 2H), 2.21 (dt, J = 6.9, 2.5 Hz, 2H), 2.10 (dt, J = 15.1, 8.2 Hz, 1H), 2.00 (dt, J = 
15.1, 3.8 Hz, 1H), 1.96 (t, J = 2.5 Hz, 1H), 1.53-1.84 (m, 10H), 1.25 (br s, 18H), 0.87 (t, 
J = 7.0 Hz, 3H); 
13
C NMR (126 MHz, CDCl3): δ 172.0, 170.4, 161.2, 83.8, 76.0, 72.0, 
68.8, 56.9, 39.0, 34.3, 33.4, 31.9, 29.6, 29.5, 29.4, 29.29, 29.26, 27.9, 27.0, 25.7, 25.2, 
22.6, 18.0, 14.1; ESI-MS: (m/z) calcd for C26H43NO5 [M+H]
+ 




Prepared according to the representative Mitsunobu 
reaction procedure using -lactone 2-13 (18 mg, 0.05 
mmol), triphenylphosphine (20 mg, 0.075 mmol), 
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N-formyl-D-leucine (16 mg, 0.1 mmol), and DIAD (15 L, 0.075 mmol) in 1.0 mL of 
THF. Purification by flash chromatography on silica gel (20% EtOAc/hexane) gave 
3-1g (18 mg, 73%) as a colorless oil. 
1
H NMR (500 MHz, CDCl3): δ 8.20 (s, 1H), 5.93 
(br d, J = 8.2 Hz, 1H), 5.02 (m, 1H), 4.63 (dt, J = 8.8, 3.0 Hz, 1H), 4.37 (m, 1H), 3.24 (dt, 
J = 7.6, 3.8 Hz, 1H), 2.20 (m, 2H), 2.16 (t, J = 7.4 Hz, 1H), 2.01 (dt, J = 14.1, 4.4 Hz, 
1H), 1.92 (t, J = 2.5 Hz, 1H), 1.50-1.84 (m, 10H), 1.25 (br s, 17H), 0.96 (d, J = 5.7 Hz, 
6H), 0.87 (t, J = 7.6 Hz, 3H); 
13
C NMR (126 MHz, CDCl3): δ 172.2, 170.7, 160.7, 83.9, 
74.4, 72.5, 68.7, 60.4, 56.8, 49.7, 41.3, 38.5, 36.6, 33.8, 31.9, 29.6, 29.5, 29.4, 29.3, 
29.2, 28.0, 27.1, 25.7, 25.2, 24.9, 24.7, 22.8, 22.6, 21.8, 18.1, 14.2, 14.1; ESI-MS: 
(m/z) calcd for C29H46NO5 [M+H]
+




TMAL reaction:  
Prepared according to the 
representative TMAL 
reaction procedure using 
ZnCl2 (359 mg, 2.64 
mmol), aldehyde 2-(S)-8b (450 mg, 1.32 mmol) and ketene acetal 2-11 (831 mg, 1.98 
mmol) in 5.0 mL of DCM. Purification by flash chromatography on silica gel (5% 
EtOAc/hexanes) to provide the mixture of silyloxy--lactone diastereomers as a 
colorless oil. 
1
H NMR (500 MHz) analysis of the mixture of diastereomers indicated a 
diastereomeric ratio of 8:1. Without further purification, the mixture was used directly 
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in the next step.
 1
H NMR (500 MHz, CDCl3): δ 4.41 (m, 1H), 3.83 (m, 1H), 3.18 (dt, J = 
7.6, 3.8 Hz, 1H), 2.24 (m, 2H), 1.82-1.84 (m, 2H), 1.26 (br s, 26H), 0.90 (m, 12H), 0.15 
(s, 9H), 0.07 (s, 6H); 
13
C NMR (126 MHz, CDCl3): δ 171.4, 106.7, 84.9, 75.2, 68.6, 
56.0, 41.9, 37.9, 31.9, 29.7, 29.63, 29.61, 29.57, 29.54, 29.3, 28.2, 27.3, 26.0, 25.9, 25.8, 





Prepared according to the representative O-desilylation 
reaction procedure using the above mixture of 
silyloxy--lactones (360 mg, 0.67 mmol) and 0.6 mL of 
HF (48%)  in 2 mL of CH3CN. Purification by flash chromatography on silica gel (5% 
EtOAc/hexanes) to provide the hydroxy--lactone 3-4 (167 mg, 30%) and a mixture of 
the two diastereomers (67 mg, 12%) as white solids (42% overall two steps). 
Spectroscopic data are reported for the major diastereomeric--lactone 3-4. 1H NMR 
(500 MHz, CDCl3): δ 4.50 (dt, J = 8.2, 4.4 Hz, 1H), 3.80 (m, 1H), 3.27 (dt, J = 8.2, 3.8 
Hz, 1H), 2.13 (m, 2H), 1.93 (ddd, J = 13.9, 8.8, 3.2, 1H), 1.85 (dd, J = 9.5, 4.5 Hz, 1H), 
1.82-1.76 (m, 2H), 1.55-1.38 (m, 7H), 1.25 (br s, 17H), 0.87 (t, J = 6.3 Hz, 3H), 0.14 (s, 
9H); 
13
C NMR (126 MHz, CDCl3): δ 171.4, 106.8, 85.0, 75.6, 68.5, 56.4, 41.8, 38.2, 





C-desilylation: Prepared according to the representative 
C-desilylation reaction procedure using 3-4 (80 mg, 0.19 
mmol) and AgNO3 (6.5 mg, 0.04 mmol in 1.0 mL of a 
mixture of acetone/H2O/2,6-lutidine (3:1:0.l). Purification by chromatography on silica 
gel (10% EtOAc/hexanes) gave 3-5 (55 mg, 85%) as a colorless oil. 
1
H NMR (500 
MHz, CDCl3): δ 4.50 (dt, J = 8.8, 4.4 Hz, 1H), 3.78-3.84 (m, 1H), 3.29 (dt, J = 8.2, 3.8 
Hz, 1H), 2.21 (dt, J = 6.3, 2.5 Hz, 2H), 1.95 (t, J = 2.5 Hz, 1H), 1.94 (ddd, J = 13.9, 8.2, 
2.5 Hz, 1H), 1.78-1.87 (m, 3H), 1.48-1.62 (m, 8H), 1.26 (br s, 16H), 0.88 (t, J = 7.6 Hz, 
3H); 
13
C NMR (125 MHz, CDCl3): 171.3, 83.9, 75.6, 68.7, 68.5, 56.4, 41.8, 38.1, 31.9, 
29.63, 29.6, 29.55, 29.49, 29.3, 28.0, 27.2, 25.8, 25.4, 22.7, 18.1, 14.1; ESI-MS: (m/z) 
calcd for C22H38O3 [M+Na]
+




Prepared according to the representative Mitsunobu 
reaction procedure using -lactone3-5 (14 mg, 0.04 
mmol), triphenylphosphine (21 mg, 0.08 mmol), 
N-formyl-L-alanine (10 mg, 0.08 mmol), and DIAD (12 
L, 0.08 mmol) in 1.0 mL of THF. Purification by chromatography on silica gel (20% 
EtOAc/hexanes) yielded 3-1h (7 mg, 36%) as a colorless oil. 
1
H NMR (500 MHz, 
CDCl3): δ 8.18 (s, 1H), 6.17 (br s, 1H), 5.04-5.09 (m, 1H), 4.62 (quin, J = 7.6 Hz, 1H), 
4.34-4.37 (m, 1H), 3.24 (dt, J = 7.6, 3.8 Hz, 1H), 2.21 (dt, J = 6.3, 2.5 Hz, 2H), 
2.19-2.14 (m, 1H), 2.03 (dt, J = 13.9, 5.0 Hz, 1H) 1.96 (t, J = 2.5 Hz, 1H), 1.84-1.54 
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(m, 10 H), 1.45 (d, J = 6.9 Hz, 3H), 1.27 (br s, 17H), 0.88 (t, J = 7.6 Hz, 3H); 
13
C 
NMR (126 MHz, CDCl3): δ 172.2, 170.5, 160.4, 83.9, 74.6, 72.7, 68.7, 56.8, 47.1, 
38.7, 33.9, 31.9, 29.6, 29.5, 29.4, 29.3, 29.2, 27.9, 27.1, 25.7, 25.2, 22.7, 18.2, 18.1, 
14.1; ESI-MS: (m/z) calcd for C26H43NO5 [M+Na]
+




Prepared according to the representative Mitsunobu 
reaction procedure using -lactone 3-5 (14 mg, 0.04 
mmol), triphenylphosphine (21 mg, 0.08 mmol), 
N-formyl-L-glycine (10 mg, 0.1 mmol) and DIAD (12 
L, 0.08 mmol) in 1.0 mL of THF. Purification by flash chromatography on silica gel 
(15% EtOAc/hexanes) gave 3-1i (8 mg, 46%) as a colorless oil. 
1
H NMR (500 MHz, 
CDCl3): δ 8.26 (s, 1H), 6.11 (br s, 1H), 5.10-5.15 (m, 1H), 4.33-4.36 (m, 1H), 4.12 
(dd, J = 19.0, 5.7 Hz, 1H), 4.04 (dd, J = 19.0, 5.0 Hz, 1H), 3.23 (dt, J = 7.6, 3.8 Hz, 
1H), 2.22 (dt, J = 7.0, 2.5 Hz, 2H), 2.1 (dt, J = 15.1, 7.6 Hz, 1H), 2.03 (dt, J = 14.5, 
4.4, 1H), 1.96 (t, J = 2.5 Hz, 1H), 1.86-1.73 (m, 9H), 1.26 (br s, 14H), 0.88 (t, J = 7.6 
Hz, 3H); 
13
C NMR (126 MHz, CDCl3): δ 170.5, 169.2, 160.9, 83.8, 74.9, 73.0, 68.8, 
56.9, 40.1, 38.9, 34.1, 31.9, 29.6, 29.5, 29.4, 29.32, 29.26, 27.9, 25.7, 25.2 22.7, 18.1, 
14.1; ESI-MS: (m/z) calcd for C25H41NO5 [M+H]
+





Prepared according to the representative Mitsunobu 
reaction procedure using -lactone 3-5 (14 mg, 0.04 
mmol), triphenylphosphine (21 mg, 0.08 mmol), 
N-formyl-L-isoleucine (14 mg, 0.08 mmol) and DIAD 
(12 L, 0.08 mmol) in 1.0 mL of THF. Purification by flash chromatography on silica 
gel (15% EtOAc/hexanes) gave 3-1j (8 mg, 41%) as a colorless oil. 
1
H NMR (500 
MHz, CDCl3): δ 8.23 (s, 1H), 6.16 (br s, 1H), 5.02-5.03 (m, 1H), 4.61 (dd, J = 8.2, 4.4 
Hz, 1H), 4.34-4.37 (m, 1H), 3.23 (dt, J = 7.6, 3.8 Hz, 1H), 2.20-2.15 (m, 3H), 1.93 (t, 
J = 2.5 Hz, 1H), 1.60-1.25 (m, 30 H), 0.96 (d, J = 7.0 Hz, 2H), 0.93 (d, J = 7.6 Hz, 
3H), 0.87 (t, J = 6.9 Hz, 3H); IT-TOF-MS: (m/z) calcd for C29H49NO5 [M+H]
+
 calcd 




Prepared according to the general Mitsunobu reaction 
procedure using -lactone 2-24 (13 mg, 0.04 mmol), 
PPh3 (47 mg, 0.18 mmol), N-formyl-L-alanine (21 mg, 
0.18 mmol) and DEAD (27 L, 0.17 mmol) in 1.0 mL of 
THF. Purification by flash chromatography on silica gel (hexanes/EtOAc, 100:0 to 4:1) 
to give 3-2b (13 mg, 73%) as white solids.
 1
H NMR (500 MHz, CDCl3): δ 8.18 (s, 
1H), 6.21 (br d, J = 6.3 Hz, 1H), 5.05-5.07 (m, 1H), 4.61-4.67 (m, 1H), 4.30 (m, 1H), 
3.21 (dt, J = 7.6, 3.8 Hz, 1H), 2.15 (dt, J = 7.0, 2.5 Hz, 3H), 2.00 (dt, J = 15.1, 4.5 Hz, 
1H), 1.93 (t, J = 2.5 Hz, 1H), 1.80-1.50 (m, 8H), 1.45 (d, J = 6.9 Hz, 3H), 1.39-1.27 
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(m, 18H), 0.88 (t, J = 7.0 Hz, 3H); 
13
C NMR (126 MHz, CDCl3): δ 172.1, 170.7, 
160.4, 84.7, 74.9, 73.0, 68.1, 57.1, 47.1, 38.9, 34.2, 31.4, 29.3, 29.2, 29.16, 29.0, 28.9, 
28.7, 28.4, 27.6, 26.7, 25.1, 22.5, 18.3, 14.4, 14.0; TOF-MS: (m/z) calcd for 
C26H43NO5 [M+Na]
+ 




Prepared according to the general Mitsunobu reaction 
procedure using -lactone 2-24 (12 mg, 0.03 mmol), 
PPh3 (45 mg, 0.17 mmol), N-formyl-L-glycine (18 mg, 
0.17 mmol) and DEAD (25 L, 0.16 mmol) in 1.0 mL of 
THF. Purification by flash chromatography on silica gel (hexanes/EtOAc, 100:0 to 4:1) 
to give 3-2c (15 mg, 70%) as a colourless oil: 
1
H NMR (500 MHz, CDCl3): δ 8.04 (s, 
1H), 6.21 (br s, 1H), 5.09-5.14 (m, 1H), 4.31-4.34 (m, 1H), 4.11 (dd, J = 18.3, 5.7 Hz, 
1H), 4.02 (dd, J = 18.3, 5.1 Hz, 1H), 3.18-3.22 (m, 1H), 2.17 (dt, J = 6.9, 2.5 Hz, 2H), 
2.10-2.15 (m, 1H), 2.01 (dt, J = 15.2, 4.2 Hz, 1H), 1.93 (t, J = 2.5 Hz, 1H), 1.81-1.71 
(m, 5H), 1.51 (quin., J = 7.0 Hz, 2H), 1.41-1.27 (m, 16H), 0.88 (t, J = 6.3 Hz, 3H); 
13
C NMR (126 MHz, CDCl3): δ 170.8, 169.2, 161.0, 84.7, 75.0, 73.0, 68.1, 57.0, 40.1, 
38.9, 34.1, 31.4, 29.3, 29.2, 29.0, 28.9, 28.7, 28.4, 27.6, 26.7, 25.1, 22.5, 18.4, 14.0; 
TOF-MS: (m/z) calcd for C25H41NO5 [M+Na]
+ 





Prepared according to the general Mitsunobu reaction 
procedure using -lactone 2-24 (12 mg, 0.03 mmol), 
PPh3 (45 mg, 0.17 mmol), N-formyl-L-isoleucine (27 
mg, 0.17 mmol) and DEAD (25 L, 0.16 mmol) in 1.0 
mL of THF. Purification by flash chromatography on silica gel (hexanes/EtOAc, 
100:0 to 4:1) to give 3-2d (11 mg, 63%) as white solids. 
1
H NMR (500 MHz, CDCl3): 
δ 8.25 (s, 1H), 6.05 (br d, J = 8.8 Hz, 1H), 5.00-5.05 (m, 1H), 4.66 (dd, J = 8.8, 5.1 
Hz, 1H), 4.28 (dt, J = 7.6, 4.4 Hz, 1H), 3.23 (dt, J = 8.2, 4.4 Hz, 1H), 2.15 (dt, J = 
14.5, 5.1 Hz, 3H), 2.01 (dt, J = 14.5, 5.1 Hz, 1H), 1.93 (t, J = 2.5 Hz, 1H), 1.85-1.25 
(m, 26H), 0.96 (d, J = 7.0 Hz, 3H), 0.95 (d, J = 7.0 Hz, 3H), 0.88 (t, J = 7.6H, 3H);
 
13
C NMR (126 MHz, CDCl3): δ 170.9, 170.7, 160.7, 84.8, 74.6, 72.9, 68.1, 57.1, 55.4, 
38.6, 37.6, 33.9, 31.5, 29.3, 29.2, 29.0, 28.9, 28.7, 28.4, 27.7, 26.7, 25.1, 24.9, 22.5, 









Prepared according to the general Mitsunobu reaction 
procedure using -lactone 2-24 (15 mg, 0.04 mmol), 
PPh3 (56 mg, 0.22 mmol), N-formyl-D-leucine (34 mg, 
0.22 mmol) and DEAD (41 L, 0.21 mmol) in 1.0 mL of 
THF. Purification by flash chromatography on silica gel (hexanes/EtOAc, 100:0 to 9:1) 
followed by second purification by flash chromatography on silica gel 
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(hexanes/EtOAc, 9:1 to 4:1) to give 3-2e (8 mg, 36%) as white solids. 
1
H NMR (500 
MHz, CDCl3): δ 8.20 (s, 1H), 5.91 (br d, J = 5.3 Hz, 1H), 5.00-5.05 (m, 1H), 
4.64-4.69 (m, 1H), 4.34-4.37 (m, 1H), 3.22 (dt, J =6.9, 4.4 Hz, 1H), 2.18 (dt, J = 6.9, 
2.5 Hz, 1H), 2.02 (dt, J = 14.5, 4.5 Hz, 1H), 1.93 (t, J = 2.5 Hz, 1H), 1.86-1.27 (m, 
29H), 0.97 (d, J = 5.0 Hz, 6H), 0.88 (t, J = 7.0 Hz, 3H); 
13
C NMR (126 MHz, CDCl3): 
δ 172.2, 170.9, 160.6, 84.7, 74.6, 72.6, 68.1, 57.0, 49.6, 41.5, 38.5, 33.8, 31.5, 29.34, 
29.32, 29.2, 29.0, 28.9, 28.7, 27.6, 26.7, 25.6, 25.2, 24.9, 22.8, 22.5, 21.9, 18.4, 14.0; 
TOF-MS: (m/z) calcd for C29H49NO5 [M+H]
+ 
492.361, found 492.344. 
 
(S)-pentadec-1-en-14-yn-4-ol (3-6) 
Prepared according to the general asymmetric allylation 
reaction procedure using aldehyde 2-18 (300 mg, 1.66 
mmol), (R)-BINOL (106 mg, 0.37 mmol), InCl3 [73 mg, 0.33 
mmol, azeotropically dried over THF (2 ×3 mL)], allyltributyltin (1.10 g, 3.32 mmol) to 
provide (S)-homoallylic alcohol 3-6 (252 mg, 53%, 50% ee, determined using Mosher 
ester analysis) as a colourless oil. 
1
H NMR (500 MHz, CDCl3): δ 5.83 (m, 1H), 5.15 (br 
d, J = 3.2 Hz, 1H), 5.12 (d, J = 1.3 Hz, 1H), 3.64 (br s, 1H), 2.29 (m, 1H), 2.18 (dt, J = 
7.0, 2.5 Hz, 2H), 2.19-2.11 (m, 3H), 1.54-1.29 (m, 17H).  
 
(S)-tert-butyldimethyl(pentadec-1-en-14-yn-4-yloxy)silane (3-7) 
Prepared according to the general TBS-protection reaction 
procedure using homoallylic alcohol 3-6 (234 mg, 1.0 mmol), 
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imidazole (202 mg, 2.97 mmol), TBSCl (268 mg, 1.78 mmol) and DMAP (24 mg, 0.2 
mmol) to provide (S)-silyl ether 3-7 (321 mg, 95%) as a colorless oil.
 1
H NMR (500 
MHz, CDCl3): δ 5.81 (m, 1H), 5.03 (dd, J = 9.5, 1.9 Hz, 1H), 5.01 (s, 1H), 3.68 (quin., 
J = 5.7 Hz, 1H), 2.19 (m, 5H), 1.93 (t, J = 2.5 Hz, 1H), 1.54-1.28 (m, 17H), 0.89 (s, 9H), 
0.05 (s, 6H). 
 
(S)-3-((tert-butyldimethylsilyl)oxy)tetradec-13-ynal (3-8) 
Prepared according to the general ozonolysis reaction 
procedure using silyl ether 3-7 (320 mg, 0.95 mmol), and 
Et3N (0.3 mL, 1.9 mmol) to provide aldehyde 3-8 (205 mg, 
64%) as a colorless oil.
 1
H NMR (500 MHz, CDCl3): δ 9.81 (s, 1H), 4.17 (quin, J = 5.7 
Hz, 1H), 2.51 (dd, J = 6.3, 2.5 Hz, 2H), 2.18 (dt, J = 6.9, 2.5 Hz, 2H), 1.93 (t, J = 2.5 Hz, 
1H), 1.52-1.28 (m, 16H), 0.87 (s, 9H), 0.07 (s, 3H), 0.06 (s, 3H). 
 
(3R,4R)-3-hexyl-4-((S)-2-hydroxytridec-12-yn-1-yl)oxetan-2-one (3-9) 
TMAL reaction:  
Prepared according to 
the general TMAL 
reaction procedure using 
aldehyde 3-8 (200 mg, 0.59 mmol, ZnCl2 (161 mg, 1.18 mmol) and ketene acetal 2-23 
(272 mg, 0.89 mmol) in DCM (4.0 mL). Purification by flash chromatography on silica 
gel (hexanes/EtOAc, 100:0 to 95:5) gave the mixture of silyloxy--lactone 
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diastereomers as a colorless oil. Without further purification, the mixture was used 
directly in the next step. 
1
H NMR (500 MHz, CDCl3): δ 4.42 (m, 1H), 3.83 (m, 1H), 
3.18 (m, 1H), 2.18 (dt, J = 6.9, 2.5 Hz, 2H), 1.94 (t, J = 2.5 Hz, 1H), 1.87-1.72 (m, 3H), 
1.62-1.28 (m, 25H), 0.90 (s, 9H), 0.89 (t, J = 6.9 Hz, 3H), 0.07 (s, 6H); 
13
C NMR (126 
MHz, CDCl3): δ 171.7, 84.8, 75.2, 68.6, 68.0, 56.1, 42.0, 37.9, 31.5, 29.7, 29.5, 29.4, 
29.1, 28.9, 28.7, 28.5, 27.7, 26.7, 25.9, 25.8, 24.6, 22.5, 18.3, 18.0, 14.0, -4.3, -4.8. 
 
O-desilylation:  
Prepared according to the general O-desilylation reaction 
procedure using silyloxy--lactone (190 mg, 0.42 mmol) 
and 40% HF (460 L). Purification by flash 
chromatography on silica gel (hexanes/EtOAc, 100:0 to 96:4) gave the 
hydroxy--lactone 3-9 (68 mg, 37%) and a mixture of the two diastereomers (18 mg, 
10%) as a colorless oil (47% overall, 2 steps).
 1
H NMR (500 MHz, CDCl3): δ 4.50 (m, 
1H), 3.81 (m, 1H), 3.26 (dt, J = 8.1, 4.1 Hz, 1H), 2.18 (dt, J = 7.4, 2.6 Hz, 2H), 1.94 (t, 
J = 2.6 Hz, 1H), 1.92-1.74 (m, 4H), 1.55-1.29 (m, 24H), 0.88 (t, J = 6.6 Hz, 3H); 
13
C 
NMR (126 MHz, CDCl3): δ 171.6, 84.8, 68.5, 68.1, 56.6, 41.8, 38.1, 31.5, 29.4, 29.36, 
29.0, 28.9, 28.7, 28.5, 27.7, 26.8, 25.4, 22.5, 18.4, 14.0; ESI-MS: (m/z) calcd for 
C22H38O3 [M+H]
+ 






Prepared according to the general Mitsunobu reaction 
procedure using -lactone 3-9 (15 mg, 0.04 mmol), PPh3 
(43 mg, 0.16 mmol), N-formyl-L-leucine (27 mg, 0.17 
mmol) and DEAD (25L, 0.16 mmol) in THF (1.0 mL). 
Purification by flash chromatography on silica gel (hexanes/EtOAc, 100:0 to 4:1) to 
give 3-2f (13 mg, 81%) as a colourless oil.
 1
H NMR (500 MHz, CDCl3): δ 8.20 (s, 
1H), 5.95 (br s, 1H), 5.02-5.04 (m, 1H), 4.66-4.69 (m, 1H), 4.26-4.31 (m, 1H), 3.21 
(m, 1H), 2.17 (dt, J = 6.9, 2.5 Hz, 2H), 1.98-2.02 (m, 1H), 1.93 (t, J = 2.5 Hz, 1H) 
1.65-1.82 (m, 6H), 1.48-1.58 (m, 4H), 1.28 (br s, 18H), 0.96 (d, J = 6.3 Hz, 6H), 0.88 
(t, J = 6.3 Hz, 3H); 
13
C NMR (126 MHz, CDCl3): δ 172.2, 170.9, 160.6, 84.7, 74.5, 
72.5, 68.0, 57.0, 47.6, 41.5, 38.7, 33.8, 31.4, 29.3, 29.2, 29.0, 28.9, 28.7, 28.4, 27.6, 
26.7, 25.2, 24.9, 22.8, 22.5, 21.8, 18.3, 14.0; ESI-MS: (m/z) calcd for C29H49NO5 
[M+Na]
+ 




Prepared according to the general Mitsunobu 
reaction procedure using-lactone 2-17 (100 
mg, 0.28 mmol), PPh3 (110 mg, 0.42 mmol), 
acid 3-11 (106 mg, 0.42 mmol) and DIAD (77 
L, 0.39 mmol) in THF (5.0 mL). Purification by flash chromatrography on silica gel 
(hexanes/EtOAc, 100:0 to 80:20) to give 3-3b (49 mg, 30%) as white solids. 
1
H NMR 
(500 MHz, CDCl3): δ 5.77 (d, J = 8.2 Hz, 1H), 5.00 (m, 1H), 4.59 (dt, J = 8.8, 5.1 Hz, 
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1H), 4.27-4.30 (m, 1H), 3.21 (dt, J = 7.6, 3.8 Hz, 1H), 2.23 (t, J = 7.6 Hz, 2H), 2.19 
(dt, J = 8.0, 2.5 Hz, 2H), 2.14 (t, J = 7.6 Hz, 2H), 1.98 (dt, J = 15.2, 4.4 Hz, 1H), 1.93 
(t, J = 2.5 Hz, 1H), 1.71-1.82 (m, 2H), 1.42-1.67 (m, 14H), 1.26 (br s, 22H), 0.96 (d, J 
= 5.1 Hz, 3H), 0.95 (d, J = 5.1 Hz, 3H), 0.88 (t, J = 7.0 Hz, 6H). 
13
C NMR (126 MHz, 
CDCl3): δ 172.6, 172.5, 170.7, 84.4, 74.8, 72.4, 68.3, 57.1, 51.0, 41.7, 38.7, 36.3, 34.1, 
31.9, 31.5, 29.61, 29.60, 29.5, 29.4, 29.3, 29.0, 28.3, 28.1, 27.7, 26.7, 25.1, 25.01, 
25.0, 22.9, 22.7, 22.5, 21.9, 18.2, 14.1, 14.0; ESI-MS: (m/z) calcd for C36H63NO5 
[M+H]
+
 590.5; found 590.4. 
 
(S)-tert-butyl 4-methyl-2-(oct-7-ynamido)pentanoate (3-10) 
To a solution of oct-7-ynoic acid (175 mg, 1.25 
mmol) in DCM (7 cm) was added EDC•HCl (288 
mg, 1.5 mmol), HOBt (203 mg, 1.5 mmol) and 
DIEA (0.30 mL, 2 mmol). After 10 min, NH2-Leu-OtBu
1
 (281 mg, 1.5 mmol) in DCM 
(2 mL) was added dropwise. The reaction was stirred at rt for 21 h. The organic phase 
was extracted with an 1 N HCl solution (10 mL), saturated NaHCO3 (10 mL), brine (10 
mL) and dried over anhydrous Na2SO4. The residue was purified by flash 
chromatography on silica gel (hexanes/EtOAc, 4:1) to give amide 3-10 (258 mg, 67%) 
as a colorless oil. 
1
H NMR (300 MHz, CDCl3): δ 5.81 (d, J = 8.0 Hz, 1H), 4.53 (dt, J = 
8.6, 5.4 Hz, 1H), 2.22 (t, J = 7.1 Hz, 2H), 2.19 (dt, J = 7.1, 2.6 Hz, 2H), 1.93 (t, J = 2.6 
Hz, 1H), 1.49-1.71 (m, 9H), 1.46 (s, 9H), 0.95 (d, J = 6.4 Hz, 6H). 
13
C NMR (126 MHz, 
CDCl3): δ 172.5, 172.4, 84.4, 81.9, 68.3, 51.2, 42.1, 36.5, 28.3, 28.1, 28.0, 25.04, 
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24.98, 22.8, 22.2, 18.3. 
 
(S)-4-methyl-2-(oct-7-ynamido)pentanoic acid (3-11) 
TFA (2 mL) was added to a solution of 3-10 (233 mg, 
0.75 mmol) in DCM (5 mL) cooled at 0 °C. The 
reaction mixture was warmed to room temperture 
and left to stir for 5 h. The solvent was evaporated under reduced pressure and the crude 




Prepared according to the general Mitsunobu reaction 
procedure using -lactone 2-27 (30 mg, 0.086 mmol), 
PPh3 (34 mg, 0.13 mmol), acid 3-11 (24 mg, 0.13 mmol) 
and DIAD (26 L, 0.13 mmol) in THF (1.0 mL). 
Purification by flash chromatrography on silica gel (10 % EtOAc/hexane) to give 3-3c 
(19 mg, 66%) as white solids. 
1
H NMR (500 MHz, CDCl3): δ 6.25 (d, J = 8.2 Hz, 1H), 
5.00-5.05 (m, 1H), 4.58-4.62 (m, 1H), 4.28-4.31 (m, 1H), 3.23 (dt, J = 3.8, 7.6 Hz, 
1H), 2.85 (s, 1H), 2.22 (dt, J = 2.5, 6.3 Hz, 2H), 2.15 (t, J = 8.2 Hz, 1H), 2.01 (dt, J = 
4.4, 15.2 Hz, 1H), 1.95 (t, J = 2.5 Hz, 1H), 1.73-1.85 (m, 2H), 1.63-1.68 (m, 3H), 
1.54-1.68 (m, 8H), 1.25 (br s, 16H), 0.97 (d, J = 6.3 Hz, 3H), 0.96 (d, J = 6.3 Hz, 3H), 
0.88 (t, J = 7.0 Hz, 3H). 
13
C NMR (126 MHz, CDCl3): δ 171.4, 170.4, 151.7, 83.9, 
76.7, 74.6, 74.1, 72.8, 68.7, 56.9, 51.4, 41.2, 38.7, 34.0, 31.9, 29.6, 29.5, 29.4, 29.3 
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(2), 28.0, 27.1, 25.7, 25.1, 24.9, 22.8, 22.7, 21.8, 18.1, 14.1. ESI-MS: (m/z) calcd for 
C31H49NO5 [M+H]
+














To a solution of biotin-azide 2-34 (222 mg, 0.5 mmol) in THF (7 mL) and 
H2O (2 mL) was added triphenyl phosphine (157 mg, 0.6 mmol) and stirred at rt for 
12 h. The solvent was evaporated, and the residue was washed with ether (3  20 mL), 
DCM (2  10 mL) and dried in vacuo to yield biotin-PEG-NH2 as a pale white solid 
(188 mg, 90%). Without further purification, the mixture was used directly in the next 
step. To a solution of compound 3-12
[64]
 (42 mg, 0.1 mmol) in anhydrous DMF (3 mL) 
was added biotin-PEG-NH2 (42 mg, 0.1 mmol) in anhydrous DMF (2 mL). The 
reaction was complete after stirring at room temperature for 12 h and concentrated. The 
 
 229 
crude product was purified by flash chromatrography on silica gel (10% MeOH/DCM) 
to give 3-13 as yellow-colored solids (62 mg, 87%). IT-TOF-MS: (m/z) calcd for 
C33H45N9O7S [M+H]
+ 
712.316, found 712.329. 
 
1-(2-amino-9H-purin-6-yl)-1-methylpyrrolidin-1-ium chloride (3-14) 
To a solution of 6-chloro-guanine (1.0 g, 5.9 mmol) in DMSO/DMF 
(5 mL/40 mL) was added 1-methyl-pyrrolidin (1.4 mL, 13.2 mmol). 
After 18 h, 2 mL of acetone and hexane (1:1) were added to complete 
the precipitation. The solid was filtered, washed with ether and dried in vacuo, to give 
3-14 (0.9 g, 66%). Without further purification, the mixture was used directly in the 
next step. 
1
H NMR (300 MHz, DMSO-d6): δ 13.46 (s, 1H), 8.34 (s, 1H), 7.10 (s, 2H), 
4.60 (m, 2H), 4.01 (m, 2H), 3.65 (s, 3H), 2.24 (m, 2H), 2.06 (m, 2H); IT-TOF-MS: (m/z) 
calcd for C10H15ClN6 [M-Cl]
+
 219.14, found 219.14. 
 
6-((4-(azidomethyl)benzyl)oxy)-9H-purin-2-amine (3-16) 
To a solution of (4-(azidomethyl)phenyl)methanol 3-15 
(333 mg, 2.04 mmol) in dry DMF (10 mL) was added NaH 
(60% dispersed in oil) (256 mg, 6.40 mmol) at 0 °C. Then 
570 mg (2.24 mmol) of 3-14 and 20 mg (0.16 mmol) of 4-dimethylaminopyridine were 
added subsequently. The resulting reaction mixture was stirred at rt for 4 h. The 
reaction was quenched by addition of water (1 mL). The solvent was removed under 
reduced pressure. The resulting residue was purified by chromatography with 
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dichloromethane:methanol (30:1) to give 3-16 (350 mg, 52.7%). 
1
H NMR (300 MHz, 
DMSO-d6): δ 12.35 (bs, 1H), 7.81 (s, 1H), 7.53 (d, J = 8.1 Hz 2H), 7.39 (d, J = 7.8 Hz, 
2H), 6.08 (s, 1H), 5.53 (s, 2H), 4.46 (s, 2H); 13C NMR (300 MHz, DMSO-d6) δ 159.9, 
137.2, 135.7, 128.9, 128.7, 66.8, 53.8; IT-TOF-MS: (m/z) calcd for C13H12N8O [M+H]
+
 





To a mixture of di-alkyne -lactone 
3-17
[57b]
 (10.2 mg, 0.022 mmol) and 
BG-azide 3-16 (6.5 mg, 0.022 mmol) 
in a mixture of DMSO/H2O (3/1, 
400 L) was added CuI (4.2 mg, 0.022 mmol) and DIPEA (8 L, 0.044 mmol). The 
reaction mixture was stirred at room temperature for 72 h. The reaction mixture was 
then diluted with water (1 mL) and extracted with EtOAc (3  1 mL). The combined 
organic phase was extracted with 1M EDTA solution (3  1 mL), brine (2 mL) and 
dried over anhydrous Na2SO4. The product was used for next step without purification. 
LC-ESI-MS: (m/z) calcd for C38H52N9O6Si [M+H]
+ 
758.4, found 758.4.  
To a solution of the above mixture in DMF (200 L) was added a solution of 
tris(dimethylamino)sulfonium difluorotrimethylsilicate (TAS-F) (8.0 mg, 0.029 mmol) 
in DMF (200 L). The reaction mixture was stirred at room temperature for 12 h. The 
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reaction mixture was diluted with water (500 L) and the aqueous phase was 
extracted with EtOAc (3  1 mL). The combined organic phase was washed with 
brine (1 mL) and dried over anhydrous NaSO4. The residue was purified by 
preparative HPLC (Phenomenex Luna C18, 5 M, 50  3 mm; 0-10 min, 20-95% 
CH3CN; 10-12 min, 100% CH3CN; flow rate: 0.5 mL/min) to give 3-4 (2.6 mg, 17% 
yield over two steps) as a colourless oil. 
l
H NMR (500 MHz, CDCl3): δ 7.99 (s, 1H), 
7.63 (s, 1H), 7.50 (d, J = 7.6 Hz, 2H), 7.41 (s, 1H), 7.24 (d, J = 7.6 Hz, 2H), 5.62 (d, J 
= 14.5 Hz, 1H), 5.52-5.55 (m, 1H), 5.43 (d, J = 12 Hz, 1H), 5.38 (d, J = 14.5 Hz, 1H), 
4.94 (br s, 1H), 4.85 (br s, 1H), 4.49 (br s, 1H), 4.27 (dt, J = 8.2, 4.4 Hz, 1H), 3.20 (dt, 
J = 8.3, 3.8 Hz, 1H), 2.79 (t, J = 6.3 Hz, 1H), 2.17-2.20 (m, 2H), 2.09-2.15 (m, 2H), 
2.00-2.07 (m, 2H), 1.95 (t, J = 2.5 Hz, 1H), 1.51-1.77 (m, 5H), 0.97 (d, J = 6.3 Hz, 
3H), 0.94 (d, J = 6.3 Hz, 3H). IT-TOF-MS: (m/z) calcd for C35H43N9O6 [M+H]
+ 
686.3415, found 686.3416. 
 
8.3.2 Cell Biological Assays 
Cell-culture conditions, cell-proliferation assay, in situ proteomic profiling, 
pull-down and mass spectrometry identification, and fluorescence microscopy were 
carried out using the general protocols as described in 7.1.2. 
 
8.3.2.1 Chemicals and Antibodies 
Monoclonal ANTI-FLAG M2 antibody was purchased from Sigma. The 
bacterial His-AGT plasmid, mammalian plasmids FLAG-Cox8A-SNAP, 
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FLAG-H2B-SNAP, FLAG-KDEL-SNAP, FLAG-NK1R-SNAP, mCherry-Cox8A and 
mCherry-KDEL were generous gifts from Christopher J. Chang (University of 
California, Berkeley). AGT-deficient CHO-9 cell line was generous gift from Institute 
of Toxicology, University of Mainz (Germany). Recombinant expression and 
purification of His-AGT protein was as previously reported.
[62d] 
 
8.3.2.2 In Vitro His-AGT Labeling with (3-4) and Analysis by TOF-MS 
His-AGT (2 M) was incubated in PBS with 1 M of 3-4 for different 
lengths of time (15 min, 2 h and 4 h) at room temperature, then incubated with BGFL 
(100 M) for 15 min followed by SDS-PAGE and in-gel fluorescence scanning. The 
deconvoluted MS data were collected by ESI-TOF-MS. 
 
8.3.2.3 Fluorescence Microscopy 
AGT-deficient CHO-9 cells were seeded on coverslips and left to adhere for 
24 h prior to transfection. Transient transfection was carried out by the standard 
protocol of Endofectin (Genecopoeia). Cells were incubated for 48 h prior to labeling. 
Then cells were incubated in growth medium containing 3-4 (30 M) at culture 
temperature and 5% CO2 for 4 h. The cells were then washed twice with PBS, and 
fixed with 4% paraformaldehyde in PBS for 15 min at room temperature and washed 
twice with PBS, and permeabilized with 0.1% Triton-X 100 in PBS for 15 min at 
room temperature, and washed twice with PBS. The cells were blocked with 2% 
bovine serum albumin (BSA) in PBS for 30 min at room temperature, and washed 
twice with PBS. The cells were then treated with a freshly pre-mixed click chemistry 
reaction solution in PBS for 1 h at room temperature. The cells were washed with 
PBS, cold methanol, 1% Tween-20 and 0.5 mM of EDTA in PBS, and PBS. The cells 
were then incubated in PBS containing 0.25 g/mL of Hoechst for 15 min at room 
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temperature to stain the nuclear DNA, and washed twice with PBS and a final wash 
with deionized water before mounting. For colocalization of SNAP protein expressed, 
indirect immunofluorescent cytochemical staining was carried out according the 
manufacturer’s instructions. Cells were blocked with 10% BSA in PBS for 30 min, 
and washed twice with PBS. Then the cells were incubated with monoclonal 
Anti-FLAG M2 antibody diluted in 1:2000 in 3% BSA in PBS for 2 h at 37 
o
C, and 
washed twice with PBS. Then secondary antibody goat-anti-mouse IgG-FITC (Santa 
Cruz) diluted in 1:100 in 3% BSA in PBS for 45 min at 37 ℃, and washed twice with 
PBS. Images were acquired using Observer Z1 (Zeiss, Germany) equipped with a 63X 
NA1.4 objective and a CoolSNAP HQ2 CCD camera (Photometrics, USA), or LSM 




8.4 Chapter 4 
Cell-culture conditions, Guava ViaCount assay, in situ proteomic profiling, 
pull-down and mass spectrometry identification (T. brucei trypanosomes (~1-5  109 
cells, ~5 mg) in growth media (1  107 cells/mL)), and fluorescence microscopy were 
carried out using the general protocols as described in 8.1.2. 
 
Chemicals and Antibodies. 4’,6-diamidino-2-phenylindole (DAPI) was purchased 
from Sigma-Aldrich. MitoTracker Red CMXRos was from Invitrogen.  
 
Fluorescence Microscopy 
Drug uptake analysis. Trypanosomes (1×10
5
 cells/mL for both forms) were 
incubated in growth medium containing different concentrations of THL-R at culture 
temperature and 5% CO2 for 2 h. Medium containing 1% DMSO was used as 
negative control. The parasites were then washed twice with PBS, and fixed with 4% 
paraformaldehyde in PBS for 15 min at room temperature and washed twice with PBS, 
and then sedimented to poly-L-lysine-coated coverslips. Fixed cells were 
permeabilized with 0.25% Triton-X 100 in PBS for 15 min at room temperature, and 
washed twice with PBS. The cells were blocked with 3% BSA in PBS for 30 min at 
room temperature, and washed twice with PBS. The cells were then treated with a 
freshly premixed click chemistry reaction solution in PBS for 1 h at room temperature. 
The cells were washed with PBS, cold methanol, 1% Tween-20 and 0.5 mM EDTA in 
PBS, and PBS. The cells were then incubated in PBS containing 2 g/mL DAPI for 
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15 min at room temperature to stain kinetoplast and nuclear DNA, and washed twice 
with PBS and a final wash with deionized water before mounting with Fluoromount G 
(Emsdiasum, Fort Washington, PA). Images were acquired using Observer Z1 (Zeiss) 
equipped with a 63X NA1.4 objective and a CoolSNAP HQ2 CCD camera 
(Photometrics), or LSM 510 META (Zeiss) equipped with an EC Plan-Neofluar 100x 
NA1.3 objective. 
Immunofluorescence analysis. Cells treated with THL-R for 24 h were attached to 
coverslips, fixed with 4% paraformaldehyde, blocked with 3% BSA in PBS and then 
incubated with corresponding antibodies. Anti-TbBiP, Anti-TbTrypanopain, and 
Anti-TbSKL were used to label the ER, the lysosome, and the glycosome, respectively. 
DAPI (2 g/ml) was used to stain kinetoplast and nuclear DNA. 
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8.5 Chapter 5 
8.5.1 Chemical Syntheis 
Diethyl phenylthiomethylphosphonate (5-4) 
To a cooled (0°C) and stirred suspension of hexane-washed NaH 
(60% in mineral oil; 1.0 g, 24 mmol) in dry THF (100 mL) at 
0 °C was added dropwise benzenethiol (2.0 mL, 20 mmol) via syringe. The mixture 
was stirred for an additional 30 min at 0 °C until effervescence ceased. Diethyl 
iodomethylphosphonate (4.0 mL, 22 mmol) was added dropwise and stirred for 12 h. 
A cold HCl solution (1 N) was added to break up the gelatinous emulsion until pH 6-7 
was reached, and concentrated in vacuo. Diluted with H2O (150 mL) and extracted 
with EtOAc (3  50 mL). The combined organic extracts were washed with saturated 
aqueous NaHCO3 and brine, dried over Na2SO4, filtered and concentrated in vacuo. 
Purification by flash column chromatography on silica gel using 20 to 50% EtOAc in 
hexanes to give the product 5-4 as a colorless liquid (4.79 g, 92%). 
1
H NMR (300 
MHz, CDCl3): δ 1.30 (t, J = 7.1, 6H), 3.20 (d, J = 14.0 Hz, 2H), 4.09-4.20 (m, 4H), 
7.20-7.33 (m, 3H), 7.42-7.46 (m, 2 H). 
 
Diethyl phenylsulfonylmethylphosphonate (5-5) 
To a solution of compound 5-4 (5.0 g, 19.2 mmol) in CH2Cl2 
(100 mL) at 0 °C was added m-chloroperbenzoic acid (12.9 g of 
77% m-CPBA, 57.2 mmol) over 1 h. The mixture was stirred overnight while 
warming to room temperature. The solution was then cooled to 0 °C and was treated 
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with NaOH (2 N) until pH 8-9 was reached. The organic phase was separated, dried 
over Na2SO4, filtered, and concentrated to dryness, giving the product 5-5 as a 
colorless oil (5.6 g, 94%). 
1
H NMR (300 MHz, CDCl3): δ 1.30 (t, J = 7.1 Hz, 6H), 
3.77 (d, J = 17.0 Hz, 2H), 4.11-4.21 (m, 4 H), 7.55-7.61 (m, 2 H), 7.65-7.71 (m, 1 H), 
7.98-8.01 (m, 2 H); 
13
C NMR (75 MHz, CDCl3): δ 1.30 (t, J = 7.1 Hz, 6H), 3.77 (d, J 
=17.0 Hz, 2H), 4.11-4.21(m, 4H), 7.55-7.61 (m, 2H), 7.65-7.71 (m, 1 H), 7.98-8.01 
(m, 2 H). 
 
(S)-tert-butyl [1-(methoxymethylcarbamoyl)-3-phenylpropyl]carbamate (5-6) 
To a solution of (S)-Boc-Homophenylalanine (5.59 g, 20 mmol) 
in dry THF (100 mL) at 0 °C was added EDC•HCl (4.60 g, 24 
mmol), HOBt (3.24 g, 12 mmol), N,O-dimethylhydroxylamine 
hydrochloride (2.34 g, 24 mmol) and DIPEA (5.2 mL, 30 mmol). The reaction was 
stirred at room temperature for 12 h, and concentrated in vacuo. Diluted with H2O 
(150 mL) and extracted with EtOAc (3  50 mL). The combined organic extracts were 
washed with 1 wt% HCl, 20 wt% Na2CO3 and brine, dried over Na2SO4, filtered and 
concentrated in vacuo. The crude product was purified by column chromatography on 
silica gel using 20 to 50% EtOAc in hexanes to give Boc-Hph-N(Me)OMe (5-6) as a 
white solid (6.20 g, 96%). 
1
H NMR (300 MHz, CDCl3): δ 1.45 (s, 9H), 1.80-2.02 (m, 




(S)-tert-butyl (1-formyl-3-phenylpropyl)carbamate (Boc-Homophenylalaninal, 
Boc-HphH, 5-7)  
To a solution of 5-6 (3.2 g, 10 mmol) in dry THF (50 mL) at 0 °C 
was added LiAlH4 (0.45 g, 12 mmol) over 10 min, with vigorous 
stirring. The mixture was stirred for an additional 20 min at 0 °C, 
whereupon cold water was carefully added until effervescence ceased. A cold HCl 
solution (1 N) was added to break up the gelatinous emulsion until pH 6~7 was 
reached. Diluted with H2O (150 mL) and extracted with EtOAc (3  50 mL). The 
combined organic extracts were washed with saturated aqueous NaHCO3 and brine, 
dried over Na2SO4, filtered and concentrated in vacuo. Purification by flash column 
chromatography on silica gel using 20 to 50% EtOAc in hexanes to give the product 
5-7 as a white solid (1.92 g, 73%). 
1
H NMR (300 MHz, CDCl3): δ 1.46 (s, 9H), 
1.83-1.95 (m, 1H), 2.22 (m, 1H), 2.67 (t, J = 7.6 Hz, 2H), 4.24 (m, 1H), 5.09 (br s, 
1H), 7.17-7.32 (m, 5H), 9.55 (s, 1H). 
 
(S)-tert-butyl (3-benzenesulfonyl-1-phenethylallyl)carbamate (Boc-HphVSPh,5-8) 
To a cooled (0°C) and stirred suspension of n-hexane-washed 
NaH (60% in mineral oil; 0.24 g, 6 mmol) in dry THF (50 mL) 
at 0 °C was added dropwise 5-5 (1.61 g, 5.5 mmol) in dry THF 
(10 mL) via syringe. The mixture was stirred for an additional 30 min at 0 °C and 5-7 
(1.32 g, 5 mmol) in dry THF (10 mL) was added dropwise and stirred for 1 h. A cold 
5 wt% NaHSO4 solution was added to break up the gelatinous emulsion until pH 6~7 
was reached, and concentrated in vacuo. Diluted with water (100 mL) and extracted 
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with EtOAc (3  25 mL). The combined organic extracts were washed with saturated 
aqueous NaHCO3 and brine, dried over Na2SO4, filtered and concentrated under 
vacuum. Purification by flash column chromatography on silica gel using 20 to 50% 
EtOAc in hexanes to give the product 5-8 as a white foam (1.4 g, 70%). 
1
H NMR (500 
MHz, CDCl3): δ 1.40 (s, 9H), 1.83-1.94 (m, 2H), 2.62-2.70 (m, 2H), 4.36 (br s, 1H), 
4.52 (br s, 1H), 6.43 (br d, J = 14.5 Hz, 1H), 6.87-6.90 (m, 1H), 7.13-7.30 (m, 5H), 
7.51-7.61 (m, 3H), 7.61 (d, J = 6.0 Hz, 2H); IT-TOF-MS: (m/z) calcd for C22H27NO4S 
[M+Na]
+
 424.1661, found: 424.1575. 
 
(S)-3-benzenesulfonyl-1-phenethylallylamine trifluoroacetate (TFA•HphVSPh, 5-9) 
To a cooled (0°C) and stirred solution of 5-8 (1.2 g, 3 
mmol) in DCM (15 mL) was added dropwise TFA (5 mL) 
via syringe. After being stirred for 2 h, Et2O (100 mL) 
was added with stirring. The precipitate was filtered off, washed twice with Et2O, and 
finally dried in vacuo to give 73.4 g (76%) of 5-9. 
1
H NMR (300 MHz, CDCl3): δ 
1.34 (br s, 2H), 1.76-1.86 (m, 2H), 2.68 (t, J = 7.9 Hz, 2H), 3.53 (m, 1H), 6.49 (m, 
1H), 6.98 (dd, J = 5.6, 14.9 Hz, 1H), 7.12-7.30 (m, 5H), 7.51-7.56 (m, 3H), 7.86 (d, J 
= 7.3 Hz, 2H). This material was pure enough to be used in the next step without 
further purification. 
 
(S)-N-(4-chlorobenzylidene)phenylalanine methyl ester (HCl•Phe-OMe, 5-10) 
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To a cooled (0 °C) and stirred suspension of phenylalanine (16.5 
g, 100 mmol) in dry MeOH (150 mL) was added dropwise SOCl2 
(9 mL, 120 mmol) over a 1 h period. During the addition the 
mixture was cooled in ice-bath in order to keep the temperature < 5 
o
C. The clear 
solution was stirred for 12 h and subsequently for 2 h at 50 
o
C. After evaporation of 
the solvent under reduced pressure, Et2O (100 mL) was added with stirring. The 
precipitate was filtered off, washed twice with ether, and finally dried in vacuo to give 
21.6 g (98 %) of 5-10 as a white solid. This material was pure enough to be used in 
the next step without further purification.  
 
Methyl (S)-2-isocyanato-3-phenylpropanoate (OCN-PheOMe, 5-11) 
To a solution of 5-10 (5.5 g, 25.5 mmol) in DCM (50 mL) at 
0 °C was added saturated aqueous NaHCO3 (50 mL) and 
triphosgene (2.52 g, 8.42 mmol) in a single portion with vigorous 
stirring. The reaction mixture was stirred at 0 °C for 15 min and then poured into a 
250-mL separatory funnel. The organic layer was collected, and the aqueous layer is 
extracted with DCM (3  50 mL). The combined organic layers were washed with 
brine, dried (Na2SO4), vacuum filtered, and concentrated at reduced pressure using a 
rotary evaporator to give the product 5-11 as a colorless oil. 
1
H NMR (300 MHz, 
CDCl3): δ 3.03 (dd, J = 7.8, 13.8 Hz, 1H), 3.16 (dd, J = 4.8, 13.6 Hz, 1H), 3.81 (s, 
3H), 4.27 (dd, J = 4.61, 7.8 Hz, 1H), 7.18-7.21 (m, 2H), 7.27-7.36 (m, 3H). This 
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material was used in the next step without further purification, assuming a 
quantitative yield. 
 
tert-butyl 1-piperazinecarboxylate (5-12) 
To a solution of di-tert-butyl dicarbonate (5.80 g, 25.54 mmol) solution in 50 
mL of dry MeOH was added drop-wise a solution of piperazine (4.0 g, 46.44 
mmol) in 100 mL of dry MeOH previously cooled at 0 °C. After 30 min, all 
ditert-butyl dicarbonate had been added and the mixture was warmed to room 
temperature. After 2 d, the solution was concentrated under reduced pressure and the 
crude solid was dissolved in 200 mL of Et2O, and the white precipitate left was 
filtered off. The aqueous solution obtained by extracting the organic solution with 1 N 
citric acid (aq.) (3 × 100 mL) was washed with EtOAc (3 × 100 mL) and brought to 
pH ~ 11 by adding solid K2CO3. The turbid solution was extracted with EtOAc (3 × 
100 mL) and dried over Na2SO4. The solution was concentrated under reduced 
pressure at 40 °C and stripped with DCM to yield clear oil which was crystallized into 
a white solid upon drying under reduced pressure. Yield: 71%; 
1
H NMR (300 MHz, 
CDCl3): δ 3.45-3.33 (m, 4H), 2.88-2.74 (m, 4H), 1.57 (s, 1H), 1.46 (s, 9H). 
 
tert-Butyl 4-propargylpiperazine-1-carboxylate (5-13)  
To a solution of 5-12 (1.86 g, 10 mmol) and diisopropylethylamine (1.9 mL, 
11mmol) in CHCl3 (50 mL) at 0 °C was added drop-wise a solution of 
propargyl bromide (80% in toluene, 1.2 mL, 10mmol) in CHCl3 (50 mL). 
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After the mixture was stirred for 24 h at room temperature, the solution obtained was 
washed with 5% NaHCO3 (3 × 50mL), brine (2 × 50mL), and then dried over Na2SO4. 
The solution was filtered and evaporated to provide a brown oil. Purification by flash 
column chromatography on silica gel using 50% EtOAc in hexanes to give the 
product 5-13 as a yellow oil (1.4 g, 86%), which ultimately crystallized upon standing. 
1
H NMR (500 MHz, CDCl3): 1.49 (s, 9H), 2.26 (t, J = 2.5 Hz, 1H), 2.51 (t, J = 5.0 Hz, 
4H), 3.32 (d, J = 2.55 Hz, 2H), 3.47 (t, J = 5.0 Hz, 4H); 
13
C NMR (126 MHz, CDCl3): 
δ 29.10, 47.67, 52.32, 74.10, 79.10, 80.40, 155.39. 
 
N-Propargylpiperazine•TFA salt (5-14) 
To a solution of 5-13 (1.12g, 5 mmol) in CH2Cl2 (25 mL) at 0 °C was 
added trifluoroacetic acid (25mL). The solution was stirred at room 
temperature overnight, and then was evaporated to dryness in vacuum. 
Assumed quantitative yield of 1.16 g. The residue was suspended in 20 mL THF and 




To a solution of 5-14 (0.7 g, 2 mmol) in dry THF (10 mL) 
at 0 °C was added drop-wise a solution of DIEA (0.7 mL, 
4 mmol) in 10 mL of dry THF previously cooled at 0 °C. 
After 10 min, a solution of 5-11 (0.68 g, 2.4 mmol) in dry 
THF (10 mL) was added at 0 °C. The mixture was stirred for 12 h and was 
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concentrated in vacuo to give a brown oil, and diluted with water (100 mL) and 
extracted with EtOAc (3  50 mL). The combined organic extracts were washed with 
saturated aqueous NaHCO3 and brine, dried over Na2SO4, filtered and concentrated 
under vacuum. Purification by flash column chromatography on silica gel using 5 to 
10% methanol in DCM gave the product 5-15 as a white solid (0.53 g, 80%).
 1
H NMR 
(500 MHz, CDCl3): δ 2.49-2.56 (m, 4H), 3.08-3.16 (m, 2H), 3.31-3.43 (m, 6H), 3.72 
(s, 3H), 4.77-4.80 (m, 1H), 4.81-4.91 (m, 1H), 7.10-7.11 (m, 2H), 7.23-7.30 (m, 3H); 
13
C NMR (126 MHz, CDCl3): δ 38.97, 44.24, 47.53, 52.02, 52.87, 55.00, 74.23, 78.88, 
127.68, 129.17, 129.96, 136.87, 157.07, 173.74; IT-TOF-MS: (m/z) calcd for 
C18H23N3O3 [M+Na]
+
 352.1739, found 352.1738. 
 
(S)-3-phenyl-2-(4-(prop-2-yn-1-yl)piperazine-1-carboxamido)propanoic acid 
hydrochloride (5-16)  
To a solution of 5-15 (0.6 g, 1.8 mmol) in THF (30 mL) at 
0 °C was added drop-wise a solution of LiOH•H2O (0.23 g, 
5.5 mmol) in 10 mL of H2O. The mixture was stirred for 4 
h, and 4 N HCl in dioxane was then added slowly to adjust 
the pH of the reaction mixture to ~ 2 at 0 °C. The resulting solution was evaporated in 
vacuo. The residue was washed with Et2O (2  25 mL), dried in vacuo, and then 
lyophilized overnight to give the crude product 5-16, along with a little LiCl, which 





propan-2-yl)-4-(prop-2-yn-1-yl)piperazine-1-carboxamide (5-1, VS-1) 
To a solution of 5-16 (215 mg, 0.6 mmol) in 
DMF (5 mL) was added EDC•HCl (115 mg, 
0.6 mmol), HOBt (81 mg, 0.6 mmol) and 
DIEA (0.4 mL, 2.4 mmol). After 10 min, 
TFA•HphVSPh 5-9 (208 mg, 0.5 mmol) in 
DMF (5 mL) was added dropwise. The reaction was stirred at rt for 21 h. The 
resulting solution was evaporated in vacuo to give a brown oil, and diluted with water 
(50 mL) and extracted with DCM (3  50 mL). The combined organic extracts were 
washed with saturated aqueous NaHCO3 and brine, dried over Na2SO4, filtered and 
concentrated under vacuum. Purification by flash column chromatography on silica 
gel using 5 to 10% methanol in DCM gave the product 5-1 as a white solid (165 mg, 
55%).
 1
H NMR (500 MHz, CDCl3): δ 1.72-1.75 (m, 1H), 1.82-1.84 (m, 1H), 
2.44-2.56 (m, 7H), 3.01 (d, J = 7.6 Hz, 2H), 3.27-3.37 (m, 6H), 4.54-4.60 (m, 2H), 
5.13 (d, J = 7.6 Hz, 1H), 6.09 (dd, J = 1.2, 15.1 Hz, 1H), 6.78 (dd, J = 4.9, 15.1 Hz, 
1H), 6.87 (d, J = 8.3 Hz, 1H), 7.02 (d, J = 7.3 Hz, 2H), 7.11-7.24 (m, 8H), 7.54 (t, J = 
7.6 Hz, 2H), 7.62 (t, J = 7.6 Hz, 1H), 7.84 (d, J = 7.6 Hz, 2H). 
13
C NMR (126 MHz, 
CDCl3): δ 31.77, 35.70, 36.49, 38.48, 43.71, 46.82, 49.10, 51.26, 56.01, 73.66, 78.14, 
126.25, 127.14, 127.66, 128.37, 128.56, 128.72, 129.26, 129.30, 130.48, 133.47, 
136.66, 140.23, 140.44, 145.66, 156.90, 171.86; IT-TOF-MS: (m/z) calcd for 
C34H38N4O4S [M+H]
+
 599.2614, found 599.2545. 
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(S)-benzyl-2-isocyanato-3-phenylpropionate (OCN-PheOBzl, 5-17) 
To a solution of (S)-Benzyl-2-amino-3-phenylpropionate 
hydrochloride (HCl•PheOBzl) (3.72 g, 12.75 mmol) in DCM (50 
mL) at 0 °C was added saturated aqueous NaHCO3 (50 mL) and 
triphosgene (1.25 g, 4.21 mmol) in a single portion with vigorous stirring. The 
reaction mixture was stirred at 0 °C for 15 min and then poured into a 250-mL 
separatory funnel. The organic layer was collected, and the aqueous layer is extracted 
with DCM (3  15 mL). The combined organic layers were washed with brine, dried 
(Na2SO4), vacuum filtered, and concentrated at reduced pressure using a rotary 
evaporator to give a colorless oil. The product, OCN-PheOBzl was used in the next 
step without further purification, assuming a quantitative yield. 
 
(S)-benzyl 2-(morpholine-4-carboxamido)-3-phenylpropanoate (5-18) 
To a solution of 5-17 (3.59 g, 12.75 mmol) in dry THF (50 
mL) at 0 °C was added morpholine (1.1 mL, 12.75 mmol). 
The mixture was stirred for 1 h and was concentrated in 
vacuo to a pale orange oil, and diluted with water (100 mL) and extracted with EtOAc 
(3  50 mL). The combined organic extracts were washed with HCl (1 N), saturated 
aqueous NaHCO3 and brine, dried over Na2SO4, filtered and concentrated under 
vacuum. Purification by flash column chromatography on silica gel using 10 to 20% 
EtOAc in hexanes to give the product (S)-benzyl 
2-(morpholine-4-carboxamido)-3-phenylpropanoate (Mu-PheOBzl, 5-18) as a white 
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solid (3.9 g, 83% over two steps).
 1
H NMR (300 MHz, CDCl3): δ 3.11 (d, J = 5.3 Hz, 
2H), 3.27-3.31 (m, 4H), 3.62-3.65 (m, 4H), 4.81-4.90 (m, 2H), 5.15 (dd, J = 12.3, 
27.8 Hz, 2H), 6.99 (dd, J = 3.5, 7.0 Hz, 2H), 7.19-7.22 (m, 3H), 7.29-7.38 (m, 5H); 
13
C NMR (75 MHz, CDCl3): δ 38.22, 43.92, 54.28, 66.41, 67.20, 127.01, 128.51, 
128.58, 129.34, 135.19, 136.01, 156.66, 172.43. 
 
(S)-2-(morpholine-4-carboxamido)-3-phenylpropanoic acid (5-19)  
A solution of Mu-PheOBzl (5-18) (3.9 g, 10.6 mmol) in 1% 
HOAc/ethanol (100 mL) was charged with 10% palladium on 
active charcoal (Aldrich: 0.4 g). The solution in the Parr bottle 
was exposed to hydrogen on a Parr shaker (50 psi) for 12 h, filtered through Celite, 
and concentrated in vacuo. The residue was triturated with ether (100 mL) to remove 
residual ethanol and was reprecipitated from DCM/ether to give 2.94 g (99%) of 
(S)-2-(morpholine-4-carboxamido)-3-phenylpropanoic acid (Mu-PheOH, 5-19). 
1
H 
NMR (300 MHz, DMSO-d6): δ 2.86-2.94 (m, 1H), 3.00-3.16 (m, 1H), 3.18-3.28 (m, 
4H), 3.41-3.48 (m, 4H), 4.19-4.27 (m, 1H), 6.72 (d, J = 8.2 Hz, 1H), 7.17-7.30 (m, 
5H). 
13
C NMR (75 MHz, DMSO-d6): δ 36.60, 43.94, 65.87, 126.24, 128.08, 129.15, 
138.44, 157.37, 174.24. Without further purification, the mixture was used directly in 






Prepared according to the similar procedure 
mentioned above by using 5-19 (290 mg, 1.04 
mmol), 5-9 (420 mg, 1.0 mmol), EDC•HCl 
(190 mg, 1.0 mmol), HOBt (140 mg, 1.0 
mmg), DIEA (0.34 mL, 2 mmol) in DMF (5 
mL). Purification by flash column chromatography on silica gel using 25 to 50% 
EtOAc in hexanes to give K11002 as a white solid (450 mg, 80%). 
1
H NMR (500 
MHz, CDCl3): δ 1.74-1.90 (m, 2H), 2.55-2.60 (m, 2H), 3.25 (d, J = 4.1 Hz, 2H), 
3.25-3.34 (m, 4H), 3.59-3.65 (m, 4H), 4.51 (m, 1H), 4.62 (m, 1H), 5.06 (m, 1H), 6.10 
(dd, J = 1.65, 15.1 Hz, 1H), 6.79 (dd, J = 4.85, 15.1 Hz, 1H), 7.07 (d, J = 7.65 Hz, 
2H), 7.15-7.28 (m, 8H), 7.57 (t, J = 7.8 Hz, 2H), 7.65 (t, J = 7.4 Hz, 1H), 7.87 (d, J = 
7.5 Hz, 2H); IT-TOF-MS: (m/z) calcd for C31H35N3O5S [M+H]
+
 562.2297, found 
562.2629. 
 
(S)-benzyl 2-(4-methylpiperazine-1-carboxamido)-3-phenylpropanoate (5-20) 
Prepared according to the similar procedure mentioned 
above by using (S)-benzyl-2-amino-3-phenylpropionate 
hydrochloride (HCl•PheOBzl, 5-17) (5.84 g, 20 mmol), 
triphosgene (1.98 g, 6.67 mmol), and N-methylpiperazine (2.2 mL, 20 mmol). 
Purification by flash column chromatography on silica gel using 5 to 10% methanol in 
DCM to give 6.02 g (79%) the product MePip-PheOBzl (5-20) as a pale orange oil.  
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(S)-2-(4-methylpiperazine-1-carboxamido)-3-phenylpropanoic acid (5-21) 
Prepared according to the similar procedure mentioned 
above by using MePip-PheOBzl (5-20) (7.5 g, 19.7 mmol), 
10% Pd/C (0.75 g) in 1% HOAc/ethanol (50 mL) under 50 
psi for 12 h. The compound was obtained as white solid (5.61 g, 98%). 1H NMR (300 
MHz, DMSO-d6): δ 2.15 (s, 3H), 2.18 (m, 4H), 2.84-2.94 (dd, J = 10.8, 15.1 Hz, 1H), 
2.95-3.04 (dd, J = 5.0, 15.1 Hz, 1H), 3.14-3.30 (m, 4H), 4.17 (m, 1H), 6.65 (d, J = 8.0 




Prepared according to the similar procedure 
mentioned above by using 5-21 (291 mg, 1.0 
mmol), 5-9 (420 mg, 1.0 mmol), EDC•HCl 
(190 mg, 1.0 mmol), HOBt (140 mg, 1.0 
mmg), DIEA (0.34 mL, 2 mmol) in DMF (5 
mL). Purification by flash column chromatography on silica gel using 5 to 10% 
methanol in DCM to give K11777 as a white solid (260 mg, 45%). 
1
H NMR (500 
MHz, CDCl3): δ 1.76-1.88 (m, 2H), 2.27-2.35 (m, 7H), 2.55-2.60 (m, 2H), 3.05 (d, J 
= 7.5 Hz, 2H), 3.29-3.37 (m, 4H), 4.51 (m, 1H), 4.63 (m, 1H), 5.02 (m, 1H), 6.12 (dd, 
J = 1.55, 15.2 Hz, 1H), 6.79 (dd, J = 4.95, 15.1 Hz, 1H), 7.07 (d, J = 7.6 Hz, 2H), 
7.15-7.30 (m, 8H), 7.57 (t, J = 7.9 Hz, 2H), 7.65 (t, J = 7.25 Hz, 1H), 7.87 (d, J = 1.3 
Hz, 2H); IT-TOF-MS: (m/z) calcd for C32H38N4O4S [M+H]
+




(S)-methyl 2-((((4-ethynylbenzyl)oxy)carbonyl)amino)-3-phenylpropanoate (5-22) 
To a solution of 5-11 (2.46 g, 12 mmol) in 
anhydrous toluene (25 mL) was added 
(4-ethynylphenyl)methanol (1.32 g, 10 mmol). The 
resulting solution was heated to 100 
o
C for 6 h and was concentrated in vacuo to a 
pale orange oil, and diluted with water (100 mL) and extracted with ether (3  50 mL). 
The combined organic extracts were washed with HCl (1 N), saturated aqueous 
NaHCO3 and brine, dried over Na2SO4, filtered and concentrated under vacuum. 
Purification by flash column chromatography on silica gel using 10% EtOAc in 
hexanes to give 5-22 as a white solid (2.65 g, 79%). 
1
H NMR (300 MHz, CDCl3): δ 
3.03-3.16 (m, 2H), 3.72 (s, 3H), 4.62-4.69 (m, 1H), 5.03-5.12 (m, 2H), 5.34 (br d, J = 
12.65 Hz, 2H), 7.08-7.11 (m, 2H), 7.21-7.31 (m, 5H), 7.46 (d, J = 13.7 Hz, 2H); 
13
C 
NMR (75 MHz, CDCl3): δ 38.90, 53.01, 55.49, 67.02, 78.19, 83.98, 122.60, 127.85, 
128.46, 129.30, 129.92, 132.93, 136.32, 137.71, 156.12, 172.59. 
 
(S)-2-((((4-ethynylbenzyl)oxy)carbonyl)amino)-3-phenylpropanoic acid (5-23) 
To a solution of 5-22 (3.4 g, 10 mmol) in THF (60 
mL) at 0 °C was added dropwise an aqueous 
solution of LiOH (0.72 g, 30 mmol) in 20 mL of 
H2O. The reaction was monitored by TLC (elution with hexane/EtOAc: 1/1) until 
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complete disappearance (approximately 2 h) of the starting ester. The reaction mixture 
was then acidified with 2 N HCl (to pH ~ 2) and was extracted with EtOAc (3  50). 
After drying over Na2SO4, filtration and evaporation of the organic phase, the 
compound was used directly in the following reaction without further purification 
(quantitative yield). 
1
H NMR (300 MHz, DMSO-d6): δ 2.84 (m, 1H), 2.88-3.11 (m, 
1H), 4.17-4.23 (m, 2H), 4.99 (s, 2H), 7.20-7.31 (m, 2H), 7.45 (d, J = 13.45 Hz, 2H), 
7.68 (d, J = 13.95 Hz, 1H); 
13
C NMR (75 MHz, DMSO-d6): δ 36.49, 55.52, 64.73, 




n-3-yl)amino)propan-2-yl)carbamate (5-2, VS-2) 
Prepared according to the similar 
procedure mentioned above by 
using 5-23 (162 mg, 0.5 mmol), 5-9 
(208 mg, 0.5 mmol), EDC•HCl (115 
mg, 0.6 mmol), HOBt (81 mg, 0.6 
mmg), DIEA (0.2 mL, 1.2 mmol) in DMF (5 mL). Purification by flash column 
chromatography on silica gel using 20% EtOAc in hexanes give 5-2 as a white solid 
(258 mg, 85%). 
1
H NMR (500 MHz, CDCl3): δ 1.74-1.79 (m, 1H), 1.86-1.89 (m, 1H), 
2.52-2.57 (m, 2H), 2.95-3.03 (m, 2H), 3.09 (s, 1H), 4.27 (m, 1H), 4.64 (dd, J = 3.5, 
5.0 Hz, 1H), 5.05 (s, 2H), 5.23 (br d, J = 6.25 Hz, 1H), 5.79 (br d, J = 7.55 Hz, 1H), 
6.04 (dd, J = 0.9, 15.1 Hz, 1H), 6.75 (dd, J = 4.7, 15.1 Hz, 1H), 7.03 (d, J = 7.2 Hz, 
 251 
2H), 7.11 (d, J = 7.1 Hz, 2H), 7.16-7.28 (m, 8H), 7.44 (d, J = 8.1 Hz, 2H), 7.55 (t, J = 
7.8 Hz, 2H), 7.63 (t, J = 7.35 Hz, 1H), 7.85 (d, J = 7.65 Hz, 2H); IT-TOF-MS: (m/z) 
calcd for C36H34N2O5S [M+H]
+
 607.2188, found 607. 2078. 
 
Diethyl (((4-(prop-2-yn-1-yloxy)phenyl)sulfonyl)methyl)phosphonate (5-25) 
A mixture of 4-hydroxy-thiophenyl-methyl-diethyl- 
phosphonate sulfone 5-24
[130]
 (3.08 g, 10 mmol) and 
anhydrous K2CO3 (1.66 g, 12 mmol) in dry acetone (50 mL) 
was stirred at rt for 2 h. 80% of propargyl bromide in toluene (1.25 mL, 11 mmol) was 
added dropwise. The mixture was then stirred for 12 h, and TLC analysis indicated all 
the starting materials had been consumed. After removal of acetone under reduced 
pressure, the reaction mixture was poured into water (50 mL) and extracted with 
EtOAc (3  50 mL). The combined organic layer was washed successively with 1 N 
HCl, water, and brine. After drying over Na2SO4, filtration and evaporation of the 
organic phase, the compound was purified by flash column chromatography on silica 
gel using 50% EtOAc in hexanes give 5-25 as a white solid (3.01 g, 87%). 
1
H NMR 
(500 MHz, CDCl3): δ 1.30 (t, J = 7.0 Hz, 6H), 2.57 (t, J = 2.4 Hz, 1H), 3.74 (d, J = 







Prepared according to the similar procedure 
mentioned above by using 5-24 (3.0 g, 8.67 mmol), 
5-7 (2.1 g, 7.88 mmol), and NaH (60% in oil, 0.38 g, 
9.5 mmol) in anhydrous THF (100 mL). Purification by flash column chromatography 
on silica gel using 20% EtOAc in hexanes give 5-26 as a white solid (2.67 g, 75%). 
1
H NMR (500 MHz, CDCl3): δ 1.40 (s, 9H), 1.78-1.86 (m, 1H), 1.89-1.96 (m, 1H), 
2.55 (t, J = 2.5 Hz, 1H), 2.62-2.70 (m, 2H), 4.35 (br s, 1H), 4.52 (br s, 1H), 4.76 (d, J 
= 1.9 Hz, 2H), 6.40 (d, J = 15.1 Hz, 1H), 6.84 (dd, J = 3.8, 14.5 Hz, 1H), 7.08 (t, J = 
3.15 Hz, 2H), 7.14 (d, J = 6.95 Hz, 2H), 7.18-7.30 (m, 3H), 7.81 (dd, J = 2.55, 11.35 
Hz, 2H); 
13
C NMR (126 MHz, CDCl3): δ 28.23, 31.89, 35.96, 50.62, 56.03, 76.53, 
77.30, 80.23, 115.44, 126.32, 128.32, 128.61, 129.84, 131.09, 132.67, 140.75, 145.23, 




Prepared according to the same procedure 
mentioned above by using 5-26 (2.28 g, 5.0 
mmol) in 100 mL of TFA/DCM (1/1), followed 
by precipitation with Et2O, filtered off, washed twice with Et2O, and finally dried in 
vacuo to give 2.3 g (98%) of 5-27. This material was pure enough to be used in the 




)pent-1-en-3-yl)amino)propan-2-yl)morpholine-4-carboxamide (5-3, VS-3) 
Prepared according to the same 
procedure mentioned above by using 
5-19 (139 mg, 0.5 mmol), 5-27 (234 mg, 
0.5 mmol), EDC•HCl (115 mg, 0.6 
mmol), HOBt (81 mg, 0.6 mmg), DIEA 
(0.2 mL, 1.2 mmol) in DMF (5 mL). Purification by flash column chromatography on 
silica gel using 20% EtOAc in hexanes give 5-3 as a white solid (265 mg, 86%). 
1
H 
NMR (500 MHz, CDCl3): δ 1.64-1.85 (m, 2H), 2.41 (t, J = 7.55 Hz, 2H), 2.59 (t, J = 
1.8 Hz, 1H), 3.03-3.11 (m, 2H), 3.22-3.31 (m, 4H), 3.60-3.66 (m, 4H), 4.46 (dd, J = 
7.6, 15.2 Hz, 1H), 4.60-4.62 (m, 1H), 4.78 (d, J = 2.55 Hz, 2H), 5.03 (d, J = 7.55 Hz, 
1H), 6.39 (br s, 1H), 6.50 (br d, J = 15.15 Hz, 1H), 6.80 (dd, J = 5.0, 15.1 Hz, 1H), 
7.05 (d, J = 6.95 Hz, 2H), 7.08 (dd, J = 1.9, 6.95 Hz, 2H), 7.20-7.30 (m, 8H), 7.80 (dd, 
J = 1.85, 6.9 Hz, 2H); 
13
C NMR (126 MHz, CDCl3): δ 31.68, 35.48, 37.97, 43.92, 
49.15, 56.04, 56.20, 66.27, 76.62, 77.32, 115.41, 126.25, 127.15, 128.32, 128.53, 
128.79, 129.22, 129.84, 131.16, 132.63, 136.68, 140.37, 144.48, 157.23, 161.41, 
171.64; IT-TOF-MS: (m/z) calcd for C34H37N3O6S [M+H]
+
 616.2403, found 616. 
2293. 
 
8.5.2 Cell Biological Assays 
Cell-culture conditions, Guava ViaCount assay, in situ proteomic profiling, 
pull-down and mass spectrometry identification, and fluorescence microscopy were 
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carried out using the general protocols as described in 8.1.2. 
 
8.5.2.1 Chemicals and Antibodies 
Anti-cathepsin L (ab6314) was from Abcam. Anti-rhodesainΔC, and 
anti-TbcatB were generous gifts from James H. McKerrow (University of California, 
San Francisco). 
 
8.5.2.2 Western Blotting 
Pull-down samples from in situ labeling with VS-1 were separated on 12% 
SDS-PAGE gel together with pull-down sample from DMSO-treated (negative 
control). After SDS-PAGE gel separation, proteins were then transferred to a PVDF 
membrane and subsequently blocked with 3% (w/v) BSA/PBST overnight at 4
o
C. 
Membranes were incubated for 1 h at room temperature with the respective antibodies 
(anti-cathepsin L for HepG2; anti-rhodesainΔC, or TbcatB for T. brucei), and washed 
with PBST (3 × 15 min with gentle agitation), then followed by incubation with a 
anti-mouse-IgG conjugated secondary antibody in the blocking buffer mentioned 
above. After wash with PBST (3 × 15 min with gentle agitation), the SuperSignal 
West Pico kit (Pierce) was used to develop the blot. 
 
8.5.2.3 Fluorescence Microscopy 
Confocal images were taken on a Leica TCS SP5X Confocal Microscope 
System equipped with Leica HCX PL APO 100×/1.40 oil objective, 405 nm Diode 
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laser, White laser (470 nm to 670 nm, with 1 nm increments, with 8 channels AOTF 
for simultaneous control of 8 laser lines, each excitation wavelength provides 1.5 mV, 
PMT detector range from 420 nm to 700 nm for steady state fluorescence. DAPI, 
FITC and rhodamine were excited with a krypton/argon laser at 405, 488 nm and 554 
nm, respectively, and the emission was collected through a 420-470, 500-550 and 
565-650 nm filters, respectively. Images were processed with Leica Application Suite 
Advanced Fluorescence (LAS AF).  
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8.6 Chapter 6 
8.6.1 Chemical Syntheis 
General procedure for the preparation of 6-7ac 
To a cooled (0 °C) and stirred suspension of Boc-protected amino acid (25.0 
mmol) in dry DMF (50 mL) was added Cs2CO3 (9.0 g, 27.5 mmol). After being 
stirred for 30 min, BnBr (3.0 mL, 25.0 mmol) was added via syringe. The mixture 
was stirred for 12 h, filtered and concentrated in vacuo. The residue was diluted with 
water (50 mL), and extracted with ether (3  50 mL). The combined organic extracts 
were washed twice with water and brine, dried (Na2SO4), and the solvent was 
removed in vacuo. This material was used in the next step without further purification. 
To a stirred solution of Boc-protected amino acid benzyl ester (20 mmol) in dry THF 
(25 mL) cooled at 0 
o
C was added a 4.0 M solution of HCl in 1,4-dioxane (15 mL) 
dropwise via syringe. After being stirred for 12 h, ether (150 mL) was added with 
stirring. The precipitate was filtered off, washed twice with ether, and finally dried in 
a vacuum desiccator (P2O5). This material was pure enough to be used in the next step 
without further purification. 
 
General procedure for the preparation of 6-8ac 
To a cooled (0 °C) solution of 1,4-benzodioxane-6-carboxylic acid acid (1.80 
g, 10.0 mmol) in DMF (50 mL) was added EDC•HCl (2.31 g 12.0 mmol), HOBt (1.62 
g, 12.0 mmol), 6-7a (2.92 g, 10.0 mmol) and DIPEA (2.6 mL, 15.0 mmol). The 
reaction was stirred at room temperature for 18 h, and concentrated in vacuo. Diluted 
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with water (150 mL) and extracted with EtOAc (3  50 mL). The combined organic 
extracts were washed with 1 wt% HCl, 20 wt% Na2CO3 and brine, dried over Na2SO4, 
filtered and concentrated under vacuum. The crude product was purified by column 
chromatography on silica gel using 20 to 50% EtOAc in hexanes to give the desired 




(white solid, 90%), 
1
H NMR (300 MHz, CDCl3): δ 
3.16-3.29 (m, 2H), 4.24-4.30 (m, 4H), 5.06-5.23 (m, 3H), 
6.46 (d, J = 5.0 Hz, 1H), 6.87 (d, J = 15.0 Hz, 1H), 




(white solid, 92%), 
1
H NMR (300 MHz, CDCl3): δ 0.93 
(d, J = 3.0 Hz, 3H), 0.97 (d, J = 6.0 Hz, 3H), 2.24-2.30 
(m, 1H), 4.26-4.30 (m, 4H), 4.79-4.81 (m, 1H), 
5.15-5.24 (m, 2H), 6.51 (d, J = 6.0 Hz, 1H), 6.89 (d, J = 6.0 Hz, 1H), 7.29-7.38 (m, 
7H); 
13
C NMR (75 MHz, CDCl3): δ 17.8, 19.0, 31.7, 57.4, 64.2, 64.6, 67.1, 116.6, 





(white solid, 87%), 
1
H NMR (300 MHz, CDCl3): δ 
0.93-0.99 (m, 6H), 1.64-1.75 (m, 3H), 4.26-4.31 (m, 4H), 
4.79-4.91 (m, 1H), 5.19 (m, 2H), 6.43 (d, J = 6.0 Hz, 
1H), 6.88 (dd, J = 3.0, 6.0 Hz, 1H), 7.27-7.38 (m, 7H).  
 
General procedure for the preparation of 6-9ac 
A solution of 6-8b (2.96 g, 8.0 mmol) in a mixture of 100 mL ethanol/1 mL 
HOAc was prepared and transferred to a Parr bottle. Under a nitrogen atmosphere, a 
portion of 10% Pd/C (300 mg) was added to the solution in the Parr bottle. The Parr 
bottle was then installed on a Parr shaker apparatus and then pressurized with 
hydrogen to about 50 psi and was shaken until the hydrogen uptake ceased. The 
reaction mixture was filtered through Celite to remove the catalyst and the filtrate was 
evaporated under reduced pressure to give the product 6-9b as a white solid (2.1 g, 
94%). This material was pure enough to be used in the next step without further 
purification. 
1
H NMR (300 MHz, DMDO-d6): δ 0.93 (d, J = 6.0 Hz, 
3H), 0.95 (d, J = 6.0 Hz, 3H), 2.11-2.20 (m, 1H), 
4.21-4.29 (m, 5H), 6.92 (d, J = 9.0 Hz, 1H), 7.45 (t, J = 
3.0 Hz, 2H), 8.21 (d, J = 9.0 Hz, 1H); 
13
C NMR (75 MHz, DMDO-d6): δ 18.8, 19.3, 
29.5, 58.4, 64.0, 64.4, 104.5, 116.6, 116.7, 121.1, 127.1, 142.8, 146.1, 165.9, 173.2.  
 
General procedure for the preparation of 6-10ac 
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To a stirred solution of 6-9a (1.6 g, 4.9 mmol) in dry THF (25 mL) cooled at 
-25 
o
C was added dropwise N-methylmorpholine (NMM) (0.65 mL, 5.9 mmol), and 
isobutyl chloroformate (ISCF) (0.77 mL, 5.9 mmol) via syringe. The reaction was 
stirred for 1 h and filtered to remove the NMM•HCl salt. Methylhydrazine sulfate (1.5 
g, 10 mmol) was dissolved in H2O (1 mL) and 5 N NaOH (4 mL) was added under ice 
cooling. Methylhydrazine solution was added dropwise to the filtrate at −25 oC. The 
reaction was allowed to warm to room temperature and stirred for 24 h. After 
evaporation of the solvent, the aqueous residue was extracted with EtOAc (3  20 
mL). The combined organic extracts were washed with H2O, saturated NaHCO3, brine, 
dried over Na2SO4 and concentrated in vacuo. Purification by flash column 
chromatography on silica gel using 50 to 80% EtOAc in hexanes to give the desired 




(white solid, 1.46 g, 84%), 
1
H NMR (300 MHz, 
CDCl3): δ 1.67 (br d, J = 12.0 Hz, 2H), 3.09 (s, 3H), 
3.35 (s, 2H), 4.25-4.17 (m, 4H), 5.91-5.98 (m, 1H), 




(white solid, 1.16 g, 84%), 
1
H NMR (300 MHz, CDCl3): δ 0.94-1.03 (m, 6H), 
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2.23-2.20 (m, 1H), 3.21 (s, 3H), 4.27 (d, J = 6.0 Hz, 
4H), 5.64 (dd, J = 6.0, 9.0 Hz, 1H), 6.73 (br d, J = 9.0 




(white solid, 1.01 g, 52%), 
1
H NMR (300 MHz, 
CDCl3): δ 0.94 (d, J = 6.0 Hz, 3H), 0.98 (d, J = 3.0 Hz, 
3H), 1.6-1.76 (m, 3H), 3.76 (s, 3H), 4.28 (br s, 4H), 
4.79-4.86 (m, 1H), 6.56 (br s, 1H), 6.86-6.89 (m, 1H), 7.29-7.35 (m, 2H); 
13
C NMR 
(75 MHz, CDCl3): δ 22.0, 22.8, 24.9, 41.7, 51.0, 52.3, 64.1, 64.5, 116.6, 117.2, 120.5, 
127.1, 143.3, 146.6, 163.3, 173.8. 
 
General procedure for the preparation of 6-11ao 
To a stirred solution of 6-10a (178 mg, 0.5 mmol) in dry THF (5 mL) was 
added benzeneacetaldehyde (0.11 mL, 1.0 mmol), followed by anhydrous MgSO4 
(240 mg, 2.0 mmol). After stirring at room temperature for 4 h, one more equivalent 
(0.11 mL, 1.0 mmol) of benzeneacetaldehyde was added and stirring was continued 
for 12 h, filtered and concentrated in vacuo. Purification by flash column 
chromatography (silica gel) using 20 to 50% EtOAc in hexanes to give the desired 






 (white solid, 204 mg, 89%), 
1
H NMR (300 
MHz, CDCl3): δ 3.08-3.27 (m, 5H), 3.67 (d, 
J = 6.0 Hz, 2H), 4.25-4.29 (m, 4H), 




(white solid, 215 mg, 91%), 
1
H NMR 
(300 MHz, CDCl3): δ 2.63-2.70 (m, 2H), 
2.91 (t, J = 9.0 Hz, 2H), 3.01-3.20 (m, 
5H), 4.25-4.29 (m, 4H), 5.95-6.01 (m, 1H), 6.85 (d, J = 9.0 Hz, 2H), 7.04-7.07 (m, 




(white solid, 178 mg, 87%), 
1
H NMR (300 
MHz, CDCl3): δ 1.00 (t, J = 9.0 Hz, 3H), 
1.58-1.67 (m, 2H), 2.29-2.36 (m, 2H), 
3.08-3.27 (m, 5H), 4.24-4.30 (m, 4H), 5.96-6.02 (m, 1H), 6.86 (d, J = 8.4 Hz, 2H), 






(white solid, 126 mg, 79%), 
1
H NMR (300 MHz, 
CDCl3): δ 0.91 (d, J = 6.0 Hz, 3H), 1.00 (d, J = 6.0 Hz, 
3H), 2.15-2.26 (m, 1H), 3.23 (s, 3H), 4.26-4.30 (m, 
4H), 5.78 (dd, J = 6.0, 9.0 Hz, 1H), 6.55 (d, J = 9.0 Hz, 3H), 6.69-6.87 (m, 2H), 6.88 




(white solid, 172 mg, 84%), 
1
H NMR (300 
MHz, CDCl3): δ 0.89 (d, J = 6.9 Hz, 3H), 
0.99 (d, J = 6.9 Hz, 3H), 2.14-2.25 (m, 1H), 
3.22 (s, 3H), 3.71 (d, J = 6.0 Hz, 2H), 4.26-4.31 (m, 4H), 5.76 (dd, J = 3.0, 9.0 Hz, 
1H), 6.81 (d, J = 9.0 Hz, 1H), 6.89 (d, J = 8.4 Hz, 1H), 7.17 (t, J = 5.4 Hz, 1H), 
7.24-7.35 (m, 6H). 
 
General procedure for the preparation of 6-12ao 
To a cooled (0 °C) solution of 6-11a (184 mg, 0.4 mmol) in DCM (4 mL) 
was added a solution of p-toluenesulfonic acid (460 mg, 2.4 mmol) in DCM/MeOH 
(3:1; 8 mL), and dimethylamine borane (DMAB; 40 mg, 0.64 mmol). The mixture 
was allowed to react at room temperature for 2 h before additional 1.6 equivalents 
DMAB (40 mg, 0.64 mmol) were added. After 2 h, 1.5 N NaOH (10 mL) was added 
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and stirring was continued for 30 min. The volume was reduced in vacuo, and the 
aqueous residue was extracted with DCM (3  20 mL). The combined organic layers 
were washed with H2O and brine, and the solvent was dried (Na2SO4), filtered and 
concentrated under vacuum. This material was pure enough to be used in the next step 
without further purification. 
 
General procedure for the preparation of 6-1ao 
To a stirred solution of 6-12a (185 mg, 0.5 mmol) in dry MeOH (10 mL) was 
added anhydrous sodium acetate (164 mg, 2.0 mmol) and cyanogen bromide (106 mg, 
1.0 mmol). The mixture was stirred at room temperature for 12 h, two additional 
equivalents of cyanogen bromide (106 mg, 1.0 mmol) were added and stirring was 
continued for 24 h. The solvent was removed under reduce pressure, and the oily 
residue was suspended in H2O (10 mL). A pH of 1-2 was adjusted (10% KHSO4), it 
was extracted with EtOAc (5  20 mL), and the combined organic layers were washed 
with H2O, saturated NaHCO3 and brine. The solvent was dried (Na2SO4) and 
evaporated. Purification by flash column chromatography on silica gel using 20 to 





H NMR (500 MHz, CDCl3): δ 3.00-3.23 (m, 2H), 
3.24 (s, 3H), 3.33 (s, 3H), 4.26 (dd, J = 5.0, 15.0 
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Hz, 4H), 5.41-5.46 (m, 1H), 6.71 (d, J = 5.0 Hz, 1H), 6.84 (d, J = 10.0 Hz, 1 H), 
7.18-7.34 (m, 7H); 
13
C NMR (126 MHz, CDCl3): δ 29.7, 30.5, 37.9, 41.1, 50.7, 64.1, 
64.5, 113.5, 116.6, 117.2, 120.6, 126.7, 127.3, 128.8, 129.2, 129.6, 135.6, 143.3, 







Prepared according to the general procedure 
using 6-12b (102 mg, 0.23 mmol), sodium 
acetate (75 mg, 0.9 mmol), and cyanogen 
bromide (96 mg, 0.9 mmol) in 10 mL of dry methanol to afford 84 mg (79%) of 6-1b 
as a white solid. 
1
H NMR (500 MHz, CDCl3): δ 2.97-3.14 (m, 2H), 3.16 (s, 3H), 
4.23-4.27 (m, 4H), 4.64 (s, 2H), 5.52-5.56 (m, 1H), 6.84-6.87 (m, 2H), 7.17-7.53 (m, 
13H); 
13
C NMR (126 MHz, CDCl3): δ 32.3, 37.8, 51.3, 58.9, 64.1, 64.5, 112.3, 115.9, 
116.6, 117.2, 120.6, 126.8, 127.2, 127.4, 128.2, 128.7, 128.8, 129.1, 129.3, 129.4, 
129.5, 129.7, 130.3, 131.5, 135.8, 143.3, 146.7, 166.8, 173.8; LC-IT-TOF/MS: (m/z) 
calcd for C27H26N4O4 [M+H]
+ 




Prepared according to the general procedure using 6-12c (138 mg, 0.3 mmol), sodium 
acetate (100 mg, 1.2 mmol), and cyanogen bromide  (128 mg, 1.2 mmol) in 10 mL 
 265 
of dry methanol to afford 118 mg (81%) of 6-1c as 
a white solid. 
1
H NMR (500 MHz, CDCl3): δ 
2.85-2.89 (m, 2H), 3.06-3.16 (m, 2H), 3.18 (s, 3H), 
3.71-3.76 (m, 1H), 3.83-3.89 (m, 1H), 4.26 (dd, J = 
5.0, 10.0 Hz, 4H), 5.11-5.16 (m, 1H), 6.38 (d, J = 10.0 Hz, 1H), 6.85 (d, J = 10.0 Hz, 
1H), 7.03 (d, J = 10.0 Hz, 1H ), 7.15-7.36 (m, 11H); 
13
C NMR (126 MHz, CDCl3): δ 
31.6, 32.9, 37.7, 50.6, 54.8, 64.2, 64.5, 112.3, 116.6, 117.3, 120.5, 126.9, 127.2, 127.3, 
128.8, 128.9, 129.0, 129.2, 129.5, 135.4, 136.2, 143.4, 146.8, 166.6, 173.4; 
LC-IT-TOF/MS: (m/z) calcd for C28H28N4O4 [M+H]
+ 




Prepared according to the general procedure 
using 6-12d (160 mg, 0.34 mmol), sodium 
acetate (112 mg, 1.4 mmol), and cyanogen 
bromide (143 mg, 1.4 mmol) in 10 mL of dry 
methanol to afford 123 mg (73%) of 6-1d as a white solid. 
1
H NMR (500 MHz, 
CDCl3): δ 2.10-2.16 (m, 2H), 2.74-2.86 (m, 2H), 3.00-3.04 (m, 2H), 3.22 (s, 3H), 
3.45-3.55 (m, 2H), 4.26 (dd, J = 5.0, 10.0 Hz, 4H), 5.44-5.48 (m, 1H), 6.63 (d, J = 
10.0 Hz, 1H), 6.84 (d, J = 10.0 Hz, 1H), 7.13-7.33 (m, 11H); 
13
C NMR (126 MHz, 
CDCl3): δ 28.2, 31.6, 32.6, 38.0, 50.8, 53.6, 64.2, 64.6, 112.5, 116.6, 117.3, 120.6, 
126.4, 126.9, 127.4, 128.4, 128.7, 128.8, 129.2, 129.6, 135.7, 140.0, 143.4, 146.8, 








Prepared according to the general procedure using 
6-12e (155 mg, 0.38 mmol), sodium acetate (123 
mg, 1.5 mmol), and cyanogen bromide (160 mg, 
1.5 mmol) in 10 mL of dry methanol to afford 113 mg (69%) of 6-1e as a white solid. 
1
H NMR (500 MHz, CDCl3): δ 0.99 (t, J = 10.0 Hz, 3H), 1.47-1.56 (m, 2H), 
1.74-1.83 (m, 2H), 2.96-3.21 (m, 2H), 3.26 (s, 3H), 3.42- 3.54 (m, 2H), 4.25 (d, J = 
10.0 Hz, 4H), 5.39-5.43 (m, 1H), 6.79-6.87 (m, 2H), 7.18-7.33 (m, 6H); 
13
C NMR 
(126 MHz, CDCl3): δ 13.7, 19.6, 19.8, 28.6, 31.5, 37.7, 50.9, 53.8, 64.1, 64.5, 112.5, 
116.6, 117.2, 120.6, 126.9, 127.2, 128.7, 129.2, 129.5, 135.8, 143.3, 146.7, 166.6, 







Prepared according to the general procedure using 
6-12f (106 mg, 0.33 mmol), sodium acetate (107 
mg, 1.3 mmol), and cyanogen bromide (138 mg, 
1.3 mmol) in 10 mL of dry methanol to afford 80 mg (70%) of 6-1f as a white solid. 
1
H NMR (500 MHz, CDCl3): δ 1.04 (d, J = 10.0 Hz, 3H), 1.07 (d, J = 10.0 Hz, 3H), 
2.09-2.17 (m, 1H), 3.24 (s, 3H), 3.32 (s, 3H), 4.26-4.30 (m, 4H), 5.10-5.13 (m, 1H), 
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6.57 (d, J = 10.0 Hz, 1H), 6.88 (d, J = 5.0 Hz, 1H), 7.29-7.35 (m, 2H); 
13
C NMR (126 
MHz, CDCl3): δ 18.1, 19.6, 30.2, 31.4, 41.2, 54.0, 64.2, 64.5, 113.9, 116.6, 117.3, 
120.6, 127.0, 143.4, 146.8, 166.9, 173.0; LC-IT-TOF/MS: (m/z) calcd for C17H22N4O4 
[M+H]
+ 




Prepared according to the general procedure 
using 6-12g (140 mg, 0.35 mmol), sodium acetate 
(115 mg, 1.4 mmol), and cyanogen bromide (149 
mg, 1.4 mmol) in 10 mL of dry methanol to afford 115 mg (78%) of 6-1g as a white 
solid. 
1
H NMR (500 MHz, CDCl3): δ 1.03 (d, J = 10.0 Hz, 3H), 1.05 (d, J = 10.0 Hz, 
3H), 2.10-2.17 (m, 1H), 3.13 (s, 3H), 4.29 (dd, J = 5.0, 10.0 Hz, 4H), 4.62 (dd, J = 
15.0, 20.0 Hz, 2H), 5.26-5.30 (m, 1H), 6.54 (d, J = 10.0 Hz, 1H), 6.91 (d, J = 5.0 Hz, 
1H), 7.30-7.44 (m, 6H), 7.55 (d, J = 10.0 Hz, 1H); 
13
C NMR (126 MHz, CDCl3): δ 
18.0, 19.7, 31.5, 32.2, 54.2, 59.0, 64.2, 64.6, 112.7, 116.7, 117.3, 120.6, 127.2, 129.3, 
129.7, 130.3, 131.6, 143.4, 146.8, 167.0, 174.1; LC-IT-TOF/MS: (m/z) calcd for 
C23H26N4O4 [M+H]
+ 




Prepared according to the general procedure using 6-12h (136 mg, 0.33 mmol), 
sodium acetate (108 mg, 1.3 mmol), and cyanogen bromide (141 mg, 1.3 mmol) in 10 
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mL of dry methanol to afford 97 mg (67%) of 6-1h 
as a white solid. 
1
H NMR (500 MHz, CDCl3): δ 
0.89 (t, J = 10.0 Hz, 6H), 1.94-2.04 (m, 1H), 
3.06-3.13 (m, 2H), 3.19 (s, 3H), 3.60-3.73 (m, 1H), 
3.84-3.89 (m, 1H), 4.27-4.30 (m, 4H), 4.72 (t, J = 10.0, 1H), 6.36 (d, J = 10.0 Hz, 1H), 
6.89 (d, J = 10 Hz, 1H), 7.23-7.38 (m, 7H); 
13
C NMR (126 MHz, CDCl3): δ 17.9, 19.5, 
31.0, 31.4, 32.9, 54.1, 54.8, 64.2, 64.6, 112.6, 116.6, 117.3, 120.5, 127.1, 127.2, 128.8, 
129.2, 136.3, 143.4, 146.7, 166.9, 174.0; LC-IT-TOF/MS: (m/z) calcd for C24H28N4O4 
[M+H]
+ 




Prepared according to the general procedure 
using 12i (127 mg, 0.3 mmol), sodium acetate 
(98 mg, 1.2 mmol), and cyanogen bromide 
(127 mg, 1.2 mmol) in 10 mL of dry methanol 
to afford 101 mg (75%) of 6-1i as a white solid. 
1
H NMR (500 MHz, CDCl3): δ 1.02 
(d, J = 5.0 Hz, 3H), 1.08 (d, J = 5.0 Hz, 3H), 2.09-2.18 (m, 3H), 2.78-2.85 (m, 2H), 
3.21 (s, 3H), 3.43-3.51 (m, 2H), 4.26 (dd, J = 5.0, 10.0 Hz, 4H), 5.18 (dd, J = 5.0, 
10.0 Hz, 1H), 6.54 (d, J = 10.0 Hz, 1H), 6.89 (d, J = 10 Hz, 1H), 7.19-7.34 (m, 7H); 
13
C NMR (126 MHz, CDCl3): δ 17.8, 19.7, 28.1, 31.38, 31.42, 32.6, 53.6, 53.9, 64.2, 
64.5, 113.7, 116.6, 117.3, 120.5, 126.3, 127.2, 128.3, 128.6, 140.1, 143.4, 146.7, 








Prepared according to the general procedure using 
6-12j (124 mg, 0.34 mmol), sodium acetate (112 
mg, 1.4 mmol), and cyanogen bromide  (144 mg, 
1.4 mmol) in 10 mL of dry methanol to afford 94 mg (71%) of 6-1j as a white solid. 
1
H NMR (500 MHz, CDCl3): δ 1.02 (d, J = 5.0 Hz, 3H), 1.08 (d, J = 5.0 Hz, 3H), 
1.49-1.58 (m, 2H), 1.73-1.81 (m, 2H), 2.13-2.19 (m, 1H), 3.24 (s, 3H), 3.37-3.50 (m, 
2H), 4.26-4.30 (m, 4H), 5.14 (dd, J = 5.0, 10.0 Hz, 1H), 6.54 (d, J = 5.0 Hz, 1H), 6.89 
(d, J = 10.0 Hz, 1 H), 7.28-7.34 (m, 2H); 
13
C NMR (126 MHz, CDCl3): δ 13.7, 17.6, 
19.7, 19.8, 53.8, 54.0, 64.2, 64.5, 112.7, 116.6, 117.3, 120.5, 127.2, 143.4, 146.7, 







Prepared according to the general procedure using 
6-12k (118 mg, 0.35 mmol), sodium acetate (115 
mg, 1.4 mmol), and cyanogen bromide (149 mg, 
1.4 mmol) in 10 mL of dry methanol to afford 97 mg (77%) of 6-1k as a white solid. 
1
H NMR (500 MHz, CDCl3): δ 1.00 (d, J = 5.0 Hz, 3H), 1.05 (d, J = 5.0 Hz, 3H), 
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1.56-1.81 (m, 3H), 3.23 (s, 3H), 3.34 (s, 3H), 4.26-4.30 (m, 4H), 5.23-5.28 (m, 1H), 
6.58 (d, J = 10.0 Hz, 1H), 6.88 (d, J = 10.0 Hz, 1H), 7.27-7.32 (m, 2H); 
13
C NMR 
(126 MHz, CDCl3): δ 21.5, 32.3, 25.1, 29.7, 30.5, 41.0, 41.3, 48.2, 64.2, 64.5, 113.6, 
116.6, 117.3, 120.6, 126.8, 143.4, 146.8, 167.0, 174.7; LC-IT-TOF/MS: (m/z) calcd 
for C18H24N4O4 [M+H]
+




Prepared according to the general procedure 
using 6-12l (132 mg, 0.32 mmol), sodium acetate 
(106 mg, 1.3 mmol), and cyanogen bromide (138 
mg, 1.3 mmol) in 10 mL of dry methanol to 
afford 131 mg (81%) of 6-1l as a white solid. 
1
H NMR (500 MHz, CDCl3): δ 0.96 (t, 
J = 5.0 Hz, 6H), 1.50-1.81 (m, 3H), 3.14 (s, 3H), 4.28 (dd, J = 5.0, 15.0 Hz, 4H), 4.63 
(s, 2H), 5.41-5.45 (m, 1H), 6.67 (d, J = 10.0 Hz, 1H), 6.89 (d, J = 10.0 Hz, 1H), 
7.31-7.57 (m, 7H); 
13
C NMR (126 MHz, CDCl3): δ 21.4, 23.3, 25.0, 32.3, 41.3, 48.4, 
58.9, 64.2, 64.6, 112.4, 116.7, 117.3, 120.7, 127.0, 127.4, 128.8, 129.3, 129.8, 130.4, 
131.5, 143.4, 146.8, 167.1, 175.1; LC-IT-TOF/MS: (m/z) calcd for C24H28N4O4 
[M+H]
+ 







Prepared according to the general procedure using 
6-12m (132 mg, 0.31 mg), sodium acetate (98 mg, 
1.2 mmol), and cyanogen bromide (127 mg, 1.2 
mmol) in 10 mL of dry methanol to afford 110 mg 
(79%) of 6-1m as a white solid. 
1
H NMR (500 MHz, CDCl3): δ 0.91 (d, J = 5.0 Hz, 
3H), 0.93 (d, J = 5.0 Hz, 3H), 1.48-1.69 (m, 3H), 3.11-3.14 (m, 2H), 3.16 (s, 3H), 
3.69-3.74 (m, 1H), 3.81-3.87 (m, 1H), 4.25-4.29 (m, 4H), 5.11-5.15 (m, 1H), 6.58 (d, 
J = 5.0 Hz, 1H), 6.87 (d, J = 10.0 Hz, 1H), 7.23-7.35 (m, 7H); 
13
C NMR (126 MHz, 
CDCl3): δ 21.5, 23.2, 25.1, 31.6, 33.0, 41.1, 48.3, 54.9, 64.2, 64.5, 112.4, 116.6, 117.2, 
120.6, 127.0, 127.2, 128.8, 129.0, 136.1, 143.3, 146.7, 167.0, 175.0; LC-IT-TOF/MS: 
(m/z) calcd for C25H30N4O4 [M+H]
+ 






general was followed using 6-12n (123 mg, 
0.28 mmol), sodium acetate (92 mg, 1.1 mmol), 
and cyanogen bromide  (117, 1.1 mmol) in 10 
mL of dry methanol to afford 95 mg (73%) of 
6-1n as a white solid. 
1
H NMR (500 MHz, CDCl3): δ 0.98 (d, J = 5.0 Hz, 3H), 1.03 (d, 
J = 5.0 Hz, 3H), 1.57-1.67 (m, 2H), 1.80-1.81 (m, 1H), 2.11-2.17 (m, 2H), 2.77-2.86 
(m, 2H), 3.21 (s, 3H), 3.47-3.56 (m, 2H), 4.25-4.29 (m, 4H), 5.28-5.33 (m, 1H), 6.68 
(d, J = 10.0 Hz, 1H), 6.88 (d, J = 5.0 Hz, 1 H), 7.21-7.32 (m, 7H); 
13
C NMR (126 
MHz, CDCl3): δ 21.5, 23.3, 25.1, 28.2, 31.5, 32.6, 41.2, 48.3, 53.4, 61.1, 64.5, 112.5, 
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116.6, 117.2, 120.6, 126.4, 127.0, 128.3, 128.6, 140.1, 143.3, 146.7, 166.9, 175.0; 
LC-IT-TOF/MS: (m/z) calcd for C26H32N4O4 [M+H]
+ 




Prepared according to the general procedure using 
6-12o (132 mg, 0.35 mmol), sodium acetate (115 
mg, 1.4 mmol), and cyanogen bromide (148 mg, 
1.4 mmol) in 10 mL of dry methanol to afford 94 
mg (67%) of 6-1o as a white solid. 
1
H NMR (500 MHz, CDCl3): δ 0.98-1.05 (m, 9H), 
1.50-1.82 (m, 7H), 3.23 (s, 3H), 3.41-3.53 (m, 2H), 4.26-4.30 (m, 4H), 5.24-5.29 (m, 
1H), 6.58 (d, J = 10.0 Hz, 1H), 6.88 (d, J = 5.0 Hz, 1H), 7.28-7.32 (m, 2H); 
13
C NMR 
(126 MHz, CDCl3): δ 13.7, 19.8, 21.4, 23.3, 25.1, 28.7, 31.5, 41.3, 48.3, 53.7, 64.2, 
64.5, 112.6, 116.6, 117.2, 120.6, 127.0, 143.4, 146.7, 166.9, 174.9; LC-IT-TOF/MS: 
(m/z) calcd for C21H30N4O4 [M+H]
+ 




Prepared according to the general procedure using Boc-Phe-OH 
(6.63 g, 25.0 mmol), N-methylmorpholine (NMM) (3.3 mL, 
30.0 mmol), isobutyl chloroformate (ISCF) (3.9 mL, 30.0 mmol) 
and methylhydrazine sulfate (4.32 g, 30.0 mmol). Purification by flash column 
chromatography on silica gel using 20 to 50% EtOAc in hexanes to give the product 
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6-13 as a colourless oil (2.71 g, 37%). 
1
H NMR (300 MHz, CDCl3): δ 1.38 (s, 9H), 
2.93-2.98 (m, 2H), 3.05 (s, 3H), 3.43 (s, 2H), 5.39 (d, J = 9.0 Hz, 1H), 5.46-5.53 (m, 
1H), 7.19-7.30 (m, 5H); 
13
C NMR (75 MHz, CDCl3): δ 28.2, 38.3, 39.8, 50.7, 79.1, 
126.4, 128.0, 129.2, 155.1, 173.7; LC-IT-TOF/MS: (m/z) calcd for C15H23N3O3 
[M+H]
+




Prepared according to the general procedure using 6-13 (0.9 g, 
3.0 mmol) and formaldehyde 37% solution (0.5 mL, 6.0 mmol). 
Purification by flash column chromatography on silica gel using 
20 to 50% EtOAc in hexanes to give the product 6-14 as a colourless oil (0.6 g, 64%). 
1
H NMR (300 MHz, CDCl3): δ 1.41 (s, 9H), 2.87-2.94 (m, 1H), 3.08-3.15 (m, 1H), 
3.21 (s, 3H), 5.29 (d, J = 8.2 Hz, 1H), 5.05-5.17 (m, 1H), 6.48 (d, J = 10.5 Hz, 1H), 
6.66 (d, J = 10.5 Hz, 1H), 7.16-7.31 (m, 5H); 
13
C NMR (75 MHz, CDCl3): δ 26.8, 
28.3, 39.1, 52.2, 79.3, 126.5, 128.1, 129.4, 136.8, 155.1, 173.4; LC-IT-TOF/MS: (m/z) 
calcd for C16H23N3O3 [M+H]
+




To a cooled (0 °C) solution of 6-14 (1.53 g, 5.0 mmol) in dry 
THF (15 mL) was added acetic acid (9 mL), and NaBH3CN 
(0.79 g, 12.5 mmol). The reaction was allowed to warm to room 
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temperature and stirred overnight. After evaporation of solvent, resulting residue was 
cooled to 0 
o
C and saturated NaHCO3 was added. Aqueous solution was extracted 
with EtOAc (3  50 mL). The combined organic layers were washed with brine, dried 
over Na2SO4 and concentrated in vacuo. Purification by flash column chromatography 
on silica gel using 20 to 50% EtOAc in hexanes to give the product 6-15 as a 
colourless oil (1.41 g, 92%). 
1
H NMR (300 MHz, CDCl3): δ 1.42 (s, 9H), 2.47 (d, J = 
3.8 Hz, 3H), 2.81 (s, 1H), 2.89-3.01 (m, 2H), 3.06 (s, 3H), 5.27 (d, J = 8.7Hz, 1H), 
5.40-5.47 (m, 1H), 7.21-7.32 (m, 5H); 
13
C NMR (75 MHz, CDCl3): δ 28.3, 31.8, 35.4, 
39.9, 51.0, 79.3, 126.5, 128.2, 129.5, 137.2, 174.0; LC-IT-TOF/MS: (m/z) calcd for 
C16H25N3O3 [M+H]
+




Prepared according to the general procedure using 6-15 
(307 mg, 1.0 mmol), anhydrous sodium acetate (230 mg, 
3 mmol), and cyanogen bromide (350 mg, 3.3 mmol) in 
25 mL of dry MeOH to afford 6-2 as a pale yellow solid (246 mg, 74%). 
1
H NMR 
(500 MHz, CDCl3): δ 1.37 (s, 9H), 2.84-2.31 (m, 2H), 3.20 (s, 3H), 3.24 (s, 3H), 
4.99-5.08 (m, 2H), 7.20-7.33 (m, 5H); 
13
C NMR (126 MHz, CDCl3): δ 28.2, 30.4, 
38.5, 41.2, 51.4, 80.0, 113.4, 127.1, 128.6, 129.2, 129.5, 135.6, 155.3, 173.6; 
LC-IT-TOF/MS: (m/z) calcd for C17H24N4O3 [M+H]
+
 333.1848, found 333.1896. 
 
(S)-benzyl (1-(1-methylhydrazinyl)-1-oxo-3-phenylpropan-2-yl)carbamate (6-17a) 
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Prepared according to the general procedure using 6-16 (327 mg, 
1.0 mmol) and formaldehyde (0.2 mL, 2.0 mmol). Purification 
by flash column chromatography on silica gel using 20 to 50% 
EtOAc in hexanes to give the product 6-17a as a white solid (207 mg, 61%). 
1
H NMR 
(500 MHz, CDCl3): δ 2.91 (d, J = 6.0 Hz, 1H), 2.94 (d, J = 6.0 Hz, 1H), 3.18 (s, 3H), 
5.05 (dd, J = 6.0, 12.0 Hz, 2H), 5.51 (d, J = 6.0 Hz, 1H), 5.65 (dd, J = 6.0, 9.0 Hz, 
1H), 6.47 (d, J = 6.0 Hz, 1H), 6.65 (d, J = 6.0 Hz, 1H), 7.11 (d, J = 3.0 Hz, 2H), 
7.18-7.35 (m, 8H); 
13
C NMR (126 MHz, CDCl3): δ 26.9, 39.0, 52.8, 66.7, 126.7, 




(white solid, 393 mg, 89%), 
1
H NMR (300 MHz, 
CDCl3): δ 2.60-2.68 (m, 2H), 2.83-3.03 (m, 4H), 
3.14 (s, 3H), 5.05 (dd, J = 3.0 Hz, 2H), 5.61 (t, J = 




(white solid, 360 mg, 91%), 
1
H NMR (300 MHz, 
CDCl3): δ 0.99 (t, J = 6.0 Hz, 3H), 1.57-1.64 (m, 4H), 
2.27-2.34 (m, 2H), 2.88-3,15 (m, 2H), 3.17 (s, 3H), 5.05 





Prepared according to the general procedure using 6-17a (68 mg, 
0.2 mmol), p-toluenesulfonic acid (230 mg, 1.2 mmol), and 
dimethylamine borane (DMAB; 40 mg, 0.64 mmol). The product 
was directly used in the next reduction step, without further purification. This 
compound was pure enough to give satisfactory NMR data. 
1
H NMR (500 MHz, 
CDCl3): δ 2.46 (s, 3H), 2.91-3.00 (m, 2H), 3.02 (s, 3H), 5.01-5.10 (m, 2H), 5.47 (t, J 
= 3.0 Hz, 1H), 7.16-7.37 (m, 10H); 
13
C NMR (126 MHz, CDCl3): δ 31.8. 35.4, 35.7, 
39.7, 51.5, 66.6, 126.7, 127.9, 128.0, 128.2, 128.5, 128.6, 129.5, 136.6, 136.9, 155.9, 
173.7; LC-IT-TOF/MS: (m/z) calcd for C19H23N3O3 [M+H]
+






H NMR (300 MHz, CDCl3): δ 2.91-3.00 (m, 2H), 3.16 
(s, 3H), 3.74 (dd, J = 6.0, 9.0 Hz, 1H), 3.88 (dd, J = 6.0, 
9.0 Hz, 1H), 5.07 (dd, J = 3.0, 6.0 Hz, 2H), 5.53 (t, J = 
6.0 Hz, 2H), 7.14-7.33 (m, 15H); LC-IT-TOF/MS: (m/z) calcd for C25H27N3O3 
[M+H]
+







H NMR (300 MHz, CDCl3): δ 2.71 (br d, J = 6.0 Hz, 
2H), 2.83 (br d, J = 6.0 Hz, 2H), 2.94 (s, 3H), 
2.98-3.03 (m, 2H), 4.99-5.10 (m, 2H), 5.42-5.59 (m, 
2H), 7.10-7.30 (m, 15H); LC-IT-TOF/MS: (m/z) calcd 
for C26H29N3O3 [M+H]
+





H NMR (300 MHz, CDCl3): δ 0.90 (t, J = 6.0 Hz, 
3H), 1.33-1.35 (m, 4H), 2.59-2.98 (m, 6H), 3.01 (s, 
3H), 5.04-5.10 (m, 2H), 5.46-5.51 (m, 2H), 7.15-7.33 
(m, 10H); LC-IT-TOF/MS: (m/z) calcd for 
C23H31N3O3 [M + H]
+




Prepared according to the general procedure using 
6-18c (44 mg, 0.1 mmol), anhydrous sodium 
acetate (23 mg, 0.3 mmol), and cyanogen bromide 
(35 mg, 1.1 mmol) in dry MeOH (5 mL) at 40 °C 
for 24 h. Purification by flash column chromatography on silica gel using 20 to 50% 
EtOAc in hexanes to give the product 6-3c as a white solid (246 mg, 74%).
 1
H NMR 
(500 MHz, CDCl3): δ 2.68-2.81 (m, 2H), 2.94-2.3.11 (m, 2H), 3.15 (s, 3H), 3.68 (t, J 
= 5.0 Hz, 2H), 4.79 (br d, J = 5 Hz, 1H), 4.98-5.14 (m, 2H), 5.23-5.27 (m, 1H), 
6.99-7.30 (m, 15H); 
13
C NMR (126 MHz, CDCl3): δ 31.4, 32.8, 38.0, 51.8, 54.9, 67.0, 
112.1, 127.2, 127.9, 128.1, 128.5, 128.7, 128.8, 128.9, 129.1, 129.4, 135.1, 136.1, 
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155.9, 173.4; LC-IT-TOF/MS: (m/z) calcd for C27H28N4O3 [M+H]
+




phenylpropan-2-yl) carbamate (6-3d) 
Prepared according to the general procedure 
using 6-18d (112 mg, 0.25 mmol), sodium 
acetate (82 mg, 1.0 mmol), and cyanogen 
bromide (106 mg, 1.0 mmol) in 10 mL of dry 
methanol to afford 82 mg (72%) of 6-3d as a white solid. 
1
H NMR (500 MHz, CDCl3): 
δ 2.09-2.11 (m, 2H), 2.65-2.90 (m, 4H), 3.08-3.16 (m, 2H), 3.19 (s, 3H), 3.32-3.37 (m, 
1H), 3.44-3.49 (m, 1H), 4.98-5.15 (m, 2H), 5.32 (br s, 1H), 7.14-7.34 (m, 15H); 
13
C 
NMR (126 MHz, CDCl3): δ 28.1, 31.5, 32.5, 38.4, 52.2, 53.6, 67.0, 112.3, 126.4, 
127.3, 127.9, 128.2, 128.3, 128.5, 128.7, 128.8, 129.2, 129.5, 135.4, 139.9, 155.8, 
173.4; LC-IT-TOF/MS: (m/z) calcd for C28H30N4O3 [M+H]
+




Prepared according to the general deprotection procedure using 
Boc-Hph-N(Me)OMe (5-6) (1.6 g, 5 mmol) and 4.0 M HCl in 
1,4-dioxane (15 mL) in dry THF (10 mL) for 6 h. Dry ether (100 
mL) was added with stirring, and the precipitate was filtered off, washed twice with 
ether, and finally dried in a vacuum desiccator (P2O5). This material was pure enough 
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to be used in the next step without further purification. 
 
Mu-Phe-Hph-N(Me)OMe (6-22) 
Prepared according to the general coupling reation 
procedure using 5-19 (0.56 g, 2 mmol), EDC•HCl 
(0.42 g, 2.2 mmol), HOBt (0.32 g, 2.2 mmol), 6-20 
(0.52 g, 2 mmol) and DIPEA (0.51 mL, 3 mmol) in DMF (10 mL) for 12 h, and 
concentrated in vacuo. The crude product was purified by column chromatography on 
silica gel using 20 to 50% EtOAc in hexanes to give the product 6-22 as a white solid 
(0.82 g, 85%). 
1
H NMR (300 MHz, CDCl3): δ 1.85-2.06 (m, 2H), 2.56-2.64 (m, 2H), 
3.08-3.10 (m, 2H), 3.16 (s, 3H), 3.27-3.33 (m, 4H), 3.62-3.66 (m, 7H), 4.66 (dd, J = 
6.7, 13.7 Hz, 2H), 5.93 (brs, 1H), 5.09 (d, J = 7.2 Hz, 1H), 6.83 (d, J = 7.9 Hz, 1H), 
7.14-7.26 (m, 10H); 
13
C NMR (75 MHz, CDCl3): δ 31.52, 32.11, 33.99, 38.64, 44.00, 
49.03, 55.39, 61.49, 66.41, 126.03, 126.94, 128.36, 128.49, 128.56, 129.43, 136.81, 
140.99, 156.93, 171.68. 
 
Mu-Phe-Hph-al (6-4) 
To a solution of 6-22 (480 mg, 1 mmol) in dry THF (25 
mL) at 0 °C was added LiAlH4 (57 mg, 1.5 mmol) with 
vigorous stirring. The mixture was stirred for an 
additional 20 min at 0 °C, whereupon cold water was 
carefully added until effervescence ceased. A cold HCl solution (1 N) was added to 
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break up the gelatinous emulsion until pH 6~7 was reached. Diluted with H2O (50 mL) 
and extracted with EtOAc (3  25 mL). The combined organic extracts were washed 
with saturated aqueous NaHCO3 and brine, dried over Na2SO4, filtered and 
concentrated in vacuo. Purification by flash column chromatography on silica gel 
using 50 to 75% EtOAc in hexanes to give 350 mg (73%) of 6-4 as a white solid. 
1
H 
NMR (500 MHz, CDCl3): δ 1.79-1.85 (m, 1H), 2.10-2.13 (m, 1H), 2.50-2.60 (m, 2H), 
3.11-3.13 (m, 2H), 3.25-3.36 (m, 4H), 3.57-3.62 (m, 4H), 4.25-4.31 (m, 1H), 4.76 (dd, 
J = 10.0, 15.0 Hz, 1H), 5.60 (t, J = 10.0 Hz, 1H), 7.11-7.42 (m, 10H), 9.31 (s, 1H); 
13
C NMR (126 MHz, CDCl3): δ 30.1, 31.2, 38.7, 43.9, 55.7, 58.3, 66.2, 126.3, 127.0, 
128.3, 128.48, 128.52, 129.25, 129.31, 136.7, 140.3, 157.1, 172.9, 199.1; 
LC-IT-TOF/MS: (m/z) calcd for C24H29N3O4 [M+H]
+




Prepared according to the general procedure 
using 5-23 (1.62 g, 5 mmol), 
N-methylmorpholine (NMM) (0.65 mL, 6 mmol), 
isobutyl chloroformate (ISCF) (0.78 mL, 6 mmol), and methylhydrazine solution 
(methylhydrazine sulfate (1.5 g, 10 mmol), H2O (1 mL) and 5 N NaOH (4 mL)) in dry 
THF (50 mL) for 24 h. Purification by flash column chromatography on silica gel 
using 30 to 50% EtOAc in hexanes to give the product 6-24 as a white solid (1.15 g, 
65%). 
1
H NMR (500 MHz, CDCl3): δ 2.27-2.34 (m, 2H), 2.89 (dd, J = 7.1, 13.9 Hz, 
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1H), 3.11 (dd, J = 5.1, 13.9 Hz, 1H), 3.16 (s, 3H), 5.01 (d, J = 12.6 Hz, 1H), 5.05 (d, J 
= 12.3 Hz, 1H), 5.55 (d, J = 9.2 Hz, 1H), 5.58-5.64 (m, 1H), 7.02 (t, J = 5.2 Hz, 1H), 




Prepared according to the general procedure 
using 6-24 (176 mg, 0.5 mmol), benzaldehyde 
(0.33 mL, 3.0 mmol), and anhydrous MgSO4 
(0.6 g, 5 mmol). Purification by flash column chromatography (silica gel) using 10 to 
20% EtOAc in hexanes to give the product 6-25 as a white solid (190 mg, 87%). 
1
H 
NMR (300 MHz, DMSO-d6): δ 3.00-3.07 (m, 1H), 3.16-3.22 (m, 1H), 3.35 (s, 3H), 
5.06 (dd, J = 12.7, 19.7 Hz, 2H), 5.64 (m, 1H), 5.77-5.84 (m, 1H), 7.12-7.27 (m, 7H), 
7.41-7.47 (m, 6H), 7.47-7.68 (m, 3H); 
13
C NMR (75 MHz, CDCl3): δ 28.85, 39.92, 
53.73, 66.78, 78.04, 84.10, 123.40, 127.46, 128.04, 128.37, 128.97, 129.52, 130.05, 




Prepared according to the general procedure 
using 6-25 (110 mg, 0.25 mmol), 
p-toluenesulfonic acid (285 mg, 1.5 mmol), and 
dimethylamine borane (DMAB; 48 mg, 0.8 
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Prepared according to the general procedure 
using 6-26 (88 mg, 0.2 mmol), anhydrous 
sodium acetate (66 mg, 0.8 mmol), and 
cyanogen bromide (85 mg, 0.8 mmol) in 5 mL of dry MeOH to afford 81 (87%) mg of 
6-5 as a white solid. 
1
H NMR (500 MHz, CDCl3): δ 2.83-2.87 (m, 2H), 3.09 (s, 1H), 
3.12 (s, 3H), 4.52 (dd, J = 10.0, 15.0 Hz, 2H), 5.02-5.08 (m, 4H), 5.38 (d, J = 10.0 Hz, 
1H), 7.13-7.48 (m, 14H); 
13
C NMR (126 MHz, CDCl3): δ 32.3, 38.4, 53.5, 59.0, 66.4, 
77.6, 83.2, 112.2, 127.3, 127.7, 128.7, 129.2, 129.3, 129.5, 129.7, 129.8, 130.2, 131.2, 
132.2, 135.4, 136.8, 155.8, 173.4; LC-IT-TOF/MS: (m/z) calcd for C28H26N4O3 
[M+H]
+




Prepared according to the general procedure 
using Cbz-Phe-OH (0.75 g, 2.5 mmol), EDC•HCl 
(0.55 g, 3.0 mmol), HOBt (0.4 g, 3.0 mmol), 6-27 
(0.35 g, 2.5 mmol) and DIPEA (0.85 mL, 5 mmol) in DMF (10 mL) for 12 h. The 
crude product was purified by column chromatography on silica gel using 20 to 50% 




(500 MHz, CDCl3): δ 1.33 (d, J = 5.0 Hz, 3H), 3.03-3.13 (m, 2H), 3.71 (s, 3H), 
4.43-4.53 (m, 2H), 5.08 (s, 2H), 5.34 (br s, 1H), 6.36 (br s, 1H), 7.18-7.36 (m, 10H); 
13
C NMR (126 MHz, CDCl3): δ 18.3, 38.5, 48.2, 52.4, 56.0, 67.1, 127.1, 128.0, 128.2, 




Prepared according to the general procedure 
using 5-23 (0.8 g, 2.5 mmol), EDC•HCl 
(0.55 g, 3.0 mmol), HOBt (0.4 g, 3.0 mmol), 
6-27 (0.35 g, 2.5 mmol) and DIPEA (0.85 mL, 5 mmol) in DMF (10 mL) for 12 h. 
The crude product was purified by column chromatography on silica gel using 20 to 
50% EtOAc in hexanes to give the product 6-28b as a white solid (0.95 g, 93%). 
1
H 
NMR (500 MHz, CDCl3): δ 1.33 (d, J = 5.0 Hz, 3H), 3.06-3.08 (m, 3H), 3.71 (s, 3H), 
4.44-4.53 (m, 2H), 5.06 (m, 2H), 5.45 (br s, 1H), 6.43 (br s, 1H), 7.17-7.29 (m, 7H), 
7.46 (d, J = 5.0 Hz, 2H); 
13
C NMR (126 MHz, CDCl3): δ 18.3, 38.6, 48.1, 52.4, 56.0, 




Prepared according to the general procedure using 
6-28a (0.7 g, 1.8 mmol), LiOH•H2O (0.23 g, 5.4 
mmol) in THF/H2O (3/1, 12 mL) for 2 h. The 
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product 6-29a was pure enough to be used in the next step without further purification. 
1
H NMR (500 MHz, DMSO-d6): δ 1.31 (d, J = 10.0 Hz, 3H), 2.72 (dd, J = 10.0, 15.0 
Hz, 1H), 3.02 (dd, J = 10.0, 15.0 Hz, 1H), 4.21-4.31 (m, 2H), 4.93 (s, 2H), 7.16-7.34 
(m, 9H), 8.33 (d, J = 5.0 Hz, 1H), 12.53 (s, 1H); 
13
C NMR (126 MHz, DMSO-d6): δ 
17.1, 37.4, 47.5, 55.8, 65.1, 126.2, 127.4, 127.6, 128.0, 129.2, 137.0, 138.1, 155.8, 





Prepared according to the general procedure 
using 6-28b (0.6 g, 1.5 mmol), LiOH•H2O 
(0.19 g, 4.5 mmol) in THF/H2O (3/1, 12 mL) 
for 2 h. The product 6-29b was pure enough to be used in the next step without further 
purification. 
1
H NMR (500 MHz, DMSO-d6): δ 1.31 (d, J = 10.0 Hz, 3H), 2.72 (t, J = 
10.0 Hz, 1H), 3.02 (t, J = 10.0 Hz, 1H), 4.17 (s, 1H), 4.22-4.30 (m, 2H), 4.94 (s, 2H), 
7.19-7.31 (m, 6H), 7.43 (d, J = 5.0 Hz, 2H), 7.51 (d, J = 5.0 Hz, 1H), 8.33 (d, J = 5.0 
Hz, 1H), 12.56 (s, 1H); 
13
C NMR (126 MHz, DMSO-d6): δ 17.1, 37.4, 47.5, 55.9, 
64.6, 80.8, 83.2, 126.2, 127.4, 128.0, 129.2, 131.6, 138.0, 155.7, 171.3. 174.0.  
 
Cbz-Phe-Ala-CHN2 (6-6a) 
To a stirred solution of 6-29a (0.37 g, 1.0 




was added dropwise N-methylmorpholine (NMM, 0.15 mL, 1.2 mmol), and isobutyl 
chloroformate (ISCF, 0.17 mL, 1.2 mmol) via syringe. The reaction was stirred for 1 h 
at -15 
o
C and added of a solution of ~0.25 mmol/mL diazomethane in ether at -78 
o
C 
(15 mL). The reaction was stirred for 4 h until to 0 
o
C. After evaporation of the 
solvent, the aqueous residue was extracted with EtOAc (3  20 mL). The combined 
organic extracts were washed with H2O, saturated NaHCO3, brine, dried over Na2SO4 
and concentrated in vacuo. Purification by flash column chromatography on silica gel 
using 25 to 50% EtOAc in hexanes to give the product 6-6a as a white solid (0.35 g, 
91%). 
1
H NMR (500 MHz, DMSO-d6): δ 1.33 (d, J = 5.0 Hz, 3H), 2.78 (dd, J = 10.0, 
15.0 Hz, 1H), 3.03 (dd, J = 10.0, 15.0 Hz, 1H), 4.26-4.32 (m, 2H), 4.95 (s, 2H), 5.79 
(s, 1H), 7.19-7.34 (m, 9H), 7.56 (d, J = 10.0 Hz, 1H), 8.45 (d, J = 5.0 Hz, 1H); 
13
C 
NMR (126 MHz, DMSO-d6): δ 16.9, 37.4, 52.2, 55.9, 65.2, 126.2, 127.4, 127.6, 128.0, 
128.2, 129.3, 137.0, 137.9, 155.8, 171.3, 195.1; LC-IT-TOF/MS: (m/z) calcd for 
C21H22N4O4 [M+H]
+
 395.1641, found 395.1588. 
 
4-ethynylbenzyl ((S)-1-(((S)-4-diazo-3-oxobutan-2-yl)amino)-1-oxo-3-phenyl- 
propan-2-yl)carbamate (6-6b, alk-DMK) 
Prepared according to the general 
procedure using 6-29b (0.39 g, 1.0 
mmol), NMM (0.15 mL, 1.2 mmol), 
ISCF (0.17 mL, 1.2 mmol), and the diazomethane-ether solution. Purification by flash 
column chromatography on silica gel using 25 to 50% EtOAc in hexanes to give the 
product 6-6b as a white solid (0.37 g, 89%). 
1
H NMR (500 MHz, DMSO-d6): δ 1.22 
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(d, J = 10.0 Hz, 3H), 2.78 (dd, J = 5.0, 105.0 Hz, 1H), 3.03 (dd, J = 5.0, 10.0 Hz, 1H), 
4.18 (s, 1H), 4.26-4.32 (m, 2H), 4.96 (s, 2H), 5.80 (s, 1H), 7.16-7.32 (m, 6H), 7.44 (d, 
J = 5.0 Hz, 2H), 7.62 (d, J = 10.0 Hz, 1H), 8.45 (d, J = 5.0 Hz, 1H); 
13
C NMR (126 
MHz, DMSO-d6): δ 16.9, 37.4, 52.2, 55.9, 64.7, 80.8, 83.2, 120.9, 126.2, 127.5, 128.0, 
129.3, 131.6, 137.9, 138.0, 155.7, 171.3, 195.1; LC-IT-TOF/MS: (m/z) calcd for 
C23H22N4O4 [M+H]
+
 419.1641, found 419.1760. 
 
8.6.2 Cell Biological Assays 
Cell-culture conditions, Guava ViaCount assay, in situ proteomic profiling, 
pull-down and mass spectrometry identification, and fluorescence microscopy were 
carried out using the general protocols as described in 7.1.2. 
 
8.6.2.1 Enzyme Assays 
Cruzain and rhodesain were assayed in freshly prepared 100 mM acetate 
buffer pH 5.5, containing 5 mM dithiothreitol (DTT) and 0.001% Triton X-100. 25 L 
of reagents (cruzain, or rhodesain at 4 nM final concentration) was added to a 
384-well black plate (Greiner, Germany) that contained 1 L of test compound 
(concentration ranging from 10 M to 10 pM). The enzyme-compound mixture was 
incubated for 5 min at room temperature. Then 25 L of substrate Z-FR-AMC 
(Bachem, 10 M final concentration, in the same buffer solution as above) was added 
to the enzyme-compound mixture to initiate the reaction. The rate of increase in 
fluorescence, resulting from the proteolytic cleavage of the substrate leading to the 
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release of fluorogenic AMC was monitoring as with an automated microtiter plate 
spectrofluorimeter (BioTek Synergy 4 Fluorescence Plate Reader) with fluorescence 
readout setting of excitation at 355 nM and emission at 460 nM. Controls were 
performed using enzyme alone, enzyme with DMSO vehicle, enzyme in the presence 
of the previously known, highly effective irreversible inhibitor (Mu-Phe-HphVSPh, 
K11002), and reversible inhibitor (Mu-Phe-Hph-al, 6-4). IC50 values were determined 
by sigmoid dose-response curve fitting with GraphPad Prism software using inhibitor 
concentrations in the linear portion of a plot of inhibition versus log[I] (seven 
concentrations tested with at least two in the linear range). Data are the means of at 
least two independent assays. 
 
8.6.2.2 Western Blotting 
Pull-down samples from in situ labeling with 6-5, or alk-DMK were 
separated on 12% SDS-PAGE gel together with pull-down sample from 
DMSO-treated (negative control). After SDS-PAGE gel separation, proteins were then 
transferred to a PVDF membrane and subsequently blocked with 3% (w/v) 
BSA/PBST overnight at 4
o
C. Membranes were incubated for 1 h at room temperature 
with the respective antibodies (anti-cathepsin L for HepG2, anti-rhodesainΔC for T. 
brucei), and washed with PBST (3 × 15 min with gentle agitation), then followed by 
incubation with a anti-mouse-IgG conjugated secondary antibody in the blocking 
buffer mentioned above. After wash with PBST (3 × 15 min with gentle agitation), the 
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MS/MS Fragmentation of VPPAINQFTQALDR 
Found in gi|4506661, ribosomal protein L7a [Homo sapiens] 
Match to Query 58: 1568.930124 from (1569.937400,1+) 


















MONOISOTOPIC mass of neutral peptide Mr(calc): 1568.83 
Fixed modifications: Carbamidomethyl (C) 
Ions Score: 72, Expect: 0.00038 
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           Chapter 3_Figure S1. Observed Mass peaks for ESI-MS of His-AGT with or without 3-4 







Chapter 3_Figure S2. A full heatmap showing relative abundance of each protein identified by the probes from the pull-down/LCMS 
experiments. The resulting relative abundance is color-indicated according to their intensity (white for low abundance; red for high abundance). 
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Chapter 6_Figure S1. IC50 values of 6–1a-o, 6–2, 6–3a-e, 6–4 and K11002 against 
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Chapter 6_Figure S2. ED50 values of 6–3b, 6–3d, and 6–3e against PCF (blue) and 































Chapter 6_Figure S3. Immunofluorescence analysis of brucipain in BSF and PCF T. 
brucei treated with DMSO and 6-5 for 2 h. Live cells were treated with 6-5 or 1% 
DMSO, fixed, permeabilized, reacted with rhodamine-azide (red), incubated with 
anti-Trypanopain, visualized by staining with FITC-conjugated goat anti-rabbit IgG 
antibody. All cells were counter-stained with DAPI to visualize kinetoplast and/or 
nucleus (blue). Phase contrast images and merged fluorescence images are shown as 



















H and 13C NMR spectra of all the studied compounds (THL analogues; K11777 
analogues; aza-nitrile and diazomethyl-ketone containing inhibitors and probes) are 
listed in this Appendix.  
 
1
H and 13C NMR spectra of the intermediate compounds and representative LCMS 
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